WO2017155940A1 - Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases - Google Patents

Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases Download PDF

Info

Publication number
WO2017155940A1
WO2017155940A1 PCT/US2017/021080 US2017021080W WO2017155940A1 WO 2017155940 A1 WO2017155940 A1 WO 2017155940A1 US 2017021080 W US2017021080 W US 2017021080W WO 2017155940 A1 WO2017155940 A1 WO 2017155940A1
Authority
WO
WIPO (PCT)
Prior art keywords
dnp
diseases
day
syndrome
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/021080
Other languages
French (fr)
Inventor
John Gerard GEISLER
Robert Alonso
Peter Anthony Crooks
Narsimha Reddy PENTHALA
Zaineb ALBAYATI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas System
Mitochon Pharmaceuticals Inc
Original Assignee
University of Arkansas System
Mitochon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2018548116A priority Critical patent/JP7021098B2/en
Priority to KR1020187028903A priority patent/KR102436172B1/en
Priority to MX2018010718A priority patent/MX2018010718A/en
Priority to CA3016465A priority patent/CA3016465A1/en
Priority to BR112018067966-6A priority patent/BR112018067966B1/en
Priority to EP17763866.5A priority patent/EP3426233A4/en
Priority to AU2017229224A priority patent/AU2017229224B2/en
Priority to KR1020217037710A priority patent/KR102475875B1/en
Application filed by University of Arkansas System, Mitochon Pharmaceuticals Inc filed Critical University of Arkansas System
Priority to CN201780028100.7A priority patent/CN109195589B/en
Priority to CN202210496274.9A priority patent/CN115227685A/en
Priority to KR1020227042687A priority patent/KR20230003267A/en
Publication of WO2017155940A1 publication Critical patent/WO2017155940A1/en
Anticipated expiration legal-status Critical
Priority to AU2023200805A priority patent/AU2023200805A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid

Definitions

  • the present invention relates to development of disease modifying treatments for reversing, slowing or preventing neuromuscular, spinal muscular atrophy (SMA) syndrome (Type I, II, III and IV), neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, hearing loss related, and/or metabolic diseases, including Wolfram Syndrome, Wolcott-Rallison syndrome, and disorders in children, adults and the elderly population.
  • SMA spinal muscular atrophy
  • TBI traumatic brain injury
  • concussion keratoconjunctivitis sicca
  • Sjogren's syndrome Sjogren's syndrome
  • hearing loss related and/or metabolic diseases, including Wolfram Syndrome, Wolcott-Rallison syndrome, and disorders in children, adults and the elderly population.
  • DNP dinitrophenol
  • the invention also relates to synthesis of bipartite dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs, and use of the prodrugs and/or 2,3 -dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3, 5 -dinitrophenol for treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic diseases of the CNS, hearing loss related, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, and
  • ALS Amyotrophic Lateral Sclerosis
  • Lou Gehrig's Disease is a neurodegenerative disorder characterized by loss of neurons in the brain stem, cerebral cortex, and motor neurons of the spinal cord, that leads to progressive weakness and death within 3-5 years upon onset.
  • ALS there have been a variety of treatments, and none have been proven effective to curb progression towards death, except riluzole.
  • Riluzole extends life to a modest extent (several months) and extends the time before the patient needs ventilation support, but signs of liver toxicities (-10%) must be monitored.
  • AD Alzheimer's Disease
  • a host drug therapies the drugs have failed to significantly alter lifespan of the patients.
  • Parkinson's Disease well known for its impact on Michael J. Fox, Mohamed Ali and others, is a slow killer of dopamine producing neurons called the dopaminergic neurons.
  • Current therapies are focused on replacing dopamine and no new advancements have been made in quite a while.
  • Duchene Muscular Dystrophies a pediatric neuromuscular disease in young boys (X-Chromosome), is an aggressive disorder such that the children are in leg braces at 8 years of age and in a wheel chair at 10.
  • the loss of the dystrophin gene affects both the brain and muscle, the only two tissues in which it is expressed.
  • the loss of dystrophin causes osmotic swelling of the mitochondria, bursting, and muscle wasting.
  • Other forms of ataxia, and a host of other neurodegenerative/neuromuscular-degenerative diseases have no treatments to profoundly alter the course of disease progression towards early death.
  • Multiple sclerosis is an autoimmune disorder of the CNS with no known etiology.
  • a first aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of the CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, concussion, traumatic brain injury (TBI), drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising one or more isomers of dinitrophenol (DNP), i.e., 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP
  • a second aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of the CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising a prodrug, the prodrug being selected from the group consisting of:
  • AA esters incorporating a methylene dioxide (a formaldehyde equivalent) spacer Scheme 1, Formulas 1-11 to 1-13; Scheme 2, Formulas 11-11 to 11-13; Scheme 3, Formulas Hill to 111-13; Scheme 4, Formulas IV-11 to IV-13; Scheme 5, Formulas V-ll to V-13; and Scheme 6, Formulas VI-11 to VI-13);
  • a third aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of the CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: a phosphate prodrug altered by introducing a water-soluble prodrug moiety into the molecule through conjugation with the free phenolic functionality.
  • SMA spinal muscular atrophy
  • TBI traumatic brain injury
  • TBI traumatic
  • a fourth aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of the CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: a prodrug, the prodrug being selected from the group consisting of, 2,3- D P, 2,4-D P, 2,5-D P, 2,6-D P, 3,4-D P, or 3,5-D P "
  • a fifth aspect of the present invention provides a method for synthesizing the composition of a prodrug for treating neurodegenerative neuromuscular diseases, developmental diseases, autoimmune diseases, traumatic diseases of CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, antidepressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome.
  • SMA spinal muscular atrophy
  • SMAl, SMA2, SMA3, and SMA4 also called Type I, II, III and IV
  • TBI traumatic brain injury
  • concussion concussion
  • the method comprises: reacting 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6- dinitrophenol, 3,4- dinitrophenol, and/or 3,5-dinitrophenol with 5-(tert- butyldimethylsiloxy)isophthaloyl dichloride (2) in the presence of pyridine/ dichloromethane to afford precursor (3); and removing the TBDMS protecting group in acetone/HCl to afford the prodrug (Scheme 7).
  • a sixth aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: bioprecursors of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP that release 2,3- dinitrophenol, 2,4-dinitrophenol
  • a seventh aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: D P prodrugs and bioprecursors with linkers containing open functional groups delivered as depot nanoparticle formulations that release DNP in a slow, sustained fashion at low doses compared to dose and release of DNP alone.
  • SMA spinal muscular at
  • An eighth aspect of the present invention provides a method of treatment of neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: administering to a patient in need of treatment a dose of a composition, wherein the composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4
  • 3.5- DNP prodrugs 3.5- DNP prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof, and wherein the dose of active drug is from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment or from about 0.01 mg/kg of body weight to about 25 mg/kg of body weight of the patient in need of treatment.
  • a ninth aspect of the present invention provides a method of treatment of Traumatic Brain Injury (TBI), Ischemic stroke, Huntington's disease (Adult-onset Huntington's, Juvenile Huntington's disease), Epilepsy (Cluster Seizures, Refractory Seizures, Atypical Absence Seizures, Atonic Seizures, Clonic Seizures, myoclonic seizures, tonic seizures, Tonic-Clonic Seizures, Simple Partial Seizures, Complex Partial Seizures, Secondary Generalized Seizures, Febrile Seizures, Nonepileptic Seizures, Gelastic and Dacrystic Seizures, and Absence Seizures), Multiple Sclerosis (MS) (relapse-remitting multiple sclerosis (RRMS), Secondary-progressive MS (SPMS), Primary-progressive MS (PPMS), and Progressive-relapsing MS (PRMS)), Lupus (Systemic Lupus Erythematosus (SLE), disco
  • Figure 1 is a chart illustrating the comparative effect of two compounds of the invention at lowering or blocking progression of paralysis as monitored as a Clinical Score (EAE MS model comparing parent (2,4-DNP) to prodrug (11-38) at equivalent exposures of 5 mpk parent to 80 mpk prodrug for efficacy).
  • EAE MS model comparing parent (2,4-DNP) to prodrug (11-38) at equivalent exposures of 5 mpk parent to 80 mpk prodrug for efficacy.
  • diamond - placebo square - 2,4-DNP 5 mpk; triangle - 11-38 8 mpk; x - 11-38 16 mpk; asterisk - 11-38 80 mpk.
  • Figure 2 is a chart illustrating the comparative effect of two compounds of the invention at preventing weight loss seen in the Placebo mice (EAE MS model comparing parent (2,4-DNP) to prodrug (11-38) at equivalent exposures of 5 mpk parent to 80 mpk prodrug for body weight changes).
  • EAE MS model comparing parent (2,4-DNP) to prodrug (11-38) at equivalent exposures of 5 mpk parent to 80 mpk prodrug for body weight changes.
  • diamond - placebo square - 2,4-DNP 5 mpk; triangle - 11-38 8 mpk; x - 11-38 16 mpk; asterisk - 11-38 80 mpk. All doses significant to preserving body weight.
  • Figure 3 is a chart illustrating the comparative results of an in vivo noise exposure experiment, including DNP (2,4-DNP) and a prodrug of DNP (11-38); II-38+Noise thresholds were 5 dB, approximately 20 dB lower (better) than the Noise alone group; DNP (2,4- DNP)+Noise thresholds were 15 dB, about 10 dB lower than Noise alone suggesting that DNP (2,4-DNP) can protect against noise induced hearing loss.
  • circle - control (0 dB); triangle (pointing down) - 11-38 (5 dB); triangle (pointing up) - 2,4-DNP (15 dB); circle (solid) - noise (25 dB).
  • Figure 4 illustrates the results of single crystal X-ray diffraction of 2,4-dinitrophenyl morpholine-4-carboxylate.
  • Figure 5 illustrates a chromatogram of 11-38 eluted at 8.04 min.
  • Figure 6 illustrates the equilibrium (solubility) phase of 11-38 in HC1 buffer, pH 1.2.
  • Figure 7 illustrates chromatograms of 2,4-DNP and 11-38 prodrug in phosphate buffer, pH 7.4, eluted at 6.854 and 8.023 min, respectively.
  • Figure 9 illustrates a chromatogram of 11-38 eluted at 3.08 min in SGF.
  • Figure 11 illustrates a chromatogram of 11-38 eluted at 2.187 min in SIF.
  • Figure 13 illustrates 11-38 and 2,4-DNP released from 11-38 in rat plasma. Legend: diamond - 2,4-DNP; circle - 11-38.
  • Figure 14 illustrates 11-38 and 2,4-DNP released from 11-38 in human plasma. Legend: diamond - 2,4-DNP; circle - 11-38.
  • Figure 15 illustrates the calibration standard of 2,4-DNP in acetonitrile.
  • Figure 19 illustrates the mean plasma concentrations vs. time of 11-38 and 2,4-DNP released from 11-38 prodrug after administration of an oral dose of 8 mg/kg of 11-38 (eq. to 5 mg/kg of 11-38).
  • Figure 20 illustrates the mean plasma concentrations vs. time of 11-38 and 2,4-DNP released from 11-38 prodrug after administration of an oral dose of 40 mg/kg of 11-38 (eq. to 25 mg/kg of 11-38 formulated in methocel).
  • Figure 21 illustrates the mean plasma concentrations vs. time of 11-38 and 2,4-DNP released from 11-38 prodrug after administration of an oral dose of 40 mg/kg of 11-38 (eq. to 25 mg/kg of 11-38 formulated in PEG-400).
  • an oral dose 40 mg/kg of 11-38 (eq. to 25 mg/kg of 11-38 formulated in PEG-400).
  • Figure 22 illustrates the mean plasma concentrations vs. time of 11-38 and 2,4-DNP released from 11-38 prodrug after administration of an oral dose of 80 mg/kg of 11-38 (eq. to 50 mg/kg of 11-38).
  • prodrug refers to an inactive or partially active drug that is metabolically changed in the body to an active drug.
  • the term “depot nanoparticle formulation” unless defined otherwise refers to a biodeliverable nanoparticle, comprising a broad range of 1) bipartite 2,3- dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5- dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs, 2) Gemini prodrugs and 3) bioprecursor molecules for treating neurodegenerative or metabolic diseases.
  • AA esters incorporating a methylene dioxide (a formaldehyde equivalent) spacer Scheme 1, Formulas 1-11 to 1-13; Scheme 2, Formulas 11-11 to 11-13; Scheme 3, Formulas Hill to 111-13; Scheme 4, Formulas IV-11 to IV-13; Scheme 5, Formulas V-11 to V-13; and Scheme 6, Formulas VI-11 to VI-13);
  • the invention provides compositions and methods for treating neurodegenerative diseases such as Alzheimer's disease, Parkinson, and Huntington's disease. It is believed that the complete lack of historic success is due to most pharmaceutical industries focusing on a downstream event, such as plaques/tangles, whereas the issue is likely upstream at the mitochondria causing high cellular stress. In studies where a mouse model of Alzheimer's disease was treated with DNP under chronic treatment, short term memory was strikingly improved in the Morris Water Maze, having a profound impact on disease progression. Data from a recent study in a Parkinson model using 6-OHDA to destroy the dopaminergic neurons showed that treatment with DNP, had a positive protective effect with chronic treatment.
  • neurodegenerative diseases such as Alzheimer's disease, Parkinson, and Huntington's disease.
  • the invention provides compositions and methods for treating Huntington's disease.
  • DNP should prevent muscle loss since it reduces mitochondrial osmotic swelling by reducing intra-mitochondrial calcium concentration and inducing BDNF, which is a myokine (muscle protectant) outside of the brain.
  • BDNF myokine (muscle protectant) outside of the brain.
  • the invention provides compositions and methods for treating cognitive disorders associated with DMD in the CNS. 2,4-D P should for example help the cognitive disorders associated with DMD in the CNS.
  • the invention provides compositions and methods for treating Angelman and Rett syndromes. It is believed that oxidative stress is playing a role impairing neurodevelopment, however the fact that DNP prevents overt ROS formation, induces BDNF, reduces seizure duration activity, can have a therapeutic effect in subjects afflicted by these disorders, including children.
  • the invention provides compositions and methods for treating obesity.
  • the key to effective weight loss or mechanisms to reduce ectopic fat to improve insulin resistance, fatty liver diseases, Type-2 diabetes, cardiovascular disease, etc., without necessarily marked changes in body weight, is to take the body out of balance regarding energy-in to energy- out, and maintain a mechanism that wastes energy.
  • new pharmacological therapies focused on enhancing energy expenditure, that address metabolic disease and over-nutritional phenotypes, could potentially have a dramatic effect on the lives of individuals afflicted by these diseases.
  • compositions and methods of the invention relate to a pharmacological intervention that abolishes overt ROS production and improves the quality of the mitochondrial population by mitophagy, induces Brain Derived Neurotrophin Factor (BDNF), increases cAMP, and/or remodels cellular expression.
  • BDNF Brain Derived Neurotrophin Factor
  • a drug of the invention thus becomes "disease modifying.”
  • a prodrug of DNP (11-38) was administered to a mouse model of Multiple Sclerosis, called the EAE, 7-days after induction of the MOG 35 .55 myelin peptide.
  • the ProDrug of DNP, 11-38 was administered at multiples of exposure to 2,4-D P or DNP.
  • compositions described herein may be used to treat hearing loss.
  • 2, 4-dinitrophenol (DNP) may be used at a dose range independently selected from: 1 mg/day to 50 mg/day; 1 mg/day to 45 mg/day; 1 mg/day to 40 mg/day; 1 mg/day to 35 mg/day; 1 mg/day to 30 mg/day; 1 mg/day to 25 mg/day; 1 mg/day to 20 mg/day; 1 mg/day to 15 mg/day; 1 mg/day to 10 mg/day; 1 mg/day to 5 mg/day; 1 mg/day to 4 mg/day; 1 mg/day to 3 mg/day; 1 mg/day to 2 mg/day; 2 mg/day to 50 mg/day; 2 mg/day to 45 mg/day; 2 mg/day to 40 mg/day; 2 mg/day to 35 mg/day; 2 mg/day to 30 mg/day; 2 mg/day to 25 mg/day; 2 mg/day to 20 mg/day; 2 mg/day to 15
  • DNP 2-dinitrophenol
  • 2, 4-dinitrophenol (DNP) may be used at a dose range independently selected from: about 1 mg/day to about 50 mg/day; about 1 mg/day to about 45 mg/day; about 1 mg/day to about 40 mg/day; about 1 mg/day to about 35 mg/day; about 1 mg/day to about 30 mg/day; about
  • a prodrug of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, as described herein may be used at a dose range to achieve equivalent exposure (AUC) to DNP.
  • a prodrug of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, as described herein may be used at a dose range independently selected from: 20 mg/day to 800 mg/day; 20 mg/day to 750 mg/day; 20 mg/day to 700 mg/day; 20 mg/day to 600 mg/day; 20 mg/day to 700 mg/day; 20 mg/day to 600 mg/day; 20 mg/day to 500 mg/day; 30 mg/day to 800 mg/day; 30 mg/day to 700 mg/day; 30 mg/day to 600 mg/day; 30 mg/day to 500 mg/day; 30 mg/day to 400 mg/day; 30 mg/day to 360 mg/day; 30 mg/day to 300 mg/day; 30 mg/day to 250 mg/day; 30 mg/day to 200 mg/day; 30 mg/day to 150 mg/day; 30 mg/day to 100 mg/day; 35 mg/day to 360 mg/day;
  • a prodrug of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, as described herein may be used at a dose range independently selected from: about 20 mg/day to about 800 mg/day; about 20 mg/day to about 750 mg/day; about 20 mg/day to about 700 mg/day; about 20 mg/day to about 600 mg/day; about 20 mg/day to about 700 mg/day; about 20 mg/day to about 600 mg/day; about 20 mg/day to about 500 mg/day; about 30 mg/day to about 800 mg/day; about 30 mg/day to about 700 mg/day; about 30 mg/day to about 600 mg/day; about 30 mg/day to about 500 mg/day; about 30 mg/day to about 400 mg/day; about 30 mg/day to about 360 mg/day; about 30 mg/day to about 300 mg/day; about 30 mg/day to about 250 mg/day; about 30 mg/day to about 200 mg/
  • ROSs reactive oxygen species
  • Exposure to blast waves and continuous noise not only damaged the inner ear, but caused cell death in the hippocampus, suppressed neurogenesis and impaired memory function. Aging as well can manifest in mitochondrial dysfunction leading to hearing loss. It is emerging that attempts to treat hearing loss by targeting downstream issues is not very effective.
  • the compositions and methods of the invention relate to targeting oxidative stress upstream at the mitochondria that may be causative for many disorders.
  • DNP modulates the mitochondrial membrane potential having a significant impact at preventing ROS formation in isolated mitochondria and in the treated wildtype mice.
  • DNP treatment 3-hours post-ischemia reduced cerebral infarct volume 40% by protecting the penumbra or "threaten tissue" and could provide similar benefits after a blast to protect inner hair cells from eminent cell death.
  • DNP comes with the benefits of known risks as it was used 80-years ago for weight loss at high doses (-300 mg) in over 100,000 people, however shown recently in models of neurodegeneration at very low hormetic doses to improve cognition and learning.
  • the pharmacology which is pleiotrophic, appears to provide broad neuroprotection by lowering ROS/mTOR and increasing protective factors such as cAMP, CREB, and BDNF, could be useful for treating hearing loss.
  • prodrugs which contain a self-cleavable spacer and a water- solubilizing moiety are synthesized, to maintain the prodrug in a soluble form in the GI tract fluids, and which will then gradually revert to the parent drug without precipitation.
  • these compounds are 1,3 diketo analogs 1-22 to 1-32; 11-22 to 11-32; 111-22 to III- 32; IV-22 to IV-32; V-22 to V-32; and VI-22 to VI-32 (Schemes 1-6).
  • the increased solubility of the prodrug and the high membrane permeability of the well-dispersed parent drug will provide a higher driving force for it to be readily absorbed via the intestinal lumen.
  • Conversion of prodrug-to-parent drug involves a chemical cleavage at the self-cleavable spacer through a unique intramolecular cyclization-elimination reaction via imide formation under physiological conditions.
  • the conversion time is tunable by modifying the structure of the solubilizing moiety, the bond length of the spacer, the pKa of the amine group, and the pH of the medium.
  • the in silico predicted bioavailability may be low, it is likely to be much higher when one takes into account the unique pH-dependent and tunable hydrolysis mechanism.
  • the generation of parent drug does not rely on enzyme action, which may be an advantage in dealing with genetic variability associated with enzymatic prodrug hydrolysis in plasma.
  • one or more isomers of dinitrophenol i.e., 2,3-D P, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, and/or a broad range of 1) bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3, 5 -dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs, 2) Gemini prodrugs and 3) bioprecursor molecules, are used for treating neurodegenerative or metabolic diseases.
  • dinitrophenol i.e., 2,3-D P, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP
  • AA esters incorporating a methylene dioxide (a formaldehyde equivalent) spacer Scheme 1, Formulas 1-11 to 1-13; Scheme 2, Formulas 11-11 to 11-13; Scheme 3, Formulas Hill to 111-13; Scheme 4, Formulas IV-11 to IV-13; Scheme 5, Formulas V-ll to V-13; and Scheme 6, Formulas VI-11 to VI-13);
  • a broad range of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4- D P, or 3,5-D P prodrugs can be considered.
  • the prodrugs are represented by formulas I-l to 1-40; II-l to 11-40; III-l to 111-40; IV-1 to IV-40; V-1 to V-40; and VI- 1 to VI-40 are considered.
  • a computational screen utilizing Pharma Algorithms' ADME- Tox calculator is conducted in order to identify virtual 'hits' (i.e. prodrugs with acceptable "predicted" oral bioavailabilities and water solubilities from the 32 prodrugs listed). The virtual screen allows ranking the 10 best prodrug molecules for synthesis and testing.
  • Amino acid (AA) esters of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP Scheme 1, Formulas I-l to 1-10; Scheme 2, Formulas II-l to 11-10; Scheme 3, Formulas
  • IV- 33 to IV-39; V-33 to V-39; and VI-33 to VI-39 (Schemes 1-6); benzoate analogs 1-40, 11-40, 111-40, IV-40, V-40, and VI-40 (Schemes 1-6); and combinations thereof, may be considered.
  • Examples of ionizable amine-containing prodrugs have increased water-solubility compared to the parent compound.
  • AA ester prodrugs have the potential to further increase oral bioavailability due to active absorption by transporters (e.g., small peptide transporter PEPT1).
  • transporters e.g., small peptide transporter PEPT1.
  • the valine-containing prodrugs valacyclovir and valganciclovir are substrates for the enzyme PEPT1.
  • These AA containing prodrugs are hydrolyzed to the parent drug by aminopeptidase enzymes in the brush border membrane of the GI tract.
  • Prodrugs which can penetrate into the peripheral circulation by passive permeation and/or by active transport are hydrolyzed by various peptidase enzymes in plasma.
  • phosphate prodrugs of 2,3-D P, 2,4-D P, 2,5-D P, 2,6-D P, 3,4- D P, or 3,5-D P of formulas 1-20, 1-21, 11-20, 11-21, 111-20, 111-21, IV-20, IV-21, V-20, V-21, VI-20, and VI-21 are synthesized.
  • ADME-Tox computational data the oral bioavailability of these prodrugs can be poor, given the fact that the prediction by ADME-Tox calculator is mainly based on the physicochemical proprieties of the molecule. Since phosphoric acid is a highly polar and extensively ionized pro-moiety, phosphate prodrugs can have significantly decreased membrane permeability compared to the parent drug.
  • phosphate prodrugs of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP shown in formulas 1-20, 1-21, 11-20, 11-21, 111-20, 111-21, IV- 20, IV-21, V-20, V-21, VI-20, and VI-21 (Schemes 1-6), e.g., phosphate esters as oral prodrugs, are: 1) oral absorption is not limited by dissolution-rate, since phosphate prodrugs are highly soluble in GI tract fluids; 2) phosphate esters are chemically stable enough to prevent the precipitation of the parent drug in the GI tract; 3) phosphates are rapidly hydrolyzed by membrane-bound alkaline phosphatases, which are in abundance on the brush border surface of the cells lining the small intestine, i.e., the enterocytes. Thus, the more permeable parent drug will be released, and readily cross the enterocyte membranes and enter
  • the prodrugs that are synthesized are modified to ensure water solubility.
  • acceptable solubility is tested prior to dosing in animals. If solubility is an issue, the structure of the prodrug is altered by introducing a water-soluble prodrug moiety into the molecule through conjugation with the free phenolic functionality. In other embodiments, a prodrug linker moiety that confers water-solubility properties on the prodrug molecule is utilized.
  • a solution to any water solubility issues is utilizing soft alkyl ether prodrugs that incorporate ethyleneoxy groups into promoieties such as alkyloxycarbonylmethyl (AOCOM) and N-alkyl-N-alkyloxycarbonylamino methyl (NANAOCAM) prodrugs.
  • AOCOM alkyloxycarbonylmethyl
  • NANAOCAM N-alkyl-N-alkyloxycarbonylamino methyl
  • 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP "Gemini" prodrugs may be prepared by reacting 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4- DNP, or 3,5-DNP with triphosgene, in the presence of K 2 C0 3 in dichloromethane to get 2,4- dinitrophenyl carbonochloridate, which on further reaction with bases like morpholine, piperidine, piperazine, N-alkyl piperazine yields the DNP prodrugs as illustrated in Scheme 9.
  • 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP "Gemini" prodrugs are prepared by reacting 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP with 5-(tert-butyldimethylsiloxy)isophthaloyl dichloride (2) in the presence of pyridine/ dichloromethane to afford precursor (3); the TBDMS protecting group will then be removed in acetone/HCl to afford prodrug (4), which will afford two equivalents of 2, 4-DNP upon hydrolysis in plasma.
  • prodrug linker moiety in (4) is an ester group
  • other alternative linkers such as sterically hindered ester linkers, carbonate linkers, carbamate linkers, phosphate linkers, and AOCOM and NANAOCAM based linkers may also be incorporated into the prodrug structure in order to achieve appropriate sustained release kinetics.
  • the presence of the free phenolic group in (4) can also be utilized to improve water-solubility, if this is deemed necessary, through conjugation with appropriate hydrophilic moieties (Scheme 10).
  • Bioprecursors of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP that may release 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP after oxidative metabolism by cytochrome P-450 may be utilized.
  • Scheme 8 shows the design of two bioprecursors that can release 2- and 4-equivalents of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP,
  • DNP prodrugs and bioprecursors with linkers containing open functional groups are utilized, which allow conjugation of each of these entities to nanoparticles, such as dendrimers, in order to modulate the pharmacokinetics of the molecule to enable "trickle" drug delivery.
  • Such DNP prodrugs and bioprecursors are delivered as depot nanoparticle formulations that release DNP in a slow, sustained fashion at low doses, compared to dose and release of DNP alone, to avoid possible toxicity issues.
  • Nanotechnology presents an opportunity to increase the bioavailability of drug particles.
  • a decrease in particle size results in increased surface area, results in faster dissolution.
  • the decrease is by a small order of magnitude. In other embodiments, this may be enough to result in increased bioavailability.
  • faster dissolution may not be sufficient to overcome exposure to acid and enzymes in the gut. Additionally, as in the case with oral insulin, this exposure may require higher dosing of the drug, resulting in unnecessary and potentially undesirable subject exposure to breakdown products as well as create significant waste.
  • a depot nanoparticle formulation is specially formulated to provide slow absorption of the drug from the site of administration, often keeping therapeutic levels of the drug in the patient's system for days or weeks at a time.
  • a depot nanoparticle formulation may provide convenience for a patient in need of chronic medication. By delivering drug without exposure to the Gl tract, the potential issue of drug degradation is avoided.
  • a depot nanoparticle formulation may provide better compliance due to the infrequent dosing regimen and convenience. Additional characteristics of a depot nanoparticle formulation that will enhance patient compliance are good local tolerance at the injection site and ease of administration. Good local tolerance means minimal irritation and inflammation at the site of injection; ease of administration refers to the size of needle and length of time required to administer a dose of a particular drug formulation.
  • the prodrugs and bioprecursors of the invention encounter a wide range of pHs and enzymes when administered orally to patients.
  • the prodrug/bioprecursor is stable in the environment of the Gl tract, but releases parent drug in the plasma in a sustained manner after absorption from the GI tract.
  • Oral dosing exposes compounds to pH 1 to 2 in the stomach, pH 4.5 at the beginning of the small intestine, pH 6.6 as an average pH for the small intestine, and pHs of 5 to 9 in the colon.
  • Stability-indicating methods are performed in aqueous buffer solutions and simulated GI fluids to determine the resilience of the 2,3 -DNP, 2,4-DNP,
  • 2.6- DNP, 3,4-DNP, or 3,5-DNP_prodrug/bioprecursor candidates to determine their clinical potential.
  • Most promising preclinical prodrug/bioprecursor candidates are absorbed intact from the gastrointestinal tract and are efficiently cleaved enzymatically in plasma to afford the parent drug.
  • the presence and identification of the prodrug and the parent drug can also provide important information on the mechanism of action of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, the identification of which is of value in the selection of new structural entities for consideration in structure-activity and structural optimization studies.
  • prodrug/bioprecursor candidate i.e., the prodrug/bioprecursor that exhibits the greatest stability in the GI tract and affords sustained release of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP in vitro and in vivo in rat plasma) in the Sprague-Dawley rat.
  • a complete PK profile is obtained for the orally administered prodrug in jugular and femoral vein catheterized rats to determine half-life (ti /2 ), maximum plasma concentration (t max ), time to reach maximum plasma concentration (tma x ), volume of distribution (V ss ), area under the plasma concentration versus time curve from time 0 to infinity (AUCo- ⁇ ), and bioavailability (F%), as well as other important PK parameters such as protein binding.
  • LC/MS/MS is used as the analytical methodology to determine both the above pharmacokinetic parameters of the prodrug, and the plasma concentration and release kinetics of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP resulting from enzymatic conversion of the prodrug to 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6- DNP, 3,4-DNP, or 3,5-DNP in the plasma.
  • DNP is orally bioavailable, with good distribution and ⁇ 6-hour half-life in rats
  • the prodrug approach allows extending the plasma residence time at lower concentrations of the parent drug (DNP), by appropriate design of the prodrug release characteristics.
  • the composition for treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases is independently selected from the group consisting of 2,3-DNP, 2,4- DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4- DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof.
  • a dose of any of the foregoing embodiments of the compositions, of DNP, DNP prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof, for treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases may be from about 0.01 mg/kg to about 50 mg/kg of body weight of the patient in need of treatment; from about 25 mg/kg to about 100 mg/kg of body weight of the patient in need of treatment; or from about 25 mg/kg to about 100 mg/kg of body weight of the patient in need of treatment.
  • a dose of any of the foregoing embodiments of the compositions for treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases may be from 0.01 mg/kg to 50 mg/kg of body weight of the patient in need of treatment; from 25 mg/kg to 100 mg/kg of body weight of the patient in need of treatment; or from 25 mg/kg to 100 mg/kg of body weight of the patient in need of treatment.
  • the present invention relates to a pharmaceutical composition of DNP, or a pharmaceutically acceptable salt, solvate, hydrate and/or prodrug thereof as described herein, comprising a unit dose, wherein the unit dose is in the range of about 0.1 mg to about 3000 mg.
  • the present invention relates to a pharmaceutical composition of DNP, or a pharmaceutically acceptable salt, solvate, hydrate and/or prodrug thereof as described herein, comprising a unit dose, wherein the unit dose is in the range of 0.1 mg to 3000 mg.
  • a dose of any of the foregoing embodiments of the compositions for treatment of neuromuscular diseases, neuromuscular degenerative diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, may be independently selected from 0.01 mg/kg to 50 mg/kg of body weight; 0.01 mg/kg to 40 mg/kg of body weight; 0.01 mg/kg to 30 mg/kg of body weight; 0.01 mg/kg to
  • a dose of any of the foregoing embodiments of the compositions for treatment of neuromuscular diseases, neuromuscular degenerative diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss,, and/or metabolic diseases including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, may be independently from about 1 mg/day/70kg of body weight to about 300 mg/day/70kg of body weight of the patient in need of treatment; about 1 mg/day/70kg of body weight to about 200 mg/day
  • SMA spinal muscular atrophy
  • a dose of any of the foregoing embodiments of the compositions for treatment of neuromuscular diseases, neuromuscular degenerative diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss,, and/or metabolic diseases including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, may be independently from 1 mg/day/70kg of body weight to 300 mg/day/70kg of body weight of the patient in need of treatment; 1 mg/day/70kg of body weight to 200 mg/day/70kg of
  • a pharmaceutical composition includes D P, selected from the group consisting of DNP, 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP) prodrugs or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprising a unit dose, independently selected from: wherein the unit dose is in the range of about 0.1 mg to about 3000 mg; wherein the unit dose is in the range of about 0.1 mg to about 1000 mg; wherein the unit dose is in the range of about 0.1 mg to about 500 mg; wherein the unit dose is in the range of about 0.1 mg to about
  • a pharmaceutical composition includes DNP, selected from the group consisting of DNP, 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP) prodrugs or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprising a unit dose, independently selected from: wherein the unit dose is from the range of 0.1 mg to 3000 mg; wherein the unit dose is in the range of 0.1 mg to 1000 mg; wherein the unit dose is in the range of 0.1 mg to 500 mg; wherein the unit dose is in the range of 0.1 mg to 1000 mg; wherein the unit dose
  • the unit dose is an immediate release formation. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is an extended release formation. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is a sustained release formation. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is a controlled release formation. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is an oral dosage form. In some embodiments, the oral dosage form is a tablet.
  • the oral dosage form is a capsule. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is a capsule with no filler. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the oral dosage form is rapidly dissolving.
  • the disease may be independently selected from Traumatic Brain Injury (TBI), Concussion, Ischemic stroke, Huntington's disease (Adult-onset Huntington's, Juvenile Huntington's disease), Epilepsy (Cluster Seizures, Refractory Seizures, Atypical Absence Seizures, Atonic Seizures, Clonic Seizures, myoclonic seizures, tonic seizures, Tonic- Clonic Seizures, Simple Partial Seizures, Complex Partial Seizures, Secondary Generalized Seizures, Febrile Seizures, Nonepileptic Seizures, Gelastic and Dacrystic Seizures, and Absence Seizures), Multiple Sclerosis (MS) (relapse-remitting multiple sclerosis (RRMS), Secondary- progressive MS (SPMS), Primary-progressive MS (PPMS), and Progressive-relapsing MS (PRMS)), Lupus (Systemic Lupus Erythematosus (SLE), disc
  • the invention provides for a method of treatment of traumatic brain injury (TBI) using embodiments of the compositions and dosages described herein.
  • TBI traumatic brain injury
  • the invention relates to a method of treatment of concussion using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of ischemic stroke using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of severe burns using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of Huntington's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of adult-onset Huntington's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of juvenile Huntington's disease using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of epilepsy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of cluster seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of refractory seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of atypical absence seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of atonic seizures using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of clonic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of myoclonic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of tonic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of tonic-clonic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of simple partial seizures using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of complex partial seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of secondary generalized seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of febrile seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of nonepileptic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of gelastic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of dacrystic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of absence seizures.
  • the invention relates to a method of treatment of multiple sclerosis (MS) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of relapse-remitting multiple sclerosis (RRMS) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of secondary-progressive MS (SPMS) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of primary-progressive MS (PPMS) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of progressive-relapsing MS (PRMS).
  • MS multiple sclerosis
  • RRMS relapse-remitting multiple sclerosis
  • SPMS secondary-progressive MS
  • PPMS primary-progressive MS
  • PRMS progressive-relapsing MS
  • the invention relates to a method of treatment of diabetes mellitus using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of type-1 diabetes using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of type-2 diabetes using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of maturity onset diabetes of the young (MODY) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY1 using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of MODY2 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY3 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY4 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY5 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY6 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY7 using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of MODY8 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY9 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODYIO using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY11 using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of nonalcoholic steatohepatitis (NASH) using embodiments of the compositions and dosages described herein.
  • NASH nonalcoholic steatohepatitis
  • the invention relates to a method of treatment of muscular dystrophy using embodiments of the compositions and dosages described herein.
  • such dosages for an adult independently ranging from: 10 mg/day to 150 mg/day; 20 mg/day to 150 mg/day; 30 mg/day to 150 mg/day; 40 mg/day to 150 mg/day; 50 mg/day to 150 mg/day; 60 mg/day to 150 mg/day; 70 mg/day to 150 mg/day; 80 mg/day to 150 mg/day; 90 mg/day to 150 mg/day; 80 mg/day to 100 mg/day; 90 mg/day to 100 mg/day; 91 mg/day to 100 mg/day 92 mg/day to 100 mg/day; 93 mg/day to 100 mg/day; 94 mg/day to 100 mg/day; or independently dosages of 90 mg/day; 91 mg/day; 92 mg/day; 93 mg/day; 94 mg/day; 95 mg/day; 96 mg/day; 97 mg//day;
  • such dosages for an adolescent independently ranging from: 1 mg/day to 45 mg/day; 1 mg/day to 50 mg/day; 5 mg/day to 45 mg/day; 5 mg/day to 50 mg/day; 10 mg/day to 45 mg/day; 15 mg/day to 45 mg/day; 20 mg/day to 45 mg/day; 25 mg/day to 45 mg/day; 30 mg/day to 45 mg/day; 35 mg/day to 45 mg/day; 35 mg/day to 40 mg/day or ; independently dosages of 35 mg/day; 35 mg/day; 37 mg/day; 38 mg/day; 39 mg/day; 40 mg/day; 41 mg/day; 42 mg/day; 43 mg/day; 44 mg/day or 45 mg/day.
  • such dosages for an adult independently ranging from: about 10 mg/day to about 150 mg/day; about 20 mg/day to about 150 mg/day; about 30 mg/day to about 150 mg/day; about 40 mg/day to about 150 mg/day; about 50 mg/day to about 150 mg/day; about 60 mg/day to about 150 mg/day; about 70 mg/day to about 150 mg/day; about 80 mg/day to about 150 mg/day; about 90 mg/day to about 150 mg/day; about 80 mg/day to about 100 mg/day; about 90 mg/day to about 100 mg/day; about 91 mg/day to about 100 mg/day; about 92 mg/day to about 100 mg/day; about 93 mg/day to about 100 mg/day; about 94 mg/day to about 100 mg/day; or independently dosages of about 90 mg/day; about 91 mg/day; about 92 mg/day; about 93 mg/day; about 94 mg/day; about 95 mg/day; about 96 mg/day; about 97
  • such dosages for an adolescent independently ranging from: about 1 mg/day to about 45 mg/day; about 1 mg/day to about 50 mg/day; about 5 mg/day to about 45 mg/day; about 5 mg/day to about 50 mg/day; about 10 mg/day to about 45 mg/day; about 15 mg/day to about 45 mg/day; about 20 mg/day to about 45 mg/day; about 25 mg/day to about 45 mg/day; about 30 mg/day to about 45 mg/day; about 35 mg/day to about 45 mg/day; about 35 mg/day to about 40 mg/day or; independently dosages of about 35 mg/day; about 35 mg/day; about 37 mg/day; about 38 mg/day; about 39 mg/day; about 40 mg/day; about 41 mg/day; about 42 mg/day; about 43 mg/day; about 44 mg/day or about 45 mg/day.
  • the invention relates to a method of treatment of Duchenne muscular dystrophy (DMD) using embodiments of the compositions and dosages described herein.
  • DMD Duchenne muscular dystrophy
  • the invention relates to a method of treatment of Becker muscular dystrophy using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of myotonic muscular dystrophy using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of congenital muscular dystrophy using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of Emery-Dreifuss muscular dystrophy using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of facioscapulohumeral muscular dystrophy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of limb-girdle muscular dystrophy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of distal muscular dystrophy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of oculopharyngeal muscular dystrophy using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of amyotrophic lateral sclerosis (ALS) using embodiments of the compositions and dosages described herein.
  • ALS amyotrophic lateral sclerosis
  • the invention relates to a method of treatment of ataxia using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of Friedreich's ataxia using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of spinocerebellar ataxias 1 (SCA1) using embodiments of the compositions and dosages described herein.
  • SCA1 spinocerebellar ataxias 1
  • the invention relates to a method of treatment of Batten disease.
  • the invention relates to a method of treatment of neuronal ceroid lipofuscinoses (NCL) using embodiments of the compositions and dosages described herein.
  • NCL neuronal ceroid lipofuscinoses
  • the invention relates to a method of treatment of infantile NCL (INCL) using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of late infantile NCL (LINCL) using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of juvenile NCL (JNCL) using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of adult NCL (ANCL) using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of Alzheimer's disease using embodiments of the compositions and dosages described herein.
  • dosages independently ranging from: 1 mg/day to 45 mg/day; 5 mg/day to 45 mg/day; 10 mg/day to 45 mg/day; 15 mg/day to 45 mg/day; 20 mg/day to 45 mg/day; 25 mg/day to 45 mg/day; 30 mg/day to 45 mg/day; 35 mg/day to 45 mg/day; 35 mg/day to 40 mg/day or ; independently dosages of 31 mg/day; 32 mg/day; 33 mg/day; 34 mg/day; 35 mg/day; 36 mg/day; 37 mg/day; 38 mg/day; 39 mg/day or 40 mg/day.
  • such dosages independently ranging from: about 1 mg/day to about 45 mg/day; about 5 mg/day to about 45 mg/day; about 10 mg/day to about 45 mg/day; about 15 mg/day to about 45 mg/day; about 20 mg/day to about 45 mg/day; about 25 mg/day to about 45 mg/day; about 30 mg/day to about 45 mg/day; about 35 mg/day to about 45 mg/day; about 35 mg/day to about 40 mg/day or; independently dosages of about 31 mg/day; about 32 mg/day; about 33 mg/day; about 34 mg/day; about 35 mg/day; about 36 mg/day; about 37 mg/day; about 38 mg/day; about 39 mg/day or about 40 mg/day.
  • the invention relates to a method of treatment of early-onset Alzheimer's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of late- onset Alzheimer's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of familial Alzheimer's disease (FAD) using embodiments of the compositions and dosages described herein.
  • FAD familial Alzheimer's disease
  • the invention relates to a method of treatment of optic neuritis (ON) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of an autism spectrum disorder (ASD) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of Rett syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of Angelman's syndrome using embodiments of the compositions and dosages described herein.
  • ASD autism spectrum disorder
  • the invention relates to a method of treatment of Parkinson's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of idiopathic Parkinson's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of vascular parkinsonism using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of dementia with Lewy bodies using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of inherited Parkinson's diseases using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of drug-induced Parkinsonism using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of juvenile Parkinson's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of atypical parkinsonism using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of Wolfram syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of diabetes issues associated with Wolfram syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing issues associated with Wolfram syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of vision issues associated with Wolfram syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of ataxia associated with Wolfram syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of neurodegeneration associated with Wolfram syndrome using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of spinal muscular atrophy (SMA) type III using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of SMA type IV using embodiments of the compositions and dosages described herein.
  • SMA spinal muscular atrophy
  • the invention relates to a method of treatment of hearing loss using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing loss due to noise using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing loss due to blast noise using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing loss due to high noise using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of aging related hearing loss using embodiments of the compositions and dosages described herein.
  • the invention relates to a method of treatment of drug induced hearing loss using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of genetic hearing loss using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing loss due to concussion using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing loss due to traumatic brain injury (TBI) using embodiments of the compositions and dosages described herein.
  • TBI traumatic brain injury
  • the unit dose is delivered intravenously. In some embodiments, the unit dose is delivered by means of an intravenous drip along with saline.
  • the unit dose is delivered by means of an intravenous drip along with saline, other medications, vitamins and/or nourishment. In some embodiments, the unit dose is delivered subcutaneously. In some embodiments, the unit dose is delivered topically. In some embodiments, the unit dose is delivered transdermally. In some embodiments, the unit dose is in the form of a patch.
  • the dose may be administered as a single daily dose, a twice-daily dose, three times daily, or more frequently.
  • the dose may be administered three times weekly, twice weekly, once weekly, or less frequently.
  • administration frequency may be between 1 and 5 times a day.
  • administration frequency may be between 2 and 4 times a day.
  • administration frequency may be at least 3 times a day.
  • administration frequency may be twice a day.
  • administration frequency may be once a day.
  • administration frequency may be less frequent than once a day.
  • administration frequency may be once every 2 days or once every 3 days or once every 4 days or once every 5 days or once every 6 days.
  • administration frequency may be once a week.
  • administration frequency may change with time, starting at a certain rate, such as once or twice a day, and then decreasing to less frequently, such as once every 2 days or once every 3 days, or once a week, after the first day of treatment.
  • administration frequency may change with time, starting at a certain rate, such as once or twice a day, and then decreasing to less frequently, such as once every 2 days or once every 3 days, or once a week, after the first two or three days of treatment.
  • administration frequency may change with time, starting at a certain rate, such as once or twice a day, and then decreasing to less frequently, such as once every 2 days or once every 3 days, or once a week, after the first week of treatment.
  • administration frequency may be on demand, as therapeutic treatment is required or desired.
  • the unit dose may also be adjusted based upon the size of the patient.
  • the numbers provided herein are based upon a 60 kg patient.
  • the same therapy could be provided for a smaller or larger sized patient, by respectively reducing or increasing the dose size.
  • a 20 kg child patient would need a much smaller dose than a 60 kg adult patient.
  • Formulation approaches are employed such as controlled release technologies (polymers, liposomes, etc.) to achieve once a day PK profile for DNP.
  • DNP prodrugs and bioprecursors with linkers containing open functional groups are synthesized, which allows conjugation of each of these entities to nanoparticles, such as dendrimers, in order to modulate the pharmacokinetics of the molecule to enable "trickle" drug delivery.
  • Such DNP prodrugs and bioprecursors are delivered as depot nanoparticle formulation that release DNP in a slow, sustained fashion at low doses, compared to dose and release of DNP alone, to avoid possible toxicity issues.
  • the in vitro stability, in vivo plasma release kinetics and PK profiles are evaluated.
  • LC/MS/MS is used to analyze plasma DNP released from the various prodrug-nanoparticle formulations to determine the PK profile of DNP release in the rat model.
  • 2,4-DNP is an uncoupler organic compound biochemically active, inhibiting energy (ATP) production in cells with mitochondria. It has been used for treatment of obesity, but its abuse as a dieting agent has led to fatal severe side-effects.
  • the factor that limits the use of increasing doses of DNP is an excessive rise in body temperature due to the heat produced during uncoupling. Accordingly, DNP overdose will cause fatal hyperthermia, with body temperature rising to a fatally high temperature leading to death. It for the later severe adverse effect, that clinical doses were slowly titrated according to patient's tolerance. Therefore, a prodrug design of 2,4-DNP with a better PK will help to deliver 2,4-DNP in lower doses into the body and prevents over dosage.
  • the 11-38 prodrug was synthesized as a drug delivery system in which the end goal was to achieve release of its parent drug (2,4-DNP) in the live plasma.
  • This study investigates the in vitro chemical and enzymatic stability of 11-38 and pharmacokinetic (PK) profile of 11-38 and its parent compound (i.e., 2,4-DNP-released from 11-38).
  • Example 1 In vitro chemical and enzymatic stability study of 11-38
  • GI Stability in simulated gastric fluid (USP, 37 °C)
  • GI Stability in simulated intestinal fluid (USP, 37 °C)
  • Plasma Stability in rat and human plasma (37 °C)
  • HPLC analysis was carried out on an Agilent 1200 Infinity Series Quatpump, equipped with a photodiode array detector and a computer integrating apparatus.
  • An isocratic method with a mobile phase consisting of water/acetonitrile (70:30) containing 0.05% formic acid in each was used.
  • a flow rate of 0.9 mL/min was used and detection was carried out at a UV wavelength of 250 nm.
  • Hydrochloric acid, pH 1.2 buffer was prepared.
  • 11-38 (2.5 mg) was dissolved in 0.125 mL of DMSO (5%). Reactions were initiated by adding 11-38 dissolved in DMSO slowly and gradually to a total volume of 2.375 mL of HCl buffer, pH 1.2 (Table 1) in a Franz cell diffusion chamber preheated to 37 °C. The solution was mixed for 30 sec every half an hour using magnetic stirrer. Samples of 20 ⁇ L (20 ⁇ g/mL of 11-38) were collected at 0, 1, 2, 4, 6 and 8 h. Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 ⁇ ⁇ of the supernatant was injected into the FIPLC spectrometer for detection of 2,4-D P and 11-38 in HCl buffer, pH 1.2.
  • Table 1 Formulation of 11-38 in HCl buffer, pH 1.2.
  • Formulation of 11-38 in phosphate buffer (PB) to formulate 1 mg/mL of 11-38 in PB, 2.6 mg of 11-38 was formulated in 0.13 mL of DMSO (i.e. 5%) and added slowly and gradually to a total volume of 2.47 mL of preheated PB (Table 2) in a Franz cell diffusion chamber preheated to 37 °C. The solution was mixed for 30 sec every half an hour using magnetic stirrer. Samples of 20 (20 ug/mL of 11-38) were collected at 0, 0.5, 1, 2, 4, 6 and 8 h. Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 ⁇ of the supernatant was injected into the HPLC spectrometer.
  • DMSO i.e. 5%
  • Table 2 Formulation of 11-38 in PB. Weight of 11-38 Total Volume PBS + DMSO (mL) DMSO (5%) (mL) PB (mL)
  • Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 ⁇ of the supernatant was injected into the HPLC spectrometer.
  • Table 3 Formulation of 11-38 in SGF, pH 1.2.
  • 11-38 is stable in the SGF, predicting stability of 11-38 in vivo in the gastric fluid under acidic conditions for increasing systemic bioavailability.
  • Formulation of 11-38 in rat plasma to prepare 1 mg/mL of 11-38 in rat plasma, 2.4 mg of 11-38 was formulated in DMSO (5%) and added slowly and gradually to a total volume of 2.28 mL of premixed rat plasma (80% + PBS 15%, Table 5) in a Franz cell diffusion chamber preheated to 37 °C. The solution was mixed for 30 sec every half an hour using magnetic stirrer. Samples of 20 ⁇ L ⁇ (20 ⁇ g/mL of ⁇ -38) were collected at 0, 1, 3, 4, 5, 20, 23, and 24 h ( Figures 13 and 14).
  • Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 ⁇ of the supernatant was injected into the HPLC spectrometer.
  • Table 5 Formulation of 11-38 in rat plasma.
  • Formulation of 11-38 in human plasma to prepare 1 mg/mL of 11-38, 2.3 mg of 11-38 was formulated in DMSO (5%) and added slowly and gradually to a total volume of 2.185 mL of premixed human plasma (80% + PBS 15%, see Table 6) in a Franz cell diffusion chamber preheated to 37 °C. The solution was mixed for a min every half an hour using magnetic stirrer. Samples of 20 ⁇ (20 ⁇ g/mL of 11-38) were collected at 0, 0.5, 1, 2, 4, 6 and 8 h. Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 ⁇ of the supernatant was injected into the FIPLC spectrometer.
  • Table 6 Formulation of 11-38 in human plasma.
  • PK pharmacokinetic
  • rats were observed for signs of local infection at surgical sites, for hair yellowing, for presence of blood around the nose or eyes, for indications of lessened appetite, and for signs of lessened or absent fecal activity.
  • IV or oral dosing was performed and blood samples (0.15 mL) were collected at 0, 5, 15, 30, 45, 60, 120, 240 and 480 min. Plasma samples were prepared and analysis was run using a LC/MS/MS spectrometry.
  • 2,4-DNP was dissolved in a phosphate-saline buffer solution, pH 7.4 containing 5% DMSO and 20% PEG-400 and filtered through a 0.2- ⁇ filter.
  • rats were gavaged with 5 mg/kg in a total volume of 8 mL/kg from a stock solution containing 0.625/mL of 2,4-DNP.
  • a total volume of 0.8 mL/kg was used at a dose of 1 mg/kg from a stock solution containing 1.25 mg/mL.
  • a total volume of 0.8 mL/kg was used at a dose of 1.6 mg/kg (eq. to 1 mg/kg of 2,4-DNP).
  • stock solutions of 11-38 containing eq. to 1, 5 and 25 mg/mL of 2,4-DNP were prepared and administered to rats at final doses eq. to 1, 5 and 25 mg/kg of 2,4-DNP, respectively.
  • An oral dose of 8 mg/kg of 11-38 (eq. to 5 mg/kg) was dissolved in a phosphate-saline buffer solution, pH 7.4 containing 5% DMSO and 20% PEG- 400, while a dose of 40 mg/kg (eq.
  • blood samples (0.15 mL) were collected at 0, 5, 15, 30, 45, 60, 120, 240 and 480 min. The withdrawn blood was replaced with heparinized saline (0.15 mL). Blood samples were centrifuged at 10,000 rpm for 10 min at room temperature, and plasma samples were prepared and analysis was run using a sensitive LC/MS/MS spectrometry method (see below).
  • Blood samples (0.15 mL) were collected at 0, 5, 15, 30, 45, 60, 120, 240 and 480 min. Plasma samples were prepared and 2,4-DNP, 11-38 and 2,4-DNP-released from 11-38 concentrations were quantitated using the LC/MS/MS spectrometry assay method described below.
  • control or treated plasma fortified with 10 ⁇ of 2,4-DNP-d3 (10 ⁇ g/mL) as an internal standard to which 0.3 mL of methanol followed by 0.3 mL of acetonitrile was added.
  • the mixture was vortex-mixed for 30 s and centrifuged for 10 min at 10,000 rpm at room temperature. The supernatant was transferred into 5 mL glass tubes and evaporated to dryness at 37 °C under nitrogen gas. The pellet was reconstituted with 50 ⁇ of acetonitrile, vortex-mixed for 30 sec, followed by sonication for 1 min.
  • the mass spectrometer was an Agilent quadrupole mass spectrometer operated in the multiple reaction monitoring (MRM) mode. 2,4-DNP-d3 was used as an internal standard.
  • 2,4-DNP, 11-38 and 2,4-DNP-d3 were separated using an Alltima CI 8 column, 5 ⁇ , 3.2 X 150 mm (Grace Discovery Sciences, IL, USA) equipped with a guard column: Alltima CI 8, 5 ⁇ , 4.6 x 7.5 mm (Grace Discovery Sciences, IL, USA).
  • the mobile phase consists of water with 0.005% formic acid as solvent A and acetonitrile with 0.005% formic acid as solvent B.
  • MRM transitions monitored were as follows: 2,4-DNP- m/z 183.0 /123.0, m/z 183.0/153.0, for 2,4-DNP-d3- m/z 186.0/126.0, m/z 186.0/156.0 and for 11-38- m/z 297.2/183.2.
  • Two separate standard curves of 2,4-DNP and 11-38 in rat plasma were generated and used to quantify 2,4-DNP and 11-38, respectively.
  • AUCi.v.XDoseoral (AUCi.v.XDoseoral) ' where AUC 0 rai AUCi. v , Dose ora i, and Dosei. v . represent the AUCo-inf and corresponding dose for the oral and i.v. injections of 2,4-DNP or 11-38 prodrug, respectively.
  • the bioavailability of 2,4- DNP released from 11-38 was obtained from the AUC of 2,4-DNP released from oral and i.v. administration of 11-38 using Equation 1.
  • Equation 2 is the modified form of the bioavailability expression which takes into account the time-dependent hydrolysis of 11-38 prodrug after administration to rat.
  • the best estimate for the total bioavailability includes the AUC data for released 2,4-DNP in the plasma as well.
  • Plasma concentration of 2,4-DNP vs. time after oral dosing and i.v. injection is presented in Figure 18. Following oral dosing, 2,4-DNP absorption was fast as indicated by the plasma concentration at 5 min. The half-life for 2,4-DNP was 90 ⁇ 9.9 min and 136.2 ⁇ 10.9 min for the i.v. and oral routes, respectively Table 7.
  • Figure 18 shows the plasma concentration of 2,4-DNP vs. time after a single IV injenction, or an oral dose.
  • Figures 19, 20, 21, and 22 show mean plasma concentrations vs. time profiles of 11-38, and 2,4-DNP released from its 11-38 prodrug after oral administration of eq. doses of 5, 25 (methocel), 25 (PEG-400) and 50 mg/kg of 2,4-DNP, respectively.
  • Figure 23 compares mean plasma concentrations vs. time of 2,4-DNP oral dose of 5 mg/k to 2,4-DNP released from 11-38 after oral administration of 11-38 at doses of 8, 40 (methocel), 40 (PEG-400) and 80 mg/kg [eq.
  • 11-38 prodrug was synthesized as a drug delivery system in which the end goal was to achieve release of the parent drug (2,4-DNP) in the rat plasma.
  • 2,4-DNP parent drug
  • 11-38 prodrug was stable over a 24 h (both of 11-38 and 2,4-DNP are not presented in the graph after 24 h) time course in simulated gastric fluid and simulated intestinal fluid that had been prepared by the methods of the USP.
  • 11-38 was evaluated in vivo to investigate the PK profile and relative bioavailability of 2,4-DNP-released from 11-38 and to determine the time course of plasma levels of 2,4-DNP released from 11-38 after a single oral dose of 11-38 at 8, 40 and 80 mg/kg (eq. to 5, 25 and 50 mg/kg 2,4-DNP, respectively) or an i.v. bolus dose of 1.6 mg/kg (eq. to 1 mg/kg of 2,4-DNP) and compare the data to 2,4-DNP dosed orally at a single dose of 5 mg/kg or injected i.v. at 1 mg/kg in rats.
  • 11-38 contains equimolar amounts of 2,4-DNP, it follows that an equal amount of 11-38 must have hydrolyzed in plasma unless the carbamate linkage underwent cleavage to release 2,4-DNP in the intestine and/or liver. Alternatively, 2,4-DNP may have underwent metabolism in plasma after formation from 11-38. Nonetheless, the predictions regarding in vivo stability of the 11-38 prodrug were correct, because significant levels of 2,4-DNP were observed in all of the rats after oral and i.v.
  • a one-compartment model describes i.v. dosing of 2,4-DNP and 11-38. Peak plasma level of released 2,4-DNP ( € ims : 2.2 ⁇ 1.1 ⁇ ig/mL) was detected within 5 min indicating rapid cleavage of 11-38.
  • a non-compartment model adequately describes the PK of oral 11-38 prodrug and its released 2,4-DNP. It can be shown that at any time point, the 11-38 prodrug is present at a lower concentration than 2,4-DNP, Figures 19, 20, 21, and 22, and Tables 8 and 9.
  • Example 3 PK profile of 2,4-DNP- released from DNP-piperidino
  • Table 11 PK profile of 2,4-DNP- released from DNP-piperidino after treatment with a single oral dose of DNP-piperidino equivalent to 5 mg/kg of 2,4-DNP formulated in DMSO:PEG-400:PBS (5:20:75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMAI, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof.

Description

TITLE
DNP AND DNP PRODRUG TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL, CONCUSSION, DRY EYE DISEASE, AND/OR METABOLIC
DISEASES
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 62/304,584, filed March 7, 2016, and U.S. Provisional Application No. 62/460,318, filed February 17, 2017, all of which are incorporated herein by reference in their entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to development of disease modifying treatments for reversing, slowing or preventing neuromuscular, spinal muscular atrophy (SMA) syndrome (Type I, II, III and IV), neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, hearing loss related, and/or metabolic diseases, including Wolfram Syndrome, Wolcott-Rallison syndrome, and disorders in children, adults and the elderly population. In one aspect, the treatments for neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic diseases of the CNS, hearing loss related, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, and/or metabolic diseases and disorders, including Wolfram Syndrome, and Wolcott-Rallison syndrome, relate to the use of one or more isomers of dinitrophenol (DNP). The invention also relates to synthesis of bipartite dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs, and use of the prodrugs and/or 2,3 -dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3, 5 -dinitrophenol for treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic diseases of the CNS, hearing loss related, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, and/or metabolic diseases and disorders, including Wolfram Syndrome, and Wolcott-Rallison syndrome.
BACKGROUND
[0003] Currently drug therapy to profoundly alter the time course of insidious neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases towards early death is completely absent, therefore there is a unmet medical need. For instance, current recommendations from the NCL-Foundation due to the severity of the consequences of Batten Disease, is a palliative therapy started as early as possible. Epilepsy is treated with valproate and lamotrigine, spasms with baclofen and tetrazepam, and myoclonus epilepsy with piracetam and zonisamide (leaflet given out by NCL-Stiftung).
[0004] Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's Disease) is a neurodegenerative disorder characterized by loss of neurons in the brain stem, cerebral cortex, and motor neurons of the spinal cord, that leads to progressive weakness and death within 3-5 years upon onset. For ALS, there have been a variety of treatments, and none have been proven effective to curb progression towards death, except riluzole. Riluzole extends life to a modest extent (several months) and extends the time before the patient needs ventilation support, but signs of liver toxicities (-10%) must be monitored.
[0005] Alzheimer's Disease (AD), is a disorder characterized by loss of neurons in the brain corresponding to a decline in cognition and premature death. Despite that attempts of a host drug therapies, the drugs have failed to significantly alter lifespan of the patients. Parkinson's Disease, well known for its impact on Michael J. Fox, Mohamed Ali and others, is a slow killer of dopamine producing neurons called the dopaminergic neurons. Current therapies are focused on replacing dopamine and no new advancements have been made in quite a while.
[0006] Duchene Muscular Dystrophies (DMD), a pediatric neuromuscular disease in young boys (X-Chromosome), is an aggressive disorder such that the children are in leg braces at 8 years of age and in a wheel chair at 10. The loss of the dystrophin gene affects both the brain and muscle, the only two tissues in which it is expressed. The loss of dystrophin causes osmotic swelling of the mitochondria, bursting, and muscle wasting. Other forms of ataxia, and a host of other neurodegenerative/neuromuscular-degenerative diseases, have no treatments to profoundly alter the course of disease progression towards early death. Multiple sclerosis, is an autoimmune disorder of the CNS with no known etiology. Once disease onset occurs, the myelin sheaths (insulation surrounding nerve fibers or axons) are attacked by the immune cells, causing neuronal dysfunction between the brain and bodily organs. The results is a wide range of neurological symptoms such as involuntary movements of limbs that impair walking, visual / speech impairment, dysfunction of bladder and bowel, etc. Although lifespan is only moderately shortened, MS typically begins to manifest at the age of 20-30, with symptoms progressively getting worse over time. Currently, there are a host of drugs for immune suppression, however none are "disease-modifying" for treating MS, nor do any of the drugs protect against the disease progression.
[0007] In addition to neurodegenerative and autoimmune diseases, there is an unmet medical need for treatments of developmental diseases like Angelman Syndrome (AS), a pediatric neurodevelopmental disorder associated with developmental delay, motor dysfunction, lack of speech, and epilepsy caused by mutation in an imprinting gene called ubiquitin ligase E3A (UBE3A). Similarly, Rett Syndrome, is a pediatric degenerative disease that affects young girls (X-Chromosome, boys die in-utero) and leads to death. Currently there are no therapies to treat the effects of the disease that include respiratory issues, movement issues, seizures, etc.
[0008] In addition to the useful treatment of neurodegenerative, neuromuscular, autoimmune, and developmental diseases, the pandemic of metabolic diseases has very few drug therapy options that work to the root of the problem to resolve the effects of over-nutrition and subsequently obesity. Obesity is pandemic and intractable. There are approximately 1 -billion over- weight adults worldwide, with over 300 million clinically obese. The US alone shows 35% of Americans with a BMI over 30 and 1 out of 400 with a BMI of 50 (-800,000 individuals). Obesity can lead to ectopic lipid accumulation (e.g. nonalcoholic fatty liver disease, NAFLD) and oxidative damage from reactive oxygen species. As a result, obese individuals are at increased risk for numerous other diseases, including insulin resistance, sleep apnea, hypertension, kidney disease, inflammation, knee-joint complications, depression, high blood pressure, cardiovascular disease, Type-2 diabetes (T2D), and even some cancers. While even small amount (-5%) of weight loss can yield metabolic benefits, it is difficult for most patients to achieve and sustain such weight loss. Thus, bariatric surgery is now touted as the best method to reverse obesity. Though increasingly popular, bariatric surgery often requires a permanent anatomical change to the gastrointestinal tract that essentially enforce reduced calorie intake. These procedures are associated with mortality (1/200) and short and long term morbidity such as wound complications and venous thrombosis as well as reactive hypoglycemia, micronutrient deficiency, dumping syndrome, etc. These procedures pose additional challenges in patients with extreme obesity (BMI> 50 kg/m2). Pharmaceutical approaches to remedy obesity have focused on inducing malabsorption (e.g., orlistat) or satiety (e.g., rimonobant, sibutramine) but are minimally effective (-5% body weight) and associated with significant adverse effects (e.g. steatorrhea, depression, and MI, respectively). New pharmacological therapies are needed.
[0009] Consequently, there is a profound need for improved treatments for neurodegenerative, neuromuscular, developmental, autoimmune and/or metabolic diseases.
SUMMARY OF THE INVENTION
[0010] A first aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of the CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, concussion, traumatic brain injury (TBI), drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising one or more isomers of dinitrophenol (DNP), i.e., 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP.
[0011] A second aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of the CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising a prodrug, the prodrug being selected from the group consisting of:
an amino acid (AA) ester of 2,3-D P, 2,4-D P, 2,5-D P, 2,6-D P, 3,4-D P, or 3,5- DNP (Scheme 1, Formulas I-l to 1-10; Scheme 2, Formulas II-l to 11-10; Scheme 3, Formulas III-l to III-10; Scheme 4, Formulas IV-1 to IV-10; Scheme 5, Formulas V-1 to V-10; and Scheme 6, Formulas VI-1 to VI-10);
AA esters incorporating a methylene dioxide (a formaldehyde equivalent) spacer (Scheme 1, Formulas 1-11 to 1-13; Scheme 2, Formulas 11-11 to 11-13; Scheme 3, Formulas Hill to 111-13; Scheme 4, Formulas IV-11 to IV-13; Scheme 5, Formulas V-ll to V-13; and Scheme 6, Formulas VI-11 to VI-13);
amino carbamate 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP prodrugs (Scheme 1, Formulas 1-14 to 1-17; Scheme 2, Formulas 11-14 to 11-17; Scheme 3, Formulas III- 14 to 111-17; Scheme 4, Formulas IV-14 to IV-17; Scheme 5, Formulas V-14 to V-17; and Scheme 6, Formulas VI-14 to VI-17);
amino carbonate 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP prodrugs (Scheme 1, Formulas 1-18 and 1-19; Scheme 2, Formulas 11-18 and 11-19; Scheme 3, Formulas
III- 18 and 111-19; Scheme 4, Formulas IV-18 and IV-19; Scheme 5, Formulas V-18 and V-19; and Scheme 6, Formulas VI-18 and VI-19);
phosphate analogs 1-20, 1-21, 11-20, 11-21, 111-20, 111-21, IV-20, IV-21, V-20, V-21, VI- 20, and VI-21 (Schemes 1-6);
1,3 diketo analogs 1-22 to 1-32; 11-22 to 11-32; 111-22 to 111-32; IV-22 to IV-32; V-22 to V-32; and VI-22 to VI-32 (Schemes 1-6);
carbonate and carbamate analogs 1-33 to 1-39; 11-33 to 11-39; 111-33 to 111-39; IV-33 to
IV- 39; V-33 to V-39; and VI-33 to VI-39 (Schemes 1-6);
benzoate analogs 1-40, 11-40, 111-40, IV-40, V-40, and VI-40 (Schemes 1-6);
and combinations thereof.
[0012] A third aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of the CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: a phosphate prodrug altered by introducing a water-soluble prodrug moiety into the molecule through conjugation with the free phenolic functionality.
Scheme 1
R =
Figure imgf000008_0001
Scheme 2
R =
Figure imgf000008_0002
Scheme 3 R =
Figure imgf000009_0001
Scheme 4 R =
Figure imgf000009_0002
Scheme 5
R =
Figure imgf000010_0001
Scheme 6
R =
Figure imgf000010_0002
[0013] A fourth aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of the CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: a prodrug, the prodrug being selected from the group consisting of, 2,3- D P, 2,4-D P, 2,5-D P, 2,6-D P, 3,4-D P, or 3,5-D P "Gemini" prodrugs, wherein the prodrug is represented by Formula VII:
Figure imgf000011_0001
VII
[0014] A fifth aspect of the present invention provides a method for synthesizing the composition of a prodrug for treating neurodegenerative neuromuscular diseases, developmental diseases, autoimmune diseases, traumatic diseases of CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, antidepressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. In one embodiment, the method comprises: reacting 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6- dinitrophenol, 3,4- dinitrophenol, and/or 3,5-dinitrophenol with 5-(tert- butyldimethylsiloxy)isophthaloyl dichloride (2) in the presence of pyridine/ dichloromethane to afford precursor (3); and removing the TBDMS protecting group in acetone/HCl to afford the prodrug (Scheme 7).
Scheme 7
Figure imgf000011_0002
[0015] A sixth aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: bioprecursors of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP that release 2,3- dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5- dinitrophenol after oxidative metabolism by cytochrome P-450, wherein the bioprecursors are represented by Formulas VIII and IX (Scheme 8; including synthesis route and oxidative metabolism):
Scheme 8
Figure imgf000012_0001
[0016] A seventh aspect of the present invention provides a composition for treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: D P prodrugs and bioprecursors with linkers containing open functional groups delivered as depot nanoparticle formulations that release DNP in a slow, sustained fashion at low doses compared to dose and release of DNP alone.
[0017] An eighth aspect of the present invention provides a method of treatment of neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of CNS, metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: administering to a patient in need of treatment a dose of a composition, wherein the composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol,
3.4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or
3.5- DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof, and wherein the dose of active drug is from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment or from about 0.01 mg/kg of body weight to about 25 mg/kg of body weight of the patient in need of treatment.
[0018] A ninth aspect of the present invention provides a method of treatment of Traumatic Brain Injury (TBI), Ischemic stroke, Huntington's disease (Adult-onset Huntington's, Juvenile Huntington's disease), Epilepsy (Cluster Seizures, Refractory Seizures, Atypical Absence Seizures, Atonic Seizures, Clonic Seizures, myoclonic seizures, tonic seizures, Tonic-Clonic Seizures, Simple Partial Seizures, Complex Partial Seizures, Secondary Generalized Seizures, Febrile Seizures, Nonepileptic Seizures, Gelastic and Dacrystic Seizures, and Absence Seizures), Multiple Sclerosis (MS) (relapse-remitting multiple sclerosis (RRMS), Secondary-progressive MS (SPMS), Primary-progressive MS (PPMS), and Progressive-relapsing MS (PRMS)), Lupus (Systemic Lupus Erythematosus (SLE), discoid (cutaneous), drug-induced lupus (dil) and neonatal lupus), Diabetes mellitus (Type-1 Diabetes, Type-2 Diabetes, Maturity Onset Diabetes of the Young (MODY: MODY1, MODY2, MODY3, MODY4, MODY5, MODY6, MODY7, MODY8, MODY9, MODY10, MODY11)), Nonalcoholic Steatohepatitis (NASH), Schizophrenia (Paranoid schizophrenia, Disorganized schizophrenia, Catatonic schizophrenia, Residual schizophrenia, Schizoaffective disorder), Myasthenia gravis (MG) (ocular myasthenia gravis, Congenital MG and generalized myasthenia gravis), rheumatoid arthritis (RA), Graves' disease, Guillain-Barre syndrome (GBS), Muscular Dystrophy (Duchenne Muscular Dystrophy (DMD), Becker, Myotonic, Congenital, Emery-Dreifuss, Facioscapulohumeral, Limb-girdle, Distal, and Oculopharyngeal), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Ataxia (Friedreich's Ataxia, Spinocerebellar ataxias 1 (SCA1), Spinocerebellar ataxias 2 (SCA2), Spinocerebellar ataxias 3 (SCA3), Spinocerebellar ataxias 6 (SCA6), Spinocerebellar ataxias 7 (SCA7), Spinocerebellar ataxias 11 (SCA11), Dentatorubral pallidolusyian atrophy (DRPLA) and Gluten ataxia), Batten Disease or neuronal ceroid lipofuscinoses (NCL) (infantile NCL (INCL), late infantile NCL (LINCL), juvenile NCL (JNCL) or adult NCL (ANCL)), Alzheimer's Disease (Early-onset Alzheimer's, Late-onset Alzheimer's, and Familial Alzheimer's disease (FAD)), Optic neuritis (ON), Leber's hereditary optic neuropathy (LHON), Autism Spectrum Disorders (ASD) (Asperger's Syndrome, Pervasive Developmental Disorders (PDDs), Childhood Disintegrative Disorder (CDD), and Autistic disorder), Rett syndrome, Angelman's Syndrome, Leigh disease, Prader Willi Syndrome, Fragile-X Syndrome, Depression (Major Depression, Dysthymia, Postpartum Depression, Seasonal Affective Disorder, Atypical Depression, Psychotic Depression, Bipolar Disorder, Premenstrual Dysphoric Disorder, Situational Depression), Parkinson's disease (Idiopathic Parkinson's disease, Vascular parkinsonism, Dementia with Lewy bodies, Inherited Parkinson's, Drug-induced Parkinsonism, Juvenile Parkinson's and atypical parkinsonism), Wolfram syndrome (and any associated conditions such as diabetes issues, hearing, vision, ataxia, neurodegeneration, etc.), spinal muscular atrophy (SMA; type I, II, III and IV), hearing loss due to noise (blast and high noise), aging related hearing loss, drug induced hearing loss, and/or genetic hearing loss, concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolcott-Rallison syndrome, mitochondrial diseases, developmental disorders, metabolic syndrome (increased blood pressure, high blood sugar level, excess body fat around the waist and abnormal cholesterol levels) and/or autoimmune disorders by increasing energy expenditure and/or inducing BD F mRNA expression and protein levels with DNP treatment to reverse, slow or prevent neuromuscular and/or neurodegeneration and/or muscle wasting, comprising: administering to a patient in need of treatment a dose of .01 mg/kg to 50 mg/kg, wherein the composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP; bipartite 2,3- dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5- dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules for treating neurodegenerative neuromuscular, developmental, autoimmune and/or metabolic diseases, and combinations thereof, wherein the dose of the composition is from about .01 mg/kg to 50 mg/kg of body weight of the patient in need of treatment.
[0019] A tenth aspect of the present invention relates to a method of treating neurodegenerative diseases, neuromuscular diseases, neuromuscular degenerative diseases, developmental diseases, autoimmune diseases, traumatic diseases of CNS, and/or metabolic diseases, and/or diseases related to hearing loss due to aging, noise, drug induced, and/or genetic hearing loss, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: providing instructions to administer an effective dose of DNP, or a pharmaceutically acceptable salt thereof, or any prodrug described herein, over a period sufficiently long to achieve remission of the symptoms of the disease, wherein the effective dose of the DNP and/or prodrug thereof, is instructed to be received in the dose range of 0.001 mg/kg of body weight to 50 mg/kg of body weight.
BRIEF DESCRIPTION OF THE DRAWINGS
[0020] The foregoing summary, as well as the following detailed description of embodiments of the invention, will be better understood when read in conjunction with the appended drawings and figures.
[0021] Figure 1 is a chart illustrating the comparative effect of two compounds of the invention at lowering or blocking progression of paralysis as monitored as a Clinical Score (EAE MS model comparing parent (2,4-DNP) to prodrug (11-38) at equivalent exposures of 5 mpk parent to 80 mpk prodrug for efficacy). Legend: diamond - placebo; square - 2,4-DNP 5 mpk; triangle - 11-38 8 mpk; x - 11-38 16 mpk; asterisk - 11-38 80 mpk. P values by Ordinal Regression: 2,4-DNP 5 mpk = 0.0192; 11-38 8 mpk = 0.000954; 11-38 16 mpk = 0.000124; 11-38 80 mpk = 0.00014 (results from logistic regression model using ordinal package from cran project, www. cran.r-proj ect. org).
[0022] Figure 2 is a chart illustrating the comparative effect of two compounds of the invention at preventing weight loss seen in the Placebo mice (EAE MS model comparing parent (2,4-DNP) to prodrug (11-38) at equivalent exposures of 5 mpk parent to 80 mpk prodrug for body weight changes). Legend: diamond - placebo; square - 2,4-DNP 5 mpk; triangle - 11-38 8 mpk; x - 11-38 16 mpk; asterisk - 11-38 80 mpk. All doses significant to preserving body weight. P values by Ordinal Regression: 2,4-DNP 5 mpk = 0.0188; 11-38 8 mpk < 0.0001; 11-38 16 mpk = 0.044; 11-38 80 mpk < 0.0001.
[0023] Figure 3 is a chart illustrating the comparative results of an in vivo noise exposure experiment, including DNP (2,4-DNP) and a prodrug of DNP (11-38); II-38+Noise thresholds were 5 dB, approximately 20 dB lower (better) than the Noise alone group; DNP (2,4- DNP)+Noise thresholds were 15 dB, about 10 dB lower than Noise alone suggesting that DNP (2,4-DNP) can protect against noise induced hearing loss. Legend: circle - control (0 dB); triangle (pointing down) - 11-38 (5 dB); triangle (pointing up) - 2,4-DNP (15 dB); circle (solid) - noise (25 dB).
[0024] Figure 4 illustrates the results of single crystal X-ray diffraction of 2,4-dinitrophenyl morpholine-4-carboxylate.
[0025] Figure 5 illustrates a chromatogram of 11-38 eluted at 8.04 min.
[0026] Figure 6 illustrates the equilibrium (solubility) phase of 11-38 in HC1 buffer, pH 1.2.
[0027] Figure 7 illustrates chromatograms of 2,4-DNP and 11-38 prodrug in phosphate buffer, pH 7.4, eluted at 6.854 and 8.023 min, respectively.
[0028] Figure 8 illustrates the stability of II-38 in PB buffer at pH=7.4.
[0029] Figure 9 illustrates a chromatogram of 11-38 eluted at 3.08 min in SGF.
[0030] Figure 10A illustrates the stability of 11-38 in SGF at pH=1.2.
[0031] Figure 10B illustrates the stability of DNPmorpholine in SGF at pH=l .2.
[0032] Figure 11 illustrates a chromatogram of 11-38 eluted at 2.187 min in SIF. [0033] Figure 12A illustrates the stability of 11-38 in SIF at pH=6.8.
[0034] Figure 12 B illustrates the stability of DNPmorpholino in SIF at pH=6.8.
[0035] Figure 13 illustrates 11-38 and 2,4-DNP released from 11-38 in rat plasma. Legend: diamond - 2,4-DNP; circle - 11-38.
[0036] Figure 14 illustrates 11-38 and 2,4-DNP released from 11-38 in human plasma. Legend: diamond - 2,4-DNP; circle - 11-38.
[0037] Figure 15 illustrates the calibration standard of 2,4-DNP in acetonitrile.
[0038] Figure 16 illustrates the calibration standard of 2,4-DNP in rat plasma, n = 5.
[0039] Figure 17 illustrates the standard curve of 11-38 in rat plasma, n=3.
[0040] Figure 18 illustrates the plasma concentration of 2,4-DNP vs. time after a single iv injection of 1 mg/kg (n = 3) or an oral dose of 5 mg/kg (n =4) of 2,4-DNP in rats. Legend: diamond - 2,4-DNP, iv, 1 mg/Kg; circle - 2,4-DNP, oral, 5 mg/Kg.
[0041] Figure 19 illustrates the mean plasma concentrations vs. time of 11-38 and 2,4-DNP released from 11-38 prodrug after administration of an oral dose of 8 mg/kg of 11-38 (eq. to 5 mg/kg of 11-38). Legend: diamond - 11-38, oral: eq. 5 mg/Kg; square - 2,4-DNP, released from II- 38, oral.
[0042] Figure 20 illustrates the mean plasma concentrations vs. time of 11-38 and 2,4-DNP released from 11-38 prodrug after administration of an oral dose of 40 mg/kg of 11-38 (eq. to 25 mg/kg of 11-38 formulated in methocel). Legend: diamond - 2,4-DNP, released from 11-38, oral; square - 11-38, oral: eq. 25 mg/Kg (methocel).
[0043] Figure 21 illustrates the mean plasma concentrations vs. time of 11-38 and 2,4-DNP released from 11-38 prodrug after administration of an oral dose of 40 mg/kg of 11-38 (eq. to 25 mg/kg of 11-38 formulated in PEG-400). Legend: diamond - 2,4-DNP, released from 11-38, oral; square - 11-38, oral: eq. 25 mg/Kg (PEG-400).
[0044] Figure 22 illustrates the mean plasma concentrations vs. time of 11-38 and 2,4-DNP released from 11-38 prodrug after administration of an oral dose of 80 mg/kg of 11-38 (eq. to 50 mg/kg of 11-38). Legend: diamond - 2,4-DNP, released from 11-38, oral; square - 11-38, oral: eq. 50 mg/Kg.
[0045] Figure 23 illustrates the mean plasma concentration of 2,4-DNP and 2,4-DNP released from 11-38 after administration of 2,4-DNP at a dose of 5 mg/kg and 11-38 at doses of 8, 40 (methocel), 40 (PEG-400) and 80 mg/kg (eq. to 5, 25 (methocel), 25 (PEG-400)] and 50 mg/kg of DNP), respectively, n = 4. Legend: diamond - 2,4-DNP, oral, 5 mg/Kg; square (red) -
2.4- DNP, released from 11-38 eq. 5 mg; triangle - 2,4-DNP, released from 11-38 eq. 25 mg/Kg (methocel); square (purple) - 2,4-DNP, released from 11-38 eq. 50 mg/Kg; square (blue) - 2,4- DNP, released from 11-38 eq. to 25 mg/Kg (PEG-400).
DETAILED DESCRIPTION OF THE EMBODIMENTS OF THE INVENTION
Definitions:
[0046] Hereinafter, unless defined otherwise, the term "prodrug" refers to an inactive or partially active drug that is metabolically changed in the body to an active drug.
[0047] Hereinafter, the term "depot nanoparticle formulation" unless defined otherwise refers to a biodeliverable nanoparticle, comprising a broad range of 1) bipartite 2,3- dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5- dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs, 2) Gemini prodrugs and 3) bioprecursor molecules for treating neurodegenerative or metabolic diseases.
[0048] Hereinafter, unless otherwise defined, the term "about" means plus or minus 10% of the value referenced. For example, "about 1 mg/kg" means 0.9 mg/kg to 1.1 mg/kg.
[0049] Hereinafter, unless defined otherwise, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol,
2.5- dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3, 5 -dinitrophenol are represented by 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP; the prodrug of each isomer is represented in formulas I- VI; being selected from the group consisting of:
an amino acid (AA) ester of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP (Scheme 1, Formulas I-l to 1-10; Scheme 2, Formulas II-l to 11-10; Scheme 3, Formulas III-l to III-10; Scheme 4, Formulas IV-1 to IV-10; Scheme 5, Formulas V-1 to V-10; and Scheme 6, Formulas VI-1 to VI-10);
AA esters incorporating a methylene dioxide (a formaldehyde equivalent) spacer (Scheme 1, Formulas 1-11 to 1-13; Scheme 2, Formulas 11-11 to 11-13; Scheme 3, Formulas Hill to 111-13; Scheme 4, Formulas IV-11 to IV-13; Scheme 5, Formulas V-11 to V-13; and Scheme 6, Formulas VI-11 to VI-13);
amino carbamate 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP prodrugs (Scheme 1, Formulas 1-14 to 1-17; Scheme 2, Formulas 11-14 to 11-17; Scheme 3, Formulas III- 14 to 111-17; Scheme 4, Formulas IV-14 to IV-17; Scheme 5, Formulas V-14 to V-17; and Scheme 6, Formulas VI-14 to VI-17);
amino carbonate 2,3-D P, 2,4-D P, 2,5-D P, 2,6-D P, 3,4-D P, or 3,5-D P prodrugs (Scheme 1, Formulas 1-18 and 1-19; Scheme 2, Formulas 11-18 and 11-19; Scheme 3, Formulas
III- 18 and 111-19; Scheme 4, Formulas IV-18 and IV-19; Scheme 5, Formulas V-18 and V-19; and Scheme 6, Formulas VI-18 and VI-19);
phosphate analogs 1-20, 1-21, 11-20, 11-21, 111-20, 111-21, IV-20, IV-21, V-20, V-21, VI- 20, and VI-21 (Schemes 1-6);
1,3 diketo analogs 1-22 to 1-32; 11-22 to 11-32; 111-22 to 111-32; IV-22 to IV-32; V-22 to V-32; and VI-22 to VI-32 (Schemes 1-6);
carbonate and carbamate analogs 1-33 to 1-39; 11-33 to 11-39; 111-33 to 111-39; IV-33 to
IV- 39; V-33 to V-39; and VI-33 to VI-39 (Schemes 1-6);
benzoate analogs 1-40, 11-40, 111-40, IV-40, V-40, and VI-40 (Schemes 1-6);
and combinations thereof.
[0050] In one embodiment, the invention provides compositions and methods for treating neurodegenerative diseases such as Alzheimer's disease, Parkinson, and Huntington's disease. It is believed that the complete lack of historic success is due to most pharmaceutical industries focusing on a downstream event, such as plaques/tangles, whereas the issue is likely upstream at the mitochondria causing high cellular stress. In studies where a mouse model of Alzheimer's disease was treated with DNP under chronic treatment, short term memory was strikingly improved in the Morris Water Maze, having a profound impact on disease progression. Data from a recent study in a Parkinson model using 6-OHDA to destroy the dopaminergic neurons showed that treatment with DNP, had a positive protective effect with chronic treatment.
[0051] In one embodiment, the invention provides compositions and methods for treating Huntington's disease. In a model of Huntington's disease, treatment with DNP for over 17- weeks show protection on the spiny neurons, which receive dopamine, therefore the compounds and drugs of the invention should be ideal for the treatment of this disease. DNP should prevent muscle loss since it reduces mitochondrial osmotic swelling by reducing intra-mitochondrial calcium concentration and inducing BDNF, which is a myokine (muscle protectant) outside of the brain. [0052] In one embodiment, the invention provides compositions and methods for treating cognitive disorders associated with DMD in the CNS. 2,4-D P should for example help the cognitive disorders associated with DMD in the CNS.
[0053] In one embodiment, the invention provides compositions and methods for treating Angelman and Rett syndromes. It is believed that oxidative stress is playing a role impairing neurodevelopment, however the fact that DNP prevents overt ROS formation, induces BDNF, reduces seizure duration activity, can have a therapeutic effect in subjects afflicted by these disorders, including children.
[0054] In one embodiment, the invention provides compositions and methods for treating obesity. The key to effective weight loss or mechanisms to reduce ectopic fat to improve insulin resistance, fatty liver diseases, Type-2 diabetes, cardiovascular disease, etc., without necessarily marked changes in body weight, is to take the body out of balance regarding energy-in to energy- out, and maintain a mechanism that wastes energy. Thus, new pharmacological therapies focused on enhancing energy expenditure, that address metabolic disease and over-nutritional phenotypes, could potentially have a dramatic effect on the lives of individuals afflicted by these diseases.
[0055] Preliminary studies demonstrate (1) ROS reducing capacity and lifespan increase by mitochondrial chemical uncoupler treatment in wildtype mice, and (2) the improved metabolic profile, suggesting that chronic mitochondrial chemical uncoupling treatment is safe and improves health outcomes at low doses (-1-50 mg/day). These preliminary studies demonstrate the rationale for evaluating a mitochondrial chemical uncoupler like DNP and a prodrug formulation for extended release in representative animal models of neurodegenerative, neuromuscular, developmental, autoimmune and/or metabolic diseases, and other cases of overt ROS production, such as during stroke or ischemic events in humans.
[0056] In one embodiment, the compositions and methods of the invention relate to a pharmacological intervention that abolishes overt ROS production and improves the quality of the mitochondrial population by mitophagy, induces Brain Derived Neurotrophin Factor (BDNF), increases cAMP, and/or remodels cellular expression. In one embodiment, a drug of the invention thus becomes "disease modifying." In one embodiment, a prodrug of DNP (11-38) was administered to a mouse model of Multiple Sclerosis, called the EAE, 7-days after induction of the MOG35.55 myelin peptide. The ProDrug of DNP, 11-38, was administered at multiples of exposure to 2,4-D P or DNP. Both compounds provided a striking effect at lowering or blocking progression of paralysis as monitored as a Clinical Score (Figure 1), as well as preventing weight loss seen in the Placebo mice (Figure 2). Even though DNP historically was used in the 1930's for weight loss at high doses, here it is shown that it can paradoxically be repositioned to prevent wasting associated with neurodegenerative/autoimmune diseases at low doses.
[0057] In one embodiment, the compositions described herein may be used to treat hearing loss. In one such embodiment, 2, 4-dinitrophenol (DNP) may be used at a dose range independently selected from: 1 mg/day to 50 mg/day; 1 mg/day to 45 mg/day; 1 mg/day to 40 mg/day; 1 mg/day to 35 mg/day; 1 mg/day to 30 mg/day; 1 mg/day to 25 mg/day; 1 mg/day to 20 mg/day; 1 mg/day to 15 mg/day; 1 mg/day to 10 mg/day; 1 mg/day to 5 mg/day; 1 mg/day to 4 mg/day; 1 mg/day to 3 mg/day; 1 mg/day to 2 mg/day; 2 mg/day to 50 mg/day; 2 mg/day to 45 mg/day; 2 mg/day to 40 mg/day; 2 mg/day to 35 mg/day; 2 mg/day to 30 mg/day; 2 mg/day to 25 mg/day; 2 mg/day to 20 mg/day; 2 mg/day to 15 mg/day; 2 mg/day to 10 mg/day; 2 mg/day to 5 mg/day; 2 mg/day to 4 mg/day; 2 mg/day to 3 mg/day; 0.5 mg/day to 10 mg/day; 0.5 mg/day to 9 mg/day; 0.5 mg/day to 8 mg/day; 0.5 mg/day to 7 mg/day; 0.5 mg/day to 6 mg/day; 0.5 mg/day to 5 mg/day; 0.5 mg/day to 4 mg/day; 0.5 mg/day to 3 mg/day; 0.1 mg/day to 10 mg/day; 0.1 mg/day to 9 mg/day; 0.1 mg/day to 8 mg/day; 0.1 mg/day to 7 mg/day; 0.1 mg/day to 6 mg/day; 0.1 mg/day to 5 mg/day; 0.1 mg/day to 4 mg/day; 0.1 mg/day to 3 mg/day. In one such embodiment, 2, 4-dinitrophenol (DNP) may be used at a dose range independently selected from: about 1 mg/day to about 50 mg/day; about 1 mg/day to about 45 mg/day; about 1 mg/day to about 40 mg/day; about 1 mg/day to about 35 mg/day; about 1 mg/day to about 30 mg/day; about
1 mg/day to about 25 mg/day; about 1 mg/day to about 20 mg/day; about 1 mg/day to about 15 mg/day; about 1 mg/day to about 10 mg/day; about 1 mg/day to about 5 mg/day; about 1 mg/day to about 4 mg/day; about 1 mg/day to about 3 mg/day; about 1 mg/day to about 2 mg/day; about
2 mg/day to about 50 mg/day; about 2 mg/day to about 45 mg/day; about 2 mg/day to about 40 mg/day; about 2 mg/day to about 35 mg/day; about 2 mg/day to about 30 mg/day; about 2 mg/day to about 25 mg/day; about 2 mg/day to about 20 mg/day; about 2 mg/day to about 15 mg/day; about 2 mg/day to about 10 mg/day; about 2 mg/day to about 5 mg/day; about 2 mg/day to about 4 mg/day; about 2 mg/day to about 3 mg/day; about 0.5 mg/day to about 10 mg/day; about 0.5 mg/day to about 9 mg/day; about 0.5 mg/day to about 8 mg/day; about 0.5 mg/day to about 7 mg/day; about 0.5 mg/day to about 6 mg/day; about 0.5 mg/day to about 5 mg/day; about 0.5 mg/day to about 4 mg/day; about 0.5 mg/day to about 3 mg/day; about 0.1 mg/day to about 10 mg/day; about 0.1 mg/day to about 9 mg/day; about 0.1 mg/day to about 8 mg/day; about 0.1 mg/day to about 7 mg/day; about 0.1 mg/day to about 6 mg/day; about 0.1 mg/day to about 5 mg/day; about 0.1 mg/day to about 4 mg/day; about 0.1 mg/day to about 3 mg/day.
[0058] In another such embodiment to treat hearing loss, a prodrug of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, as described herein, may be used at a dose range to achieve equivalent exposure (AUC) to DNP. In one such embodiment, a prodrug of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, as described herein, may be used at a dose range independently selected from: 20 mg/day to 800 mg/day; 20 mg/day to 750 mg/day; 20 mg/day to 700 mg/day; 20 mg/day to 600 mg/day; 20 mg/day to 700 mg/day; 20 mg/day to 600 mg/day; 20 mg/day to 500 mg/day; 30 mg/day to 800 mg/day; 30 mg/day to 700 mg/day; 30 mg/day to 600 mg/day; 30 mg/day to 500 mg/day; 30 mg/day to 400 mg/day; 30 mg/day to 360 mg/day; 30 mg/day to 300 mg/day; 30 mg/day to 250 mg/day; 30 mg/day to 200 mg/day; 30 mg/day to 150 mg/day; 30 mg/day to 100 mg/day; 35 mg/day to 360 mg/day; 40 mg/day to 300 mg/day; 50 mg/day to 250 mg/day; or 60 mg/day to 200 mg/day; 5 mg/day to 500 mg/day; 5 mg/day to 400 mg/day; 5 mg/day to 300 mg/day; 5 mg/day to 200 mg/day; 5 mg/day to 100 mg/day; 5 mg/day to 50 mg/day; 5 mg/day to 40 mg/day; or 5 mg/day to 30 mg/day. In another such embodiment, a prodrug of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, as described herein, may be used at a dose range independently selected from: about 20 mg/day to about 800 mg/day; about 20 mg/day to about 750 mg/day; about 20 mg/day to about 700 mg/day; about 20 mg/day to about 600 mg/day; about 20 mg/day to about 700 mg/day; about 20 mg/day to about 600 mg/day; about 20 mg/day to about 500 mg/day; about 30 mg/day to about 800 mg/day; about 30 mg/day to about 700 mg/day; about 30 mg/day to about 600 mg/day; about 30 mg/day to about 500 mg/day; about 30 mg/day to about 400 mg/day; about 30 mg/day to about 360 mg/day; about 30 mg/day to about 300 mg/day; about 30 mg/day to about 250 mg/day; about 30 mg/day to about 200 mg/day; about 30 mg/day to about 150 mg/day; about 30 mg/day to about 100 mg/day; about 35 mg/day to about 360 mg/day; about 40 mg/day to about 300 mg/day; about 50 mg/day to about 250 mg/day; or about 60 mg/day to about 200 mg/day; about 5 mg/day to about 500 mg/day; about 5 mg/day to about 400 mg/day; about 5 mg/day to about 300 mg/day; about 5 mg/day to about 200 mg/day; about 5 mg/day to about 100 mg/day; about 5 mg/day to about 50 mg/day; about 5 mg/day to about 40 mg/day; or about 5 mg/day to about 30 mg/day.
[0059] Overt reactive oxygen species (ROSs) can be produced due to noise and certain ototoxic drugs that can damage the hair cells of the ear, resulting in either temporary or permanent hearing loss. Exposure to blast waves and continuous noise not only damaged the inner ear, but caused cell death in the hippocampus, suppressed neurogenesis and impaired memory function. Aging as well can manifest in mitochondrial dysfunction leading to hearing loss. It is emerging that attempts to treat hearing loss by targeting downstream issues is not very effective. In one embodiment, the compositions and methods of the invention relate to targeting oxidative stress upstream at the mitochondria that may be causative for many disorders. There have been a variety of attempts to lower cellular stress, such as administering anti-oxidants, however these drugs have limited tissue penetration into the brain and lower ROSs after they have been formed. We have observed that wildtype mice chronically treated with an extraordinarily low dose of 2, 4-dinitrophenol resulted in treated mice living longer than untreated mice. While not being bound to theory, it is postulated that DNP modulates the mitochondrial membrane potential having a significant impact at preventing ROS formation in isolated mitochondria and in the treated wildtype mice. DNP treatment 3-hours post-ischemia reduced cerebral infarct volume 40% by protecting the penumbra or "threaten tissue" and could provide similar benefits after a blast to protect inner hair cells from eminent cell death. DNP comes with the benefits of known risks as it was used 80-years ago for weight loss at high doses (-300 mg) in over 100,000 people, however shown recently in models of neurodegeneration at very low hormetic doses to improve cognition and learning. The pharmacology, which is pleiotrophic, appears to provide broad neuroprotection by lowering ROS/mTOR and increasing protective factors such as cAMP, CREB, and BDNF, could be useful for treating hearing loss. Despite DNP tainted past and common incorrect dogma of being toxic, a 28-day toxicity studies was ran and demonstrated that low doses of DNP are not toxic, have at least a lOx Safety Index with no inhibition to ion channels, CYP, Caco-2, etc., and provide therapeutically striking benefits in host CNS models representing diverse indications, thereby suggesting possible merit for inner ear and central brain hearing mitochondrial dysfunction.
Chemical Synthesis: [0060] In one embodiment, prodrugs which contain a self-cleavable spacer and a water- solubilizing moiety are synthesized, to maintain the prodrug in a soluble form in the GI tract fluids, and which will then gradually revert to the parent drug without precipitation. In some embodiments, these compounds are 1,3 diketo analogs 1-22 to 1-32; 11-22 to 11-32; 111-22 to III- 32; IV-22 to IV-32; V-22 to V-32; and VI-22 to VI-32 (Schemes 1-6). The increased solubility of the prodrug and the high membrane permeability of the well-dispersed parent drug will provide a higher driving force for it to be readily absorbed via the intestinal lumen. Conversion of prodrug-to-parent drug involves a chemical cleavage at the self-cleavable spacer through a unique intramolecular cyclization-elimination reaction via imide formation under physiological conditions. The conversion time is tunable by modifying the structure of the solubilizing moiety, the bond length of the spacer, the pKa of the amine group, and the pH of the medium. Although the in silico predicted bioavailability may be low, it is likely to be much higher when one takes into account the unique pH-dependent and tunable hydrolysis mechanism. Also, the generation of parent drug does not rely on enzyme action, which may be an advantage in dealing with genetic variability associated with enzymatic prodrug hydrolysis in plasma.
[0061] In other embodiments, one or more isomers of dinitrophenol, i.e., 2,3-D P, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, and/or a broad range of 1) bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3, 5 -dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs, 2) Gemini prodrugs and 3) bioprecursor molecules, are used for treating neurodegenerative or metabolic diseases.
[0062] Synthesis of bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6- dinitrophenol, 3,4- dinitrophenol, or 3, 5 -dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs may be performed; the prodrug being selected from the group consisting of:
an amino acid (AA) ester of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP (Scheme 1, Formulas I-l to 1-10; Scheme 2, Formulas II-l to 11-10; Scheme 3, Formulas III-l to III-10; Scheme 4, Formulas IV-1 to IV-10; Scheme 5, Formulas V-l to V-10; and Scheme 6, Formulas VI-1 to VI-10);
AA esters incorporating a methylene dioxide (a formaldehyde equivalent) spacer (Scheme 1, Formulas 1-11 to 1-13; Scheme 2, Formulas 11-11 to 11-13; Scheme 3, Formulas Hill to 111-13; Scheme 4, Formulas IV-11 to IV-13; Scheme 5, Formulas V-ll to V-13; and Scheme 6, Formulas VI-11 to VI-13);
amino carbamate 2,3-D P, 2,4-D P, 2,5-D P, 2,6-D P, 3,4-D P, or 3,5-D P prodrugs (Scheme 1, Formulas 1-14 to 1-17; Scheme 2, Formulas 11-14 to 11-17; Scheme 3, Formulas III- 14 to 111-17; Scheme 4, Formulas IV-14 to IV-17; Scheme 5, Formulas V-14 to V-17; and Scheme 6, Formulas VI-14 to VI-17);
amino carbonate 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP prodrugs (Scheme 1, Formulas 1-18 and 1-19; Scheme 2, Formulas 11-18 and 11-19; Scheme 3, Formulas
III- 18 and 111-19; Scheme 4, Formulas IV-18 and IV-19; Scheme 5, Formulas V-18 and V-19; and Scheme 6, Formulas VI-18 and VI-19);
phosphate analogs 1-20, 1-21, 11-20, 11-21, 111-20, 111-21, IV-20, IV-21, V-20, V-21, VI- 20, and VI-21 (Schemes 1-6);
1,3 diketo analogs 1-22 to 1-32; 11-22 to 11-32; 111-22 to 111-32; IV-22 to IV-32; V-22 to V-32; and VI-22 to VI-32 (Schemes 1-6);
carbonate and carbamate analogs 1-33 to 1-39; 11-33 to 11-39; 111-33 to 111-39; IV-33 to
IV- 39; V-33 to V-39; and VI-33 to VI-39 (Schemes 1-6);
[0063] benzoate analogs 1-40, 11-40, 111-40, IV-40, V-40, and VI-40 (Schemes l-6);and combinations thereof, wherein the prodrug is represented by formulas I- VI:
Scheme 1
Figure imgf000025_0001
or alky Λl) 4>0 Scheme 2
R =
Figure imgf000026_0001
Scheme 3 R =
Figure imgf000026_0002
Scheme 4
R =
Figure imgf000027_0001
Scheme 5 R =
Figure imgf000027_0002
Scheme 6
R =
Figure imgf000028_0001
[0064] In some embodiments, a broad range of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4- D P, or 3,5-D P prodrugs can be considered. In some embodiments, the prodrugs are represented by formulas I-l to 1-40; II-l to 11-40; III-l to 111-40; IV-1 to IV-40; V-1 to V-40; and VI- 1 to VI-40 are considered. A computational screen utilizing Pharma Algorithms' ADME- Tox calculator is conducted in order to identify virtual 'hits' (i.e. prodrugs with acceptable "predicted" oral bioavailabilities and water solubilities from the 32 prodrugs listed). The virtual screen allows ranking the 10 best prodrug molecules for synthesis and testing.
[0060] Amino acid (AA) esters of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP (Scheme 1, Formulas I-l to 1-10; Scheme 2, Formulas II-l to 11-10; Scheme 3, Formulas
III- l to III-10; Scheme 4, Formulas IV-1 to IV-10; Scheme 5, Formulas V-1 to V-10; and Scheme 6, Formulas VI-1 to VI-10); AA esters incorporating a methylene dioxide (a formaldehyde equivalent) spacer (Scheme 1, Formulas 1-11 to 1-13; Scheme 2, Formulas 11-11 to 11-13; Scheme 3, Formulas III-ll to 111-13; Scheme 4, Formulas IV-11 to IV-13; Scheme 5, Formulas V-ll to V-13; and Scheme 6, Formulas VI-11 to VI-13); amino carbamates 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP prodrugs (Scheme 1, Formulas 1-14 to 1-17; Scheme 2, Formulas 11-14 to 11-17; Scheme 3, Formulas 111-14 to 111-17; Scheme 4, Formulas
IV- 14 to IV-17; Scheme 5, Formulas V-14 to V-17; and Scheme 6, Formulas VI-14 to VI-17); amino carbonates 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP prodrugs (Scheme 1, Formulas 1-18 and 1-19; Scheme 2, Formulas 11-18 and 11-19; Scheme 3, Formulas III-18 and III-19; Scheme 4, Formulas IV-18 and IV-19; Scheme 5, Formulas V-18 and V-19; and Scheme 6, Formulas VI-18 and VI-19); phosphate analogs 1-20, 1-21, 11-20, 11-21, 111-20,
III- 21, IV-20, IV-21, V-20, V-21, VI-20, and VI-21 (Schemes 1-6); 1,3 diketo analogs 1-22 to I- 32; 11-22 to 11-32; 111-22 to 111-32; IV-22 to IV-32; V-22 to V-32; and VI-22 to VI-32 (Schemes 1-6); carbonate and carbamate analogs 1-33 to 1-39; 11-33 to 11-39; 111-33 to 111-39;
IV- 33 to IV-39; V-33 to V-39; and VI-33 to VI-39 (Schemes 1-6); benzoate analogs 1-40, 11-40, 111-40, IV-40, V-40, and VI-40 (Schemes 1-6); and combinations thereof, may be considered.
[0065] Examples of ionizable amine-containing prodrugs have increased water-solubility compared to the parent compound. In addition, AA ester prodrugs have the potential to further increase oral bioavailability due to active absorption by transporters (e.g., small peptide transporter PEPT1). For example, the valine-containing prodrugs valacyclovir and valganciclovir are substrates for the enzyme PEPT1. These AA containing prodrugs are hydrolyzed to the parent drug by aminopeptidase enzymes in the brush border membrane of the GI tract. Prodrugs which can penetrate into the peripheral circulation by passive permeation and/or by active transport are hydrolyzed by various peptidase enzymes in plasma.
[0066] Two types of phosphate prodrugs of 2,3-D P, 2,4-D P, 2,5-D P, 2,6-D P, 3,4- D P, or 3,5-D P of formulas 1-20, 1-21, 11-20, 11-21, 111-20, 111-21, IV-20, IV-21, V-20, V-21, VI-20, and VI-21 (Schemes 1-6) are synthesized. According to ADME-Tox computational data, the oral bioavailability of these prodrugs can be poor, given the fact that the prediction by ADME-Tox calculator is mainly based on the physicochemical proprieties of the molecule. Since phosphoric acid is a highly polar and extensively ionized pro-moiety, phosphate prodrugs can have significantly decreased membrane permeability compared to the parent drug.
[0067] The reasons for the success of phosphate prodrugs of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP shown in formulas 1-20, 1-21, 11-20, 11-21, 111-20, 111-21, IV- 20, IV-21, V-20, V-21, VI-20, and VI-21 (Schemes 1-6), e.g., phosphate esters as oral prodrugs, are: 1) oral absorption is not limited by dissolution-rate, since phosphate prodrugs are highly soluble in GI tract fluids; 2) phosphate esters are chemically stable enough to prevent the precipitation of the parent drug in the GI tract; 3) phosphates are rapidly hydrolyzed by membrane-bound alkaline phosphatases, which are in abundance on the brush border surface of the cells lining the small intestine, i.e., the enterocytes. Thus, the more permeable parent drug will be released, and readily cross the enterocyte membranes and enter the systemic circulation. Scheme 8
Figure imgf000030_0001
self cleavable linker
[0068] The prodrugs that are synthesized are modified to ensure water solubility. In some embodiments, acceptable solubility is tested prior to dosing in animals. If solubility is an issue, the structure of the prodrug is altered by introducing a water-soluble prodrug moiety into the molecule through conjugation with the free phenolic functionality. In other embodiments, a prodrug linker moiety that confers water-solubility properties on the prodrug molecule is utilized. In some embodiments, a solution to any water solubility issues is utilizing soft alkyl ether prodrugs that incorporate ethyleneoxy groups into promoieties such as alkyloxycarbonylmethyl (AOCOM) and N-alkyl-N-alkyloxycarbonylamino methyl (NANAOCAM) prodrugs. These prodrugs have been found to be useful for the delivery of phenolic drug molecules and have generally acceptable water solubility and membrane permeation characteristics, since they associate strongly with water molecules have good lipid solubility.
Synthesis of "Gemini " prodrugs of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2, 6-DNP, 3,4-DNP, or 3,5- DNP
[0069] In an embodiment, 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP "Gemini" prodrugs may be prepared by reacting 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4- DNP, or 3,5-DNP with triphosgene, in the presence of K2C03 in dichloromethane to get 2,4- dinitrophenyl carbonochloridate, which on further reaction with bases like morpholine, piperidine, piperazine, N-alkyl piperazine yields the DNP prodrugs as illustrated in Scheme 9.
Figure imgf000031_0001
[0070] In one embodiment, 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP "Gemini" prodrugs are prepared by reacting 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP with 5-(tert-butyldimethylsiloxy)isophthaloyl dichloride (2) in the presence of pyridine/ dichloromethane to afford precursor (3); the TBDMS protecting group will then be removed in acetone/HCl to afford prodrug (4), which will afford two equivalents of 2, 4-DNP upon hydrolysis in plasma. While the prodrug linker moiety in (4) is an ester group, other alternative linkers, such as sterically hindered ester linkers, carbonate linkers, carbamate linkers, phosphate linkers, and AOCOM and NANAOCAM based linkers may also be incorporated into the prodrug structure in order to achieve appropriate sustained release kinetics. The presence of the free phenolic group in (4) can also be utilized to improve water-solubility, if this is deemed necessary, through conjugation with appropriate hydrophilic moieties (Scheme 10).
Scheme 10
Figure imgf000032_0001
2.3- DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP Bioprecursors
[0071] Bioprecursors of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP that may release 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP after oxidative metabolism by cytochrome P-450 may be utilized. Scheme 8 shows the design of two bioprecursors that can release 2- and 4-equivalents of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP,
3.4- DNP, or 3,5-DNP after oxidation at the benzylic carbon by Cyt P-450 (oxidation site shown by arrows). This oxidation converts the benzylic CH2 group into a CO group to afford an ester moiety, which can then be cleaved by esterolysis to afford 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6- DNP, 3,4-DNP, or 3,5-DNP. The use of bioprecursors is often a good alternative to the prodrug approach and may provide metabolically activated slow release of 2, 4-DNP.
Scheme 11
Figure imgf000032_0002
Alternative Strategies Conjugation
[0072] In some embodiments, DNP prodrugs and bioprecursors with linkers containing open functional groups are utilized, which allow conjugation of each of these entities to nanoparticles, such as dendrimers, in order to modulate the pharmacokinetics of the molecule to enable "trickle" drug delivery. Such DNP prodrugs and bioprecursors are delivered as depot nanoparticle formulations that release DNP in a slow, sustained fashion at low doses, compared to dose and release of DNP alone, to avoid possible toxicity issues.
[0073] Nanotechnology presents an opportunity to increase the bioavailability of drug particles. A decrease in particle size results in increased surface area, results in faster dissolution. In some embodiments, the decrease is by a small order of magnitude. In other embodiments, this may be enough to result in increased bioavailability. However, faster dissolution may not be sufficient to overcome exposure to acid and enzymes in the gut. Additionally, as in the case with oral insulin, this exposure may require higher dosing of the drug, resulting in unnecessary and potentially undesirable subject exposure to breakdown products as well as create significant waste.
[0074] A depot nanoparticle formulation is specially formulated to provide slow absorption of the drug from the site of administration, often keeping therapeutic levels of the drug in the patient's system for days or weeks at a time. Alternatively, a depot nanoparticle formulation may provide convenience for a patient in need of chronic medication. By delivering drug without exposure to the Gl tract, the potential issue of drug degradation is avoided. Moreover, a depot nanoparticle formulation may provide better compliance due to the infrequent dosing regimen and convenience. Additional characteristics of a depot nanoparticle formulation that will enhance patient compliance are good local tolerance at the injection site and ease of administration. Good local tolerance means minimal irritation and inflammation at the site of injection; ease of administration refers to the size of needle and length of time required to administer a dose of a particular drug formulation.
In vitro and in vivo evaluation of prodrugs/bioprecursors
[0075] The prodrugs and bioprecursors of the invention encounter a wide range of pHs and enzymes when administered orally to patients. In one embodiment, the prodrug/bioprecursor is stable in the environment of the Gl tract, but releases parent drug in the plasma in a sustained manner after absorption from the GI tract. Oral dosing exposes compounds to pH 1 to 2 in the stomach, pH 4.5 at the beginning of the small intestine, pH 6.6 as an average pH for the small intestine, and pHs of 5 to 9 in the colon. Stability-indicating methods are performed in aqueous buffer solutions and simulated GI fluids to determine the resilience of the 2,3 -DNP, 2,4-DNP,
2.5- DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP prodrugs/bioprecursors in the GI tract, and also their susceptibility to enzymatic conversion to the parent drug in rat plasma. These are useful methods for in vitro evaluation of the chemical stability of a prodrug candidate.
[0076] Determining pH stability in aqueous buffers (37 °C, pH 1-9)
1) Determining GI stability in simulated gastric fluid (USP, 37 °C)
2) Determining GI stability in simulated intestinal fluid (USP, 37 °C)
3) Determining plasma: stability in rat plasma (37 °C)
[0077] Single compound dosing studies, are carried out on 2,3-DNP, 2,4-DNP, 2,5-DNP,
2.6- DNP, 3,4-DNP, or 3,5-DNP_prodrug/bioprecursor candidates to determine their clinical potential. Most promising preclinical prodrug/bioprecursor candidates are absorbed intact from the gastrointestinal tract and are efficiently cleaved enzymatically in plasma to afford the parent drug. The presence and identification of the prodrug and the parent drug can also provide important information on the mechanism of action of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, the identification of which is of value in the selection of new structural entities for consideration in structure-activity and structural optimization studies.
[0078] Pharmacokinetic studies are carried out on the most promising
prodrug/bioprecursor candidate (i.e., the prodrug/bioprecursor that exhibits the greatest stability in the GI tract and affords sustained release of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP in vitro and in vivo in rat plasma) in the Sprague-Dawley rat. A complete PK profile is obtained for the orally administered prodrug in jugular and femoral vein catheterized rats to determine half-life (ti/2), maximum plasma concentration (tmax), time to reach maximum plasma concentration (tmax), volume of distribution (Vss), area under the plasma concentration versus time curve from time 0 to infinity (AUCo-∞), and bioavailability (F%), as well as other important PK parameters such as protein binding. LC/MS/MS is used as the analytical methodology to determine both the above pharmacokinetic parameters of the prodrug, and the plasma concentration and release kinetics of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP resulting from enzymatic conversion of the prodrug to 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6- DNP, 3,4-DNP, or 3,5-DNP in the plasma.
[0079] Although DNP is orally bioavailable, with good distribution and ~6-hour half-life in rats, the prodrug approach allows extending the plasma residence time at lower concentrations of the parent drug (DNP), by appropriate design of the prodrug release characteristics.
[0080] In an embodiment, the composition for treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases is independently selected from the group consisting of 2,3-DNP, 2,4- DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4- DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof.
[0081] In one embodiment, a dose of any of the foregoing embodiments of the compositions, of DNP, DNP prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof, for treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases may be from about 0.01 mg/kg to about 50 mg/kg of body weight of the patient in need of treatment; from about 25 mg/kg to about 100 mg/kg of body weight of the patient in need of treatment; or from about 25 mg/kg to about 100 mg/kg of body weight of the patient in need of treatment. In one embodiment, a dose of any of the foregoing embodiments of the compositions for treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases may be from 0.01 mg/kg to 50 mg/kg of body weight of the patient in need of treatment; from 25 mg/kg to 100 mg/kg of body weight of the patient in need of treatment; or from 25 mg/kg to 100 mg/kg of body weight of the patient in need of treatment. In an embodiment, the present invention relates to a pharmaceutical composition of DNP, or a pharmaceutically acceptable salt, solvate, hydrate and/or prodrug thereof as described herein, comprising a unit dose, wherein the unit dose is in the range of about 0.1 mg to about 3000 mg. In an embodiment, the present invention relates to a pharmaceutical composition of DNP, or a pharmaceutically acceptable salt, solvate, hydrate and/or prodrug thereof as described herein, comprising a unit dose, wherein the unit dose is in the range of 0.1 mg to 3000 mg. [0082] In one embodiment, a dose of any of the foregoing embodiments of the compositions, of D P, DNP prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof, for treatment of neuromuscular diseases, neuromuscular degenerative diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, may be independently selected from about 0.01 mg/kg to about 50 mg/kg of body weight; about 0.01 mg/kg to about 40 mg/kg of body weight; about 0.01 mg/kg to about 30 mg/kg of body weight; about 0.01 mg/kg to about 20 mg/kg of body weight; about 0.01 mg/kg to about 10 mg/kg of body weight; about 0.01 mg/kg to about 5 mg/kg of body weight; about 0.01 mg/kg to about 1 mg/kg of body weight; about 0.05 mg/kg to about 50 mg/kg of body weight; about 0.05 mg/kg to about 40 mg/kg of body weight; about 0.05 mg/kg to about 30 mg/kg of body weight; about 0.05 mg/kg to about 20 mg/kg of body weight; about 0.05 mg/kg to about 10 mg/kg of body weight; about 0.05 mg/kg to about 1.0 mg/kg of body weight; about 0.05 mg/kg to about 0.1 mg/kg of body weight; about 0.1 mg/kg to about 40 mg/kg of body weight; about 0.1 mg/kg to about 50 mg/kg of body weight; about 0.1 mg/kg to about 30 mg/kg of body weight; about 0.1 mg/kg to about 20 mg/kg of body weight; about 0.1 mg/kg to about 15 mg/kg of body weight; about 0.1 mg/kg to about 12 mg/kg of body weight; about 0.1 mg/kg to about 10 mg/kg of body weight; about 0.1 mg/kg to about 9 mg/kg of body weight; about 0.1 mg/kg to about 8 mg/kg of body weight; about 0.1 mg/kg to about 7 mg/kg of body weight; about 0.1 mg/kg to about 6 mg/kg of body weight; about 0.1 mg/kg to about 5 mg/kg of body weight; about 0.1 mg/kg to about 4 mg/kg of body weight; about 0.1 mg/kg to about 3 mg/kg of body weight; about 0.1 mg/kg to about 2 mg/kg of body weight; 0.1 mg/kg to about 1.0 mg/kg of body weight; about 0.3 mg/kg to about 20 mg/kg of body weight; about 0.3 mg/kg to about 15 mg/kg of body weight; about 0.3 mg/kg to about 12 mg/kg of body weight; about 0.3 mg/kg to about 10 mg/kg of body weight; about 0.3 mg/kg to about 9 mg/kg of body weight; about 0.3 mg/kg to about 8 mg/kg of body weight; about 0.3 mg/kg to about 7 mg/kg of body weight; about 0.3 mg/kg to about 6 mg/kg of body weight; about 0.3 mg/kg to about 5 mg/kg of body weight; about 0.3 mg/kg to about 4 mg/kg of body weight; about 0.3 mg/kg to about 3 mg/kg of body weight; about 0.3 mg/kg to about 2 mg/kg of body weight; about 0.3 mg/kg to about 1.0 mg/kg of body weight; about 0.5 mg/kg to about 15 mg/kg of body weight; about 0.5 mg/kg to about 12 mg/kg of body weight; about 0.5 mg/kg to about 10 mg/kg of body weight; about 0.5 mg/kg to about 9 mg/kg of body weight; about 0.5 mg/kg to about 8 mg/kg of body weight; about 0.5 mg/kg to about 7 mg/kg of body weight; about 0.5 mg/kg to about 6 mg/kg of body weight; about 0.5 mg/kg to about 5 mg/kg of body weight; about 0.5 mg/kg to about 4 mg/kg of body weight; about 0.5 mg/kg to about 3 mg/kg of body weight; about 0.5 mg/kg to about 2 mg/kg of body weight; about 0.5 mg/kg to about 1.0 mg/kg of body weight; about 0.8 mg/kg to about 15 mg/kg of body weight; about 0.8 mg/kg to about 12 mg/kg of body weight; about 0.8 mg/kg to about 10 mg/kg of body weight; about 0.8 mg/kg to about 9 mg/kg of body weight; about 0.8 mg/kg to about 8 mg/kg of body weight; about 0.8 mg/kg to about 7 mg/kg of body weight; about 0.8 mg/kg to about 6 mg/kg of body weight; about 0.8 mg/kg to about 5 mg/kg of body weight; about 0.8 mg/kg to about 4 mg/kg of body weight; about 0.8 mg/kg to about 3 mg/kg of body weight; about 0.8 mg/kg to about 2 mg/kg of body weight; about 0.8 mg/kg to about 1.0 mg/kg of body weight; about 1 mg/kg to about 3.0 mg/kg of body; about 1.5 mg/kg to about 3.0 mg/kg of body; about 1.0 mg/kg to about 2.0 mg/kg of body; about 2.0 mg/kg to about 3.0 mg/kg of body; about 0.5 mg/kg to about 2.5 mg/kg of body weight; about 0.5 mg/kg to about 2.0 mg/kg of body weight.
[0083] In one embodiment, a dose of any of the foregoing embodiments of the compositions for treatment of neuromuscular diseases, neuromuscular degenerative diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, may be independently selected from 0.01 mg/kg to 50 mg/kg of body weight; 0.01 mg/kg to 40 mg/kg of body weight; 0.01 mg/kg to 30 mg/kg of body weight; 0.01 mg/kg to 20 mg/kg of body weight; 0.01 mg/kg to 10 mg/kg of body weight; 0.01 mg/kg to 5 mg/kg of body weight; 0.01 mg/kg to 1 mg/kg of body weight; 0.05 mg/kg to 50 mg/kg of body weight; 0.05 mg/kg to 40 mg/kg of body weight; 0.05 mg/kg to 30 mg/kg of body weight; 0.05 mg/kg to 20 mg/kg of body weight; 0.05 mg/kg to 10 mg/kg of body weight; 0.05 mg/kg to 1.0 mg/kg of body weight; 0.05 mg/kg to 0.1 mg/kg of body weight; 0.1 mg/kg to 40 mg/kg of body weight; 0.1 mg/kg to 50 mg/kg of body weight; 0.1 mg/kg to 30 mg/kg of body weight; 0.1 mg/kg to 20 mg/kg of body weight; 0.1 mg/kg to 15 mg/kg of body weight; 0.1 mg/kg to 12 mg/kg of body weight; 0.1 mg/kg to 10 mg/kg of body weight; 0.1 mg/kg to 9 mg/kg of body weight; 0.1 mg/kg to 8 mg/kg of body weight; 0.1 mg/kg to 7 mg/kg of body weight; 0.1 mg/kg to 6 mg/kg of body weight; 0.1 mg/kg to 5 mg/kg of body weight; 0.1 mg/kg to 4 mg/kg of body weight; 0.1 mg/kg to 3 mg/kg of body weight; 0.1 mg/kg to 2 mg/kg of body weight; 0.1 mg/kg to 1.0 mg/kg of body weight; 0.3 mg/kg to 20 mg/kg of body weight; 0.3 mg/kg to 15 mg/kg of body weight; 0.3 mg/kg to 12 mg/kg of body weight; 0.3 mg/kg to 10 mg/kg of body weight; 0.3 mg/kg to 9 mg/kg of body weight; 0.3 mg/kg to 8 mg/kg of body weight; 0.3 mg/kg to 7 mg/kg of body weight; 0.3 mg/kg to 6 mg/kg of body weight; 0.3 mg/kg to 5 mg/kg of body weight; 0.3 mg/kg to 4 mg/kg of body weight; 0.3 mg/kg to 3 mg/kg of body weight; 0.3 mg/kg to 2 mg/kg of body weight; 0.3 mg/kg to 1.0 mg/kg of body weight; 0.5 mg/kg to 10 mg/kg of body weight; 0.5 mg/kg to 9 mg/kg of body weight; 0.5 mg/kg to 8 mg/kg of body weight; 0.5 mg/kg to 7 mg/kg of body weight; 0.5 mg/kg to 6 mg/kg of body weight; 0.5 mg/kg to 5 mg/kg of body weight; 0.5 mg/kg to about 4 mg/kg of body weight; 0.5 mg/kg to 3 mg/kg of body weight; 0.5 mg/kg to 2 mg/kg of body weight; 0.5 mg/kg to 1.0 mg/kg of body weight; 0.8 mg/kg to 15 mg/kg of body weight; 0.8 mg/kg to 12 mg/kg of body weight; 0.8 mg/kg to 8 10 mg/kg of body weight; 0.8 mg/kg to 9 mg/kg of body weight; 0.8 mg/kg to 8 mg/kg of body weight; 0.8 mg/kg to 7 mg/kg of body weight; 0.8 mg/kg to 6 mg/kg of body weight; 0.8 mg/kg to 5 mg/kg of body weight; 0.8 mg/kg to 4 mg/kg of body weight; 0.8 mg/kg to 3 mg/kg of body weight; 0.8 mg/kg to 2 mg/kg of body weight; 0.8 mg/kg to 1.0 mg/kg of body weight; 1 mg/kg to 3.0 mg/kg of body; 1.5 mg/kg to 3.0 mg/kg of body; 1.0 mg/kg to 2.0 mg/kg of body; 2.0 mg/kg to 3.0 mg/kg of body; 0.5 mg/kg to 2.5 mg/kg of body weight; 0.5 mg/kg to 2.0 mg/kg of body weight.
[0084] In one embodiment, a dose of any of the foregoing embodiments of the compositions for treatment of neuromuscular diseases, neuromuscular degenerative diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss,, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, may be independently from about 1 mg/day/70kg of body weight to about 300 mg/day/70kg of body weight of the patient in need of treatment; about 1 mg/day/70kg of body weight to about 200 mg/day/70kg of body weight of the patient in need of treatment; about 1 mg/day/70kg of body weight to about 100 mg/day/70kg of body weight of the patient in need of treatment; about 1 mg/day/70kg of body weight to about 50 mg/day/70kg of body weight of the patient in need of treatment; about 1 mg/day/70kg of body weight to about 30 mg/day/70kg of body weight of the patient in need of treatment; about 1 mg/day/70kg of body weight to about 20 mg/day/70kg of body weight of the patient in need of treatment; about 1 mg/day/70kg of body weight to about 10 mg/day/70kg of body weight of the patient in need of treatment; about 1 mg/day/70kg of body weight to about 5 mg/day/70kg of body weight of the patient in need of treatment.
[0085] In one embodiment, a dose of any of the foregoing embodiments of the compositions for treatment of neuromuscular diseases, neuromuscular degenerative diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss,, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, may be independently from 1 mg/day/70kg of body weight to 300 mg/day/70kg of body weight of the patient in need of treatment; 1 mg/day/70kg of body weight to 200 mg/day/70kg of body weight of the patient in need of treatment; 1 mg/day/70kg of body weight to 100 mg/day/70kg of body weight of the patient in need of treatment; 1 mg/day/70kg of body weight to 50 mg/day/70kg of body weight of the patient in need of treatment; 1 mg/day/70kg of body weight to 30 mg/day/70kg of body weight of the patient in need of treatment; 1 mg/day/70kg of body weight to 20 mg/day/70kg of body weight of the patient in need of treatment; 1 mg/day/70kg of body weight to 10 mg/day/70kg of body weight of the patient in need of treatment; 1 mg/day/70kg of body weight to 5 mg/day/70kg of body weight of the patient in need of treatment. [0086] In some embodiments, a pharmaceutical composition includes D P, selected from the group consisting of DNP, 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP) prodrugs or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprising a unit dose, independently selected from: wherein the unit dose is in the range of about 0.1 mg to about 3000 mg; wherein the unit dose is in the range of about 0.1 mg to about 1000 mg; wherein the unit dose is in the range of about 0.1 mg to about 500 mg; wherein the unit dose is in the range of about 0.1 mg to about 100 mg; wherein the unit dose is in the range of about 1 mg to about 50 mg; wherein the unit dose is about 1 mg; wherein the unit dose is about 2 mg; wherein the unit dose is about 3 mg; wherein the unit dose is about 4 mg; wherein the unit dose is about 5 mg; wherein the unit dose is the range of about 5 mg to about 10 mg; wherein the unit dose is about 6 mg; wherein the unit dose is about 7 mg; wherein the unit dose is about 8 mg; wherein the unit dose is about 9 mg; wherein the unit dose is about 10 mg; wherein the unit dose is the range of about 10 mg to about 15 mg; wherein the unit dose is about 11 mg; wherein the unit dose is about 12 mg; wherein the unit dose is about 13 mg; wherein the unit dose is about 14 mg; wherein the unit dose is about 15 mg; wherein the unit dose is the range of about 15 mg to about 20 mg; wherein the unit dose is about 16 mg; wherein the unit dose is about 17 mg; wherein the unit dose is about 18 mg; wherein the unit dose is about 19 mg; wherein the unit dose is about 20 mg; wherein the unit dose is the range of about 20 mg to about 30 mg; wherein the unit dose is about 25 mg; wherein the unit dose is about 30 mg; wherein the unit dose is the range of about 30 mg to about 40 mg; wherein the unit dose is about 35 mg; wherein the unit dose is about 40 mg; wherein the unit dose is the range of about 40 mg to about 50 mg; wherein the unit dose is about 45 mg; wherein the unit dose is about 50 mg; wherein the unit dose is the range of about 50 mg to about 100 mg; wherein the unit dose is about 75 mg; wherein the unit dose is about 100 mg; wherein the unit dose is the range of about 100 mg to about 200 mg; wherein the unit dose is about 150 mg; wherein the unit dose is about 200 mg; wherein the unit dose is the range of about 200 mg to about 300 mg; wherein the unit dose is about 200 mg; wherein the unit dose is about 250 mg; wherein the unit dose is about 300 mg; wherein the unit dose is about 350 mg; wherein the unit dose is about 400 mg; wherein the unit dose is about 450 mg; wherein the unit dose is about 500 mg; wherein the unit dose is about 750 mg; wherein the unit dose is about 1000 mg; wherein the unit dose is about 1500 mg; wherein the unit dose is about 2000 mg; wherein the unit dose is about 2500 mg; or wherein the unit dose is about 3000 mg.
[0087] In some embodiments, a pharmaceutical composition includes DNP, selected from the group consisting of DNP, 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP) prodrugs or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprising a unit dose, independently selected from: wherein the unit dose is from the range of 0.1 mg to 3000 mg; wherein the unit dose is in the range of 0.1 mg to 1000 mg; wherein the unit dose is in the range of 0.1 mg to 500 mg; wherein the unit dose is in the range of 0.1 mg to 1000 mg; wherein the unit dose is in the range of 0.1 mg to 500 mg; wherein the unit dose is in the range of 0.1 mg to 100 mg; wherein the unit dose is in the range of 1 mg to 50 mg; wherein the unit dose is 1 mg; wherein the unit dose is 2 mg; wherein the unit dose is 3 mg; wherein the unit dose is 4 mg; wherein the unit dose is 5 mg; wherein the unit dose is the range of 5 mg to 10 mg; wherein the unit dose is 6 mg; wherein the unit dose is 7 mg; wherein the unit dose is 8 mg; wherein the unit dose is 9 mg; wherein the unit dose is 10 mg; wherein the unit dose is the range of 10 mg to 15 mg; wherein the unit dose is 11 mg; wherein the unit dose is 12 mg; wherein the unit dose is 13 mg; wherein the unit dose is 14 mg; wherein the unit dose is 15 mg; wherein the unit dose is the range of 15 mg to 20 mg; wherein the unit dose is 16 mg; wherein the unit dose is 17 mg; wherein the unit dose is 18 mg; wherein the unit dose is 19 mg; wherein the unit dose is 20 mg; wherein the unit dose is the range of 20 mg to 30 mg; wherein the unit dose is 25 mg; wherein the unit dose is 30 mg; wherein the unit dose is the range of 30 mg to 40 mg; wherein the unit dose is 35 mg; wherein the unit dose is 40 mg; wherein the unit dose is the range of 40 mg to 50 mg; wherein the unit dose is 45 mg; wherein the unit dose is 50 mg; wherein the unit dose is the range of 50 mg to 100 mg; wherein the unit dose is 75 mg; wherein the unit dose is 100 mg; wherein the unit dose is the range of 100 mg to 200 mg; wherein the unit dose is 150 mg; wherein the unit dose is 200 mg; wherein the unit dose is the range of 200 mg to 300 mg; wherein the unit dose is 200 mg; wherein the unit dose is 250 mg; wherein the unit dose is 300 mg; wherein the unit dose is 350 mg; wherein the unit dose is 400 mg; wherein the unit dose is 450 mg; wherein the unit dose is 500 mg; wherein the unit dose is 750 mg; wherein the unit dose is 1000 mg; wherein the unit dose is 1500 mg; wherein the unit dose is 2000 mg; wherein the unit dose is 2500 mg; or wherein the unit dose is 3000 mg.
[0088] In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is an immediate release formation. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is an extended release formation. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is a sustained release formation. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is a controlled release formation. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is an oral dosage form. In some embodiments, the oral dosage form is a tablet. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the oral dosage form is a capsule. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the unit dose is a capsule with no filler. In some embodiments of the foregoing embodiments of the composition for treatment of a disease, the oral dosage form is rapidly dissolving. In each of the foregoing embodiments, the disease may be independently selected from Traumatic Brain Injury (TBI), Concussion, Ischemic stroke, Huntington's disease (Adult-onset Huntington's, Juvenile Huntington's disease), Epilepsy (Cluster Seizures, Refractory Seizures, Atypical Absence Seizures, Atonic Seizures, Clonic Seizures, myoclonic seizures, tonic seizures, Tonic- Clonic Seizures, Simple Partial Seizures, Complex Partial Seizures, Secondary Generalized Seizures, Febrile Seizures, Nonepileptic Seizures, Gelastic and Dacrystic Seizures, and Absence Seizures), Multiple Sclerosis (MS) (relapse-remitting multiple sclerosis (RRMS), Secondary- progressive MS (SPMS), Primary-progressive MS (PPMS), and Progressive-relapsing MS (PRMS)), Lupus (Systemic Lupus Erythematosus (SLE), discoid (cutaneous), drug-induced lupus (dil) and neonatal lupus), Diabetes mellitus (Type-1 Diabetes, Type-2 Diabetes, Maturity Onset Diabetes of the Young (MODY: MODY1, MODY2, MODY3, MODY4, MODY5, MODY6, MODY7, MODY8, MODY9, MODYIO, MODYl l)), Nonalcoholic Steatohepatitis (NASH), Schizophrenia (Paranoid schizophrenia, Disorganized schizophrenia, Catatonic schizophrenia, Residual schizophrenia, Schizoaffective disorder), Myasthenia gravis (MG) (ocular myasthenia gravis, Congenital MG and generalized myasthenia gravis), rheumatoid arthritis (RA), Graves' disease, Guillain-Barre syndrome (GBS), Muscular Dystrophy (Duchenne Muscular Dystrophy (DMD), Becker, Myotonic, Congenital, Emery-Dreifuss, Facioscapulohumeral, Limb-girdle, Distal, and Oculopharyngeal), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Ataxia (Friedreich's Ataxia, Spinocerebellar ataxias 1 (SCA1), Spinocerebellar ataxias 2 (SCA2), Spinocerebellar ataxias 3 (SCA3), Spinocerebellar ataxias 6 (SCA6), Spinocerebellar ataxias 7 (SCA7), Spinocerebellar ataxias 11 (SCA11), Dentatorubral pallidolusyian atrophy (DRPLA) and Gluten ataxia), Batten Disease or neuronal ceroid lipofuscinoses (NCL) (infantile NCL (INCL), late infantile NCL (LINCL), juvenile NCL (JNCL) or adult NCL (ANCL)), Alzheimer's Disease (Early-onset Alzheimer's, Late-onset Alzheimer's, and Familial Alzheimer's disease (FAD)), Optic neuritis (ON), Leber's hereditary optic neuropathy (LHON), Autism Spectrum Disorders (ASD) (Asperger's Syndrome, Pervasive Developmental Disorders (PDDs), Childhood Disintegrative Disorder (CDD), and Autistic disorder), Rett syndrome, Angelman's Syndrome, Leigh disease, Prader Willi Syndrome, Fragile-X Syndrome, Depression (Major Depression, Dysthymia, Postpartum Depression, Seasonal Affective Disorder, Atypical Depression, Psychotic Depression, Bipolar Disorder, Premenstrual Dysphoric Disorder, Situational Depression), Parkinson's disease (Idiopathic Parkinson's disease, Vascular parkinsonism, Dementia with Lewy bodies, Inherited Parkinson's, Drug-induced Parkinsonism, Juvenile Parkinson's and atypical parkinsonism), Wolfram syndrome (and/or any associated conditions such as diabetes issues, hearing, vision, ataxia, neurodegeneration, etc.), spinal muscular atrophy (SMA; type I, II, III and IV), hearing loss due to noise (blast and high noise), aging related hearing loss, drug induced hearing loss, and/or genetic hearing loss, concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolcott- Rallison syndrome, mitochondrial diseases, developmental disorders, metabolic syndrome (increased blood pressure, high blood sugar level, excess body fat around the waist and abnormal cholesterol levels) and/or autoimmune disorders by increasing energy expenditure and/or inducing BDNF mRNA expression and protein levels with DNP treatment to reverse, slow or prevent treating neurodegenerative neuromuscular, developmental, autoimmune and/or metabolic diseases and/or muscle wasting.
[0089] In one embodiment, the invention provides for a method of treatment of traumatic brain injury (TBI) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of concussion using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of ischemic stroke using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of severe burns using embodiments of the compositions and dosages described herein.
[0090] In one embodiment, the invention relates to a method of treatment of Huntington's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of adult-onset Huntington's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of juvenile Huntington's disease using embodiments of the compositions and dosages described herein.
[0091] In one embodiment, the invention relates to a method of treatment of epilepsy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of cluster seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of refractory seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of atypical absence seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of atonic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of clonic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of myoclonic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of tonic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of tonic-clonic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of simple partial seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of complex partial seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of secondary generalized seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of febrile seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of nonepileptic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of gelastic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of dacrystic seizures using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of absence seizures.
[0092] In one embodiment, the invention relates to a method of treatment of multiple sclerosis (MS) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of relapse-remitting multiple sclerosis (RRMS) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of secondary-progressive MS (SPMS) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of primary-progressive MS (PPMS) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of progressive-relapsing MS (PRMS).
[0093] In one embodiment, the invention relates to a method of treatment of diabetes mellitus using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of type-1 diabetes using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of type-2 diabetes using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of maturity onset diabetes of the young (MODY) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY1 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY2 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY3 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY4 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY5 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY6 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY7 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY8 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY9 using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODYIO using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of MODY11 using embodiments of the compositions and dosages described herein.
[0094] In one embodiment, the invention relates to a method of treatment of nonalcoholic steatohepatitis (NASH) using embodiments of the compositions and dosages described herein.
[0095] In one embodiment, the invention relates to a method of treatment of muscular dystrophy using embodiments of the compositions and dosages described herein. In one such embodiment, such dosages for an adult independently ranging from: 10 mg/day to 150 mg/day; 20 mg/day to 150 mg/day; 30 mg/day to 150 mg/day; 40 mg/day to 150 mg/day; 50 mg/day to 150 mg/day; 60 mg/day to 150 mg/day; 70 mg/day to 150 mg/day; 80 mg/day to 150 mg/day; 90 mg/day to 150 mg/day; 80 mg/day to 100 mg/day; 90 mg/day to 100 mg/day; 91 mg/day to 100 mg/day 92 mg/day to 100 mg/day; 93 mg/day to 100 mg/day; 94 mg/day to 100 mg/day; or independently dosages of 90 mg/day; 91 mg/day; 92 mg/day; 93 mg/day; 94 mg/day; 95 mg/day; 96 mg/day; 97 mg/day; 98 mg/day or 99 mg/day. In one such embodiment, such dosages for an adolescent independently ranging from: 1 mg/day to 45 mg/day; 1 mg/day to 50 mg/day; 5 mg/day to 45 mg/day; 5 mg/day to 50 mg/day; 10 mg/day to 45 mg/day; 15 mg/day to 45 mg/day; 20 mg/day to 45 mg/day; 25 mg/day to 45 mg/day; 30 mg/day to 45 mg/day; 35 mg/day to 45 mg/day; 35 mg/day to 40 mg/day or ; independently dosages of 35 mg/day; 35 mg/day; 37 mg/day; 38 mg/day; 39 mg/day; 40 mg/day; 41 mg/day; 42 mg/day; 43 mg/day; 44 mg/day or 45 mg/day. In another such embodiment, such dosages for an adult independently ranging from: about 10 mg/day to about 150 mg/day; about 20 mg/day to about 150 mg/day; about 30 mg/day to about 150 mg/day; about 40 mg/day to about 150 mg/day; about 50 mg/day to about 150 mg/day; about 60 mg/day to about 150 mg/day; about 70 mg/day to about 150 mg/day; about 80 mg/day to about 150 mg/day; about 90 mg/day to about 150 mg/day; about 80 mg/day to about 100 mg/day; about 90 mg/day to about 100 mg/day; about 91 mg/day to about 100 mg/day; about 92 mg/day to about 100 mg/day; about 93 mg/day to about 100 mg/day; about 94 mg/day to about 100 mg/day; or independently dosages of about 90 mg/day; about 91 mg/day; about 92 mg/day; about 93 mg/day; about 94 mg/day; about 95 mg/day; about 96 mg/day; about 97 mg/day; about 98 mg/day or about 99 mg/day. In another such embodiment, such dosages for an adolescent independently ranging from: about 1 mg/day to about 45 mg/day; about 1 mg/day to about 50 mg/day; about 5 mg/day to about 45 mg/day; about 5 mg/day to about 50 mg/day; about 10 mg/day to about 45 mg/day; about 15 mg/day to about 45 mg/day; about 20 mg/day to about 45 mg/day; about 25 mg/day to about 45 mg/day; about 30 mg/day to about 45 mg/day; about 35 mg/day to about 45 mg/day; about 35 mg/day to about 40 mg/day or; independently dosages of about 35 mg/day; about 35 mg/day; about 37 mg/day; about 38 mg/day; about 39 mg/day; about 40 mg/day; about 41 mg/day; about 42 mg/day; about 43 mg/day; about 44 mg/day or about 45 mg/day. In one embodiment, the invention relates to a method of treatment of Duchenne muscular dystrophy (DMD) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of Becker muscular dystrophy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of myotonic muscular dystrophy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of congenital muscular dystrophy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of Emery-Dreifuss muscular dystrophy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of facioscapulohumeral muscular dystrophy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of limb-girdle muscular dystrophy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of distal muscular dystrophy using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of oculopharyngeal muscular dystrophy using embodiments of the compositions and dosages described herein. [0096] In one embodiment, the invention relates to a method of treatment of amyotrophic lateral sclerosis (ALS) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of ataxia using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of Friedreich's ataxia using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of spinocerebellar ataxias 1 (SCA1) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of Batten disease. In one embodiment, the invention relates to a method of treatment of neuronal ceroid lipofuscinoses (NCL) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of infantile NCL (INCL) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of late infantile NCL (LINCL) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of juvenile NCL (JNCL) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of adult NCL (ANCL) using embodiments of the compositions and dosages described herein.
[0097] In one embodiment, the invention relates to a method of treatment of Alzheimer's disease using embodiments of the compositions and dosages described herein. In one such embodiment, such dosages independently ranging from: 1 mg/day to 45 mg/day; 5 mg/day to 45 mg/day; 10 mg/day to 45 mg/day; 15 mg/day to 45 mg/day; 20 mg/day to 45 mg/day; 25 mg/day to 45 mg/day; 30 mg/day to 45 mg/day; 35 mg/day to 45 mg/day; 35 mg/day to 40 mg/day or ; independently dosages of 31 mg/day; 32 mg/day; 33 mg/day; 34 mg/day; 35 mg/day; 36 mg/day; 37 mg/day; 38 mg/day; 39 mg/day or 40 mg/day. In another such embodiment, such dosages independently ranging from: about 1 mg/day to about 45 mg/day; about 5 mg/day to about 45 mg/day; about 10 mg/day to about 45 mg/day; about 15 mg/day to about 45 mg/day; about 20 mg/day to about 45 mg/day; about 25 mg/day to about 45 mg/day; about 30 mg/day to about 45 mg/day; about 35 mg/day to about 45 mg/day; about 35 mg/day to about 40 mg/day or; independently dosages of about 31 mg/day; about 32 mg/day; about 33 mg/day; about 34 mg/day; about 35 mg/day; about 36 mg/day; about 37 mg/day; about 38 mg/day; about 39 mg/day or about 40 mg/day. In one embodiment, the invention relates to a method of treatment of early-onset Alzheimer's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of late- onset Alzheimer's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of familial Alzheimer's disease (FAD) using embodiments of the compositions and dosages described herein.
[0098] In one embodiment, the invention relates to a method of treatment of optic neuritis (ON) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of an autism spectrum disorder (ASD) using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of Rett syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of Angelman's syndrome using embodiments of the compositions and dosages described herein.
[0099] In one embodiment, the invention relates to a method of treatment of Parkinson's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of idiopathic Parkinson's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of vascular parkinsonism using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of dementia with Lewy bodies using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of inherited Parkinson's diseases using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of drug-induced Parkinsonism using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of juvenile Parkinson's disease using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of atypical parkinsonism using embodiments of the compositions and dosages described herein.
[00100] In one embodiment, the invention relates to a method of treatment of Wolfram syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of diabetes issues associated with Wolfram syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing issues associated with Wolfram syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of vision issues associated with Wolfram syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of ataxia associated with Wolfram syndrome using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of neurodegeneration associated with Wolfram syndrome using embodiments of the compositions and dosages described herein.
[00101] In one embodiment, the invention relates to a method of treatment of spinal muscular atrophy (SMA) type III using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of SMA type IV using embodiments of the compositions and dosages described herein.
[00102] In one embodiment, the invention relates to a method of treatment of hearing loss using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing loss due to noise using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing loss due to blast noise using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing loss due to high noise using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of aging related hearing loss using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of drug induced hearing loss using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of genetic hearing loss using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing loss due to concussion using embodiments of the compositions and dosages described herein. In one embodiment, the invention relates to a method of treatment of hearing loss due to traumatic brain injury (TBI) using embodiments of the compositions and dosages described herein. [00103] In some embodiments, the unit dose is delivered intravenously. In some embodiments, the unit dose is delivered by means of an intravenous drip along with saline. In some embodiments, the unit dose is delivered by means of an intravenous drip along with saline, other medications, vitamins and/or nourishment. In some embodiments, the unit dose is delivered subcutaneously. In some embodiments, the unit dose is delivered topically. In some embodiments, the unit dose is delivered transdermally. In some embodiments, the unit dose is in the form of a patch.
[00104] The dose may be administered as a single daily dose, a twice-daily dose, three times daily, or more frequently. The dose may be administered three times weekly, twice weekly, once weekly, or less frequently. In an embodiment, administration frequency may be between 1 and 5 times a day. In another embodiment, administration frequency may be between 2 and 4 times a day. In another embodiment, administration frequency may be at least 3 times a day. In another embodiment, administration frequency may be twice a day. In another embodiment, administration frequency may be once a day. In another embodiment, administration frequency may be less frequent than once a day. In other embodiments, administration frequency may be once every 2 days or once every 3 days or once every 4 days or once every 5 days or once every 6 days. In another embodiment, administration frequency may be once a week. In another embodiment, administration frequency may change with time, starting at a certain rate, such as once or twice a day, and then decreasing to less frequently, such as once every 2 days or once every 3 days, or once a week, after the first day of treatment. In another embodiment, administration frequency may change with time, starting at a certain rate, such as once or twice a day, and then decreasing to less frequently, such as once every 2 days or once every 3 days, or once a week, after the first two or three days of treatment. In another embodiment, administration frequency may change with time, starting at a certain rate, such as once or twice a day, and then decreasing to less frequently, such as once every 2 days or once every 3 days, or once a week, after the first week of treatment. In another embodiment, administration frequency may be on demand, as therapeutic treatment is required or desired.
[00105] It will be understood, based on the disclosure encompassed herein, how to determine whether a subject needs an additional and/or continued dose. It will also be understood that the selected dosing frequency may require an adjustment of the dosage of active ingredient. It will also be understood, based on the disclosure encompassed herein, that the selected dosage of active ingredient may require an adjustment of the dosing frequency. The disclosure encompassed herein, in combination with the skill in the art, will enable the skilled artisan to optimize both the dosage of the active ingredient and the frequency of administration of the active ingredient to treat a subject in need thereof.
[00106] The unit dose may also be adjusted based upon the size of the patient. In one embodiment, the numbers provided herein are based upon a 60 kg patient. The same therapy could be provided for a smaller or larger sized patient, by respectively reducing or increasing the dose size. By way of example only, a 20 kg child patient would need a much smaller dose than a 60 kg adult patient.
[00107] Formulation approaches are employed such as controlled release technologies (polymers, liposomes, etc.) to achieve once a day PK profile for DNP. In some embodiments, DNP prodrugs and bioprecursors with linkers containing open functional groups are synthesized, which allows conjugation of each of these entities to nanoparticles, such as dendrimers, in order to modulate the pharmacokinetics of the molecule to enable "trickle" drug delivery. Such DNP prodrugs and bioprecursors are delivered as depot nanoparticle formulation that release DNP in a slow, sustained fashion at low doses, compared to dose and release of DNP alone, to avoid possible toxicity issues. The in vitro stability, in vivo plasma release kinetics and PK profiles are evaluated. In vivo studies are carried out in Sprague-Dawley rats. LC/MS/MS is used to analyze plasma DNP released from the various prodrug-nanoparticle formulations to determine the PK profile of DNP release in the rat model.
[00108] The following examples describe the invention in further detail. These examples are provided for illustrative purposes only, and should in no way be considered as limiting the invention.
EXAMPLES
[00109] Synthesis of 2,4-Dinitrophenyl morpholine-4-carboxylate: 2,4-DNP ( 1 mmol) reacted with triphosgene ( 0.5 mmol), in the presence of K2C03 ( 1 mmol) in dichloromethane to get 2,4-dinitrophenyl carbonochloridate, which on further reaction with morpholine (1.1 mmol), at 0-5 °C yields the DNP -morpholine prodrug.
Figure imgf000053_0001
[00110] 2,4-Dinitrophenyl morpholine-4-carboxylate analytical data: GC MS: M+, 297 1,
HRMS: 298.0683 (M+H)+; 1H NMR (400 MHz, CDC13): δ 3.57-3.59 (m, 2 H, CH2), 3.72-3.73 (m, 2H, CH2), 3.73-3.80 (m, 4H, 2 x OCH2), 7.53 (dd, IH, Ar-H), 8.48-8.51 (dd, IH, Ar-H), 8.94 (d, IH, Ar-H) ppm. 13C NMR (75 MHz, CDC13): δ 44.99, 45.69, 66.62, 66.78, 121.94, 126.84, 129.18, 141.90, 144.85, 149.64, 151.10 ppm.
[00111] Synthesis of 2,4-dinitrophenyl piperidine-l-carboxylate: 2,4-DNP ( 1 mmol) reacted with triphosgene ( 0.5 mmol), in the presence of K2C03 ( 1 mmol) in dichloromethane to get 2,4-dinitrophenyl carbonochloridate, which on further reaction with piperidine (1.1 mmol), at 0-5 °C yields the DNP-morpholine prodru
Figure imgf000053_0002
[00112] 2,4-Dinitrophenyl piperidine-l-carboxylate analytical data: GC MS: M+, 295 1,
1H NMR (400 MHz, CDC13): δ 1.68 (m, 6 H, 3 xCH2), 3.49-3.51 (m, 2H, CH2), 3.64(m, 2H, CH2), 7.52 (d, IH, Ar-H), 8.45 (dd, IH, Ar-H), 8.89 (d, IH, Ar-H) ppm. 13C NMR (75 MHz, CDC13): δ 24.05, 25.44, 25.67, 45.77, 46.67, 121.48, 126.52, 128.66, 141.73, 144.22, 149.74, 150.66 ppm.
[00113] Synthesis of 2,4-dinitrophenyl 4-methylpiperazine-l-carboxylate: 2,4-DNP ( 1 mmol) reacted with triphosgene ( 0.5 mmol), in the presence of K2C03 ( 1 mmol) in dichloromethane to get 2,4-dinitrophenyl carbonochloridate, which on further reaction with N- methyl piperazine (1.1 mmol), at 0-5 °C yields the DNP-N-methyl piperazine prodrug. GCMS complies: 310.26.
Figure imgf000054_0001
[00114] Synthesis of 2,4-dinitrophenyl 4-(2-(piperidin-l-yl)ethoxy)benzoate: 4-(2- (piperidin-l-yl)ethoxy)benzoic acid (1 mmol) on reflux with thionyl chloride (1.25 mmol) in dichloromethane gives its acid chloride, 4-(2-(piperidin-l-yl)ethoxy)benzoyl chloride, which on further reaction with phenol (1 mmol), in presence of triethyl amine (2.0 mmol) affords the final product of 2,4-dinitrophenyl 4-(2-(piperidin-l-yl)ethoxy)benzoate.
Figure imgf000054_0002
[00115] 2,4-dinitrophenyl 4-(2-(piperidin-l-yl)ethoxy)benzoate analytical data:
1H NMR (400 MHz, CDC13); δ 1.60 (s, 2H), 1.96 (s, 4H), 3.08 (bs, 1H, 4H), 3.32 (s, 2H, N- CH2), 4.56 (s, 2H, 0-CH2), 7.04 (d, J= 8.8 Hz, 2H), 7.65 (d, J= 8.8 Hz, 1H), 8.14 (d, J= 8.8 Hz, 2H), 8.56-8.58 (q, j= 2.4 Hz, 8.8 Hz, 1 H), 8.99 (d, J = 2.8 Hz, 1H ) ppm. 1H NMR (75 MHz, CDC13); δ 22.42, 23.59, 54.48, 56.51, 64.04, 114.95, 120.59, 121.78, 126.95, 129.11, 133.23, 141.96, 145.01, 149.10, 162.91, 163.00 ppm.
[00116] Introduction: Pharmacokinetic Analysis and Bioavailability Studies of 2,4-DNP and its prodrug 11-38 in male Sprague-Dawley male rats
[00117] 2,4-DNP is an uncoupler organic compound biochemically active, inhibiting energy (ATP) production in cells with mitochondria. It has been used for treatment of obesity, but its abuse as a dieting agent has led to fatal severe side-effects. The factor that limits the use of increasing doses of DNP is an excessive rise in body temperature due to the heat produced during uncoupling. Accordingly, DNP overdose will cause fatal hyperthermia, with body temperature rising to a fatally high temperature leading to death. It for the later severe adverse effect, that clinical doses were slowly titrated according to patient's tolerance. Therefore, a prodrug design of 2,4-DNP with a better PK will help to deliver 2,4-DNP in lower doses into the body and prevents over dosage. The 11-38 prodrug was synthesized as a drug delivery system in which the end goal was to achieve release of its parent drug (2,4-DNP) in the live plasma. This study investigates the in vitro chemical and enzymatic stability of 11-38 and pharmacokinetic (PK) profile of 11-38 and its parent compound (i.e., 2,4-DNP-released from 11-38).
[00118] Example 1: In vitro chemical and enzymatic stability study of 11-38
To determine the stability of 11-38 prodrug over the time course of 24 h in chemical buffers adjusted to pH 1.2 and 7.4 and simulated gastric fluid and simulated intestinal fluid as well as in rat and human plasma. Prodrugs encounter a wide range of pHs when administered orally to patients. Oral dosing exposes compounds to pH 1 to 2 in the stomach, pH 4.5 at the beginning of the small intestine, pH 6.6 as an average pH for the small intestine, and pH 5 to 9 in the colon. These are useful pHs for in vitro evaluation of the chemical stability of a prodrug candidate as II- 38. The following experiments were performed in aqueous solutions to determine stability of the 11-38 prodrug in the GI tract and susceptibility to enzymatic hydrolysis to the parent drug (2,4- DNP) in plasma:
pH: Stability in aqueous buffers (37 °C, pHs 1.2 and 7.4)
GI: Stability in simulated gastric fluid (USP, 37 °C)
GI: Stability in simulated intestinal fluid (USP, 37 °C)
Plasma: Stability in rat and human plasma (37 °C)
[00119] HPLC chromatography conditions
HPLC analysis was carried out on an Agilent 1200 Infinity Series Quatpump, equipped with a photodiode array detector and a computer integrating apparatus. An Inertsil ODS-3 column, CI 8, 5 μπι, 4.6 x 50 mm (GL Science Inc. Japan) protected with a guard column: Alltima C18, 5 μπι, 4.6 x 7.5 mm (Grace Discovery Sciences, IL, USA) was used as the stationary phase. An isocratic method with a mobile phase consisting of water/acetonitrile (70:30) containing 0.05% formic acid in each was used. A flow rate of 0.9 mL/min was used and detection was carried out at a UV wavelength of 250 nm.
[00120] Stability of 11-38 in hydrochloric (HCl) acid buffer, pH 1.2
Hydrochloric acid, pH 1.2 buffer was prepared. 11-38 (2.5 mg) was dissolved in 0.125 mL of DMSO (5%). Reactions were initiated by adding 11-38 dissolved in DMSO slowly and gradually to a total volume of 2.375 mL of HCl buffer, pH 1.2 (Table 1) in a Franz cell diffusion chamber preheated to 37 °C. The solution was mixed for 30 sec every half an hour using magnetic stirrer. Samples of 20 μL (20 μg/mL of 11-38) were collected at 0, 1, 2, 4, 6 and 8 h. Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 μΐ^ of the supernatant was injected into the FIPLC spectrometer for detection of 2,4-D P and 11-38 in HCl buffer, pH 1.2.
Table 1 : Formulation of 11-38 in HCl buffer, pH 1.2.
Weight of 11-38 Total Volume PBS + DMSO (mL) DMSO (5%) (mL) HQ buffer (mL)
2.5 mg 5 0.125 2.375
As presented in Figure 5, no significant hydrolysis of 11-38 occurred within 8 h as indicated by a single chromatogram eluted at 8.04 min. The slope seen between 0 and 2 h represents an equilibrium (solubility) phase of 11-38 in HCl buffer (Figure 6).
[00121] Stability of 11-38 in phosphate buffer, pH 7.4
Formulation of 11-38 in phosphate buffer (PB): to formulate 1 mg/mL of 11-38 in PB, 2.6 mg of 11-38 was formulated in 0.13 mL of DMSO (i.e. 5%) and added slowly and gradually to a total volume of 2.47 mL of preheated PB (Table 2) in a Franz cell diffusion chamber preheated to 37 °C. The solution was mixed for 30 sec every half an hour using magnetic stirrer. Samples of 20 (20 ug/mL of 11-38) were collected at 0, 0.5, 1, 2, 4, 6 and 8 h. Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 μΕ of the supernatant was injected into the HPLC spectrometer.
Table 2: Formulation of 11-38 in PB. Weight of 11-38 Total Volume PBS + DMSO (mL) DMSO (5%) (mL) PB (mL)
2.6 mg 2^6 0.130 2^47
As presented in Figures 7 and 8, no significant hydrolysis of 11-38 occurred within 8 h in PB as indicated by a single chromatogram eluted at 8.023 min.
[00122] Stability of 11-38 in simulated gastric fluid (SGF), pH 1.2 To formulate 1 mg/mL of 11-38 in SGF, 3.1 mg of 11-38 was dissolved in 0.155 mL of DMSO (i.e. 5%) and added slowly and gradually to a total volume of 2.945 mL of preheated SGF (Table 3) in a cell diffusion chamber preheated to 37 °C. The solution was mixed for 30 sec. every half an hour using magnetic stirrer. Samples of 20 μΐ^ (20 μg/mL of 11-38) were collected at 0, 1, 2, 4, 6 and 8 h. Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 μΕ of the supernatant was injected into the HPLC spectrometer.
Table 3 : Formulation of 11-38 in SGF, pH 1.2.
Weight of 11-38 Total Volume SGF + DMSO (mL) DMSO (5%) (mL) SGF (mL)
Figure imgf000057_0001
As presented in Figures 9, 10A, and 10B, 11-38 is stable in the SGF, predicting stability of 11-38 in vivo in the gastric fluid under acidic conditions for increasing systemic bioavailability.
[00123 ] Stability of 11-38 in simulated intestinal fluid (SIF), pH 6.8
Formulation of 11-38 in SIF buffer, pH 6.8: to formulate 1 mg/mL of 11-38 in SIF, 2.6 mg of II- 38 was dissolved in 0.13 mL of DMSO (i.e. 5%) and titrated slowly and gradually to a total volume of 2.47 mL of preheated SIF (Table 4) in a cell diffusion chamber preheated to 37 °C. The solution was mixed for 30 sec every half an hour using magnetic stirrer. Samples of 20 μΕ (20 μg/mL of 11-38) were collected at 0, 0.5, 1, 2, 4, 6 and 8 h (Figures 12A and 12B). Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 μΕ of the supernatant was injected into the HPLC spectrometer (Figure 11).
Table 4: Formulation of 11-38 in SIF Weight of 11-38 Total Volume PBS + DMSO (mL) DMSO (5%) (mL) SIF (mL) 2.6 mg 2^6 0Λ3 2ΛΊ
[00124] Stability of 11-38 in rat and human plasma
Formulation of 11-38 in rat plasma: to prepare 1 mg/mL of 11-38 in rat plasma, 2.4 mg of 11-38 was formulated in DMSO (5%) and added slowly and gradually to a total volume of 2.28 mL of premixed rat plasma (80% + PBS 15%, Table 5) in a Franz cell diffusion chamber preheated to 37 °C. The solution was mixed for 30 sec every half an hour using magnetic stirrer. Samples of 20 μL· (20 μg/mL of Π-38) were collected at 0, 1, 3, 4, 5, 20, 23, and 24 h (Figures 13 and 14). Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 μΕ of the supernatant was injected into the HPLC spectrometer.
Table 5 : Formulation of 11-38 in rat plasma.
Wt. of 11-38 Total volume of rat plasma rat plasma PBS DMSO
(Mg) (80%) + PBS 15% + DMSO 5%, mL (80%), mL (15%), mL 5%, mL
2A0 2A0 L92 036 0.12
[00125] Detection of 2, 4-DNP and 11-38 in human plasma using HPLC
Formulation of 11-38 in human plasma: to prepare 1 mg/mL of 11-38, 2.3 mg of 11-38 was formulated in DMSO (5%) and added slowly and gradually to a total volume of 2.185 mL of premixed human plasma (80% + PBS 15%, see Table 6) in a Franz cell diffusion chamber preheated to 37 °C. The solution was mixed for a min every half an hour using magnetic stirrer. Samples of 20 μΕ (20 μg/mL of 11-38) were collected at 0, 0.5, 1, 2, 4, 6 and 8 h. Each sample was mixed with acetonitrile QS to 1 mL, vortex-mixed for 30 sec and centrifuged at 10,000 rpm at room temp. A volume of 10 μΕ of the supernatant was injected into the FIPLC spectrometer.
Table 6: Formulation of 11-38 in human plasma.
Wt. of 11-38 Total volume of human plasma human plasma PBS DMSO (Mg) (80%) + PBS 15% + DMSO (mL) (80%) mL (15%) mL 5% (mL)
23 23 L84 0.345 0.1 15
[00126] SUMMARY
Data from stability study of 11-38 in different nonenzymatic aqueous buffers clearly indicate that 11-38 did not show significant hydrolysis in acidic and basic buffers media. It can be concluded that 11-38 will be stable enough in the GI tract when administered orally to be absorbed as a single chemical entity. However, hydrolysis of 11-38 in 80% rat and human plasma predicted that 11-38 would hydrolyze in systemic circulation to produce its parent drug, 2,4-DNP. The carbamate linkage in 11-38 was cleaved in the plasma to produce 2,4-DNP at a slow rate, which allows 11-38 to act as a chemical reservoir of 2,4-DNP for a prolonged period of time. [00127] Example 2: Pharmacokinetic analysis of 2,4-DNP and 11-38
The oral bioavailability and plasma pharmacokinetic (PK) properties of 11-38 prodrug and 2,4- DNP-released from 11-38 prodrug was investigated in Sprague-Dawley (S-D) male rats after a single i.v. injection of 11-38 at 1.6 mg/kg (eq. to 1 mg/kg 2,4-DNP) and an oral dose eq. to 5, 25 and 50 mg/kg of 2,4-DNP. Blood samples were taken up to 24 hour.
[00128] Animals
All procedures that involved the use of rats were conducted in accordance with the guidelines set forth by the University of Arkansas for Medical Sciences (UAMS) Institutional Animal Care and Use Committee established by the National Institutes of Health's Guide for the Care and Use of Laboratory Animals (1996). Male Sprague-Dawley rats weighing 250 - 300 grams were housed three per cage with ad libitum access to food and water in the Division of Laboratory Animal Resources, UAMS. Rats were anesthetized with isofluorane (2-5%)/oxygen (1.5-2.0 L/min) and surgically implanted with cannulae in the jugular (i.v. dosing) and femoral (blood sampling) veins. After 3 - 4 days post-surgery, rats were observed for signs of local infection at surgical sites, for hair yellowing, for presence of blood around the nose or eyes, for indications of lessened appetite, and for signs of lessened or absent fecal activity. Following appropriate evidence of successful recovery from surgery, IV or oral dosing was performed and blood samples (0.15 mL) were collected at 0, 5, 15, 30, 45, 60, 120, 240 and 480 min. Plasma samples were prepared and analysis was run using a LC/MS/MS spectrometry.
[00129] 2, 4-DNP dose preparation
2,4-DNP was dissolved in a phosphate-saline buffer solution, pH 7.4 containing 5% DMSO and 20% PEG-400 and filtered through a 0.2-μπι filter. For the oral route, rats were gavaged with 5 mg/kg in a total volume of 8 mL/kg from a stock solution containing 0.625/mL of 2,4-DNP. For the i.v. injection, a total volume of 0.8 mL/kg was used at a dose of 1 mg/kg from a stock solution containing 1.25 mg/mL.
[00130] 11-38 dose preparation
For the i.v. injection, a total volume of 0.8 mL/kg was used at a dose of 1.6 mg/kg (eq. to 1 mg/kg of 2,4-DNP). For the oral route, stock solutions of 11-38 containing eq. to 1, 5 and 25 mg/mL of 2,4-DNP were prepared and administered to rats at final doses eq. to 1, 5 and 25 mg/kg of 2,4-DNP, respectively. An oral dose of 8 mg/kg of 11-38 (eq. to 5 mg/kg) was dissolved in a phosphate-saline buffer solution, pH 7.4 containing 5% DMSO and 20% PEG- 400, while a dose of 40 mg/kg (eq. to 25 mg/kg) was formulated with 0.5% methyl cellulose (methocel) containing 1% DMSO. A high dose of 11-38 (eq. 50 mg/kg) was formulated with water containing 1% DMSO and 40% PEG-400. Because of the different vehicles used in formulations of 11-38, a dose eq. to 25 mg/kg of 2,4-DNP was repeated using a vehicle consisting of DMSO, PEG-400, and water (1%: 40%: 59%). The later dose was utilized for comparison of PK data of 2,4-DNP -released from 11-38 for differences in formulations.
[00131] Oral and i. v. animal experiments of 2, 4-DNP
Jugular and femoral vein- catheterized Sprague-Dawley male rats (weights 250-300 g) were treated with 2,4-DNP at a single oral dose of 5 mg/kg (n = 4) or a single i.v. dose of 1 mg/kg (n =3). For each i.v. and oral experiment, blood samples (0.15 mL) were collected at 0, 5, 15, 30, 45, 60, 120, 240 and 480 min. The withdrawn blood was replaced with heparinized saline (0.15 mL). Blood samples were centrifuged at 10,000 rpm for 10 min at room temperature, and plasma samples were prepared and analysis was run using a sensitive LC/MS/MS spectrometry method (see below).
[00132] Oral and i. v. animal experiments of 11-38
Jugular and femoral vein-catheterized Sprague-Dawley male rats (weights 250-300 g, n =4) were treated with 11-38 at a single oral dose of 8, 40 and 80 mg/kg (eq. to 5, 25 and 50 mg/kg of 2,4- DNP, respectively) or injected a single i.v. dose of 1.6 mg/kg of II-38(eq. to 1 mg/kg 2,4-DNP, n =2). Blood samples (0.15 mL) were collected at 0, 5, 15, 30, 45, 60, 120, 240 and 480 min. Plasma samples were prepared and 2,4-DNP, 11-38 and 2,4-DNP-released from 11-38 concentrations were quantitated using the LC/MS/MS spectrometry assay method described below.
[00133] Preparation of plasma samples and extraction procedure
To isolate the analytes from rat plasma, 50 μΕ of control or treated plasma fortified with 10 μΕ of 2,4-DNP-d3 (10 μg/mL) as an internal standard to which 0.3 mL of methanol followed by 0.3 mL of acetonitrile was added. The mixture was vortex-mixed for 30 s and centrifuged for 10 min at 10,000 rpm at room temperature. The supernatant was transferred into 5 mL glass tubes and evaporated to dryness at 37 °C under nitrogen gas. The pellet was reconstituted with 50 μΕ of acetonitrile, vortex-mixed for 30 sec, followed by sonication for 1 min. Following centrifugation at 1000 rpm for 10 min at room temperature, 5 μΕ of the supernatant was then injected onto the column, and analytes were quantified by a LC/MS/MS spectrometry. [00134] LC/MS/MS analysis
A sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay has been applied to quantify 2,4-DNP and 11-38 in rat plasma as follows:
1- Plasma concentrations of 2,4-DNP after a single i.v. injection of 2,4-DNP of 1 mg/kg or 5 mg/kg oral administration; 2- Plasma concentrations of 11-38 and 2,4-DNP-released from 11-38 after an i.v. injection 1.6 mg/kg of 11-38 eq. to 1 mg/kg of 2,4-DNP or an oral dose of 8, 40 and 80 mg/kg of 11-38 eq. to 5, 25 and 50 mg/kg of 2,4-DNP, respectively. The mass spectrometer was an Agilent quadrupole mass spectrometer operated in the multiple reaction monitoring (MRM) mode. 2,4-DNP-d3 was used as an internal standard. 2,4-DNP, 11-38 and 2,4-DNP-d3 were separated using an Alltima CI 8 column, 5 μπι, 3.2 X 150 mm (Grace Discovery Sciences, IL, USA) equipped with a guard column: Alltima CI 8, 5 μπι, 4.6 x 7.5 mm (Grace Discovery Sciences, IL, USA). The mobile phase consists of water with 0.005% formic acid as solvent A and acetonitrile with 0.005% formic acid as solvent B. For analysis of 2,4-DNP, 11-38 and 2,4- DNP-d3 compounds, the separation was achieved using a gradient of 10 to 90% solvent B in 3.5 min, which was maintained at 90% B for the next 3.30 min and then equilibrated back to the initial conditions over 3.20 min. The flow rate was 0.8 mL/min with a column temperature of 30 °C. The sample injection volume was 5 μL. The mass spectrometer was operated in the negative electrospray ionization mode with optimal ion source settings determined using standards of 2,4-DNP, 11-38 and 2,4-DNP-d3 with a collision energy of 15 V, and a fragmentor of 75 V. MRM transitions monitored were as follows: 2,4-DNP- m/z 183.0 /123.0, m/z 183.0/153.0, for 2,4-DNP-d3- m/z 186.0/126.0, m/z 186.0/156.0 and for 11-38- m/z 297.2/183.2. Two separate standard curves of 2,4-DNP and 11-38 in rat plasma were generated and used to quantify 2,4-DNP and 11-38, respectively.
[00135] Standard curve of 2, 4-DNP in acetonitrile (A CN)
Stock solution of 2,4-DNP was prepared in acetonitrile. Standard curve with 8 different concentrations was prepared. Calibration curve was obtained using quadratic least- squares regression of area-under-the-curve (AUC) vs. 2,4-DNP concentration. The curve was linear between 0.01-1 μg/ml with a correlation coefficient of R2 = 0.9874 (Figure 15).
[00136] Standard curves of 2, 4-DNP and 11-38 in plasma
Stock solutions of each of 2,4-DNP and 11-38 and internal standard (2,4-DNP-d3) were prepared in acetonitrile. Serial dilutions of the 2,4-DNP and 11-38 solutions were prepared and LC/MS/MS chromatograms of 2,4-DNP and 11-38 calibration standards generated for each analyte over the concentration range 1-2000 ng/mL in plasma (n = 5). The calibration curves and chromatograms showed excellent linearity between 20-2000 ng/mL and 200-1000 ng/mL for 2,4-DNP and 11-38, respectively, with a correlation coefficient of R2 = 0.9988 and 0.9739 for 2,4- DNP and 11-38, respectively (Figures 16 and 17).
[00137] Plasma Pharmacokinetics
Individual 2,4-DNP and 11-38 prodrug plasma concentration-time profiles after i.v. bolus administration were calculated using a one-compartment open model and first order elimination (Phoenix WinNonlin, Professional, version 6.2, Pharsight, Mountain View, CA).
Following oral administration, data were analyzed by a non-compartment open model and first order absorption to determine peak concentration (Cmax), TmaX; and area under the curve from 0 to infinity (AUCo-inf). Actual apparent bioavailability of 2,4-DNP, 11-38 prodrug and 2,4-DNP- released from 11-38 was determined using Equation 1 :
= (Auc0r C Dosei ) (Equation 1)
(AUCi.v.XDoseoral) ' where AUC0rai AUCi.v, Doseorai, and Dosei.v. represent the AUCo-inf and corresponding dose for the oral and i.v. injections of 2,4-DNP or 11-38 prodrug, respectively. The bioavailability of 2,4- DNP released from 11-38 was obtained from the AUC of 2,4-DNP released from oral and i.v. administration of 11-38 using Equation 1.
[00138] Total apparent bioavailability of 11-38 prodrug was estimated in the same manner using AUC data for both 11-38 prodrug and 2,4-DNP. Equation 2 is the modified form of the bioavailability expression which takes into account the time-dependent hydrolysis of 11-38 prodrug after administration to rat. The best estimate for the total bioavailability includes the AUC data for released 2,4-DNP in the plasma as well.
[00139] The release of 2,4-DNP from 11-38 prodrug occurs in an equimolar ratio. Since the prodrug is being hydrolyzed to release 2,4-DNP in a 1 : 1 ratio, it follows that an equal amount of 11-38 has hydrolyzed to form 2,4-DNP. The calculation of oral bioavailability of the prodrug involves two different metrics. Actual apparent bioavailability takes into account the time- dependent hydrolysis of 11-38 prodrug. To estimate total apparent bioavailability of the 11-38, systemic exposure to both 11-38 prodrug and its released 2,4-DNP must be considered. It can be calculated using Equation 2:
(AUCii ,oral +AUC -DNpi0rai)( DoseH j
F% = X 100 (Equation 2)
(AUCII_38ii.Vi+ AUC -DNP,i.v.)(D o s eH ,oral)
Plasma concentration of 2,4-DNP vs. time after oral dosing and i.v. injection is presented in Figure 18. Following oral dosing, 2,4-DNP absorption was fast as indicated by the plasma concentration at 5 min. The half-life for 2,4-DNP was 90 ± 9.9 min and 136.2 ± 10.9 min for the i.v. and oral routes, respectively Table 7.
[00140] Oral administration of 11-38 prodrug in S-D rats at doses eq. to 5, 25 (methocel), 25 (PEG-400) and 50 mg/kg of 2,4-DNP resulted in delivery of 2,4-DNP with peak plasma concentrations of 3.2 ± 0.2, 9.4 ± 0.6, 9.1 ± 0.84 and 15.2 ± 2.7 μg/mL being reached within 120 ± 16.9, 161.3 ± 39.4, 240 and 180 ± 34.6 min respectively (Table 8). It is noteworthy that the PK profile for 11-38 formulated in DMSO:PEG-400: water (1 :40:59) vehicle compares well with the methocel formulation.
Table 7: PK profile of 2,4-DNP after treatment with a single i.v. dose of 1 mg/kg (n =3) or a single oral dose of 5 mg/kg of 2,4-DNP (n = 4 rats)
Figure imgf000063_0001
[00141] Figure 18 shows the plasma concentration of 2,4-DNP vs. time after a single IV injenction, or an oral dose. Figures 19, 20, 21, and 22 show mean plasma concentrations vs. time profiles of 11-38, and 2,4-DNP released from its 11-38 prodrug after oral administration of eq. doses of 5, 25 (methocel), 25 (PEG-400) and 50 mg/kg of 2,4-DNP, respectively. Figure 23 compares mean plasma concentrations vs. time of 2,4-DNP oral dose of 5 mg/k to 2,4-DNP released from 11-38 after oral administration of 11-38 at doses of 8, 40 (methocel), 40 (PEG-400) and 80 mg/kg [eq. to 5, 25 (methocel), 25 (PEG-400)] and 50 mg/kg of 2,4-DNP], respectively, n = 4. The carbamate linkage of 11-38 prodrug apparently cleaved in vivo to produce 2,4-DNP as a hydrolysis product of the 11-38 prodrug. Bioavailabilities of 2,4-DNP released from 11-38 and II- 38 are presented in Tables 8, 9, and 10, respectively.
Table 8: PK profile of 2,4-DNP at an oral dose of 5 mg/kg and 2,4-DNP- released from 11-38 after treatment with a single oral dose of 11-38 eq. to 5, 25 (methocel), 25 (PEG=500) and 50 mg/kg of 2,4-DNP, respectively, n = 4 rats
Figure imgf000064_0001
Table 8.1 : PK profile of M101 administered orally and M101 released from M201
(MlOl-morpholino) after treatment with a single oral dose of M201
(equivalent to 5, 25 and 50 mg/kg of M101, respectively)
Figure imgf000064_0002
*Last time point was 30 h Table 9: PK profile of 11-38 after treatment with a single oral dose of 11-38 eq. to 5, 25
(methocel), 25 (PEG=500) and 50 mg/kg of 2,4-DNP, respectively, n = 4 rats
Figure imgf000065_0001
Table 10: PK profile of 11-38 and 2,4-DNP released from 11-38 after a single i.v. injection of II- 38 at 1.6 mg/kg (eq. to 1 mg/kg 2,4-DNP), n = 2 rats
Figure imgf000065_0002
[00142] Discussion
[00143] 11-38 prodrug was synthesized as a drug delivery system in which the end goal was to achieve release of the parent drug (2,4-DNP) in the rat plasma. In vitro stability studies of 11-38 (chapter 1) have indicated no evidence of 2,4-DNP formation from 11-38 over the time course of 24 h in chemical buffers adjusted to pH 1.2 and 7.4. Likewise, 11-38 prodrug was stable over a 24 h (both of 11-38 and 2,4-DNP are not presented in the graph after 24 h) time course in simulated gastric fluid and simulated intestinal fluid that had been prepared by the methods of the USP. Thus, it can be predicted that 11-38 delivered orally, will be absorbed via the GI tract into the systemic circulation as a stable entity and would be hydrolyzed under enzymatic conditions in the systemic circulation to release 2,4-DNP in plasma.
[00144] 11-38 was evaluated in vivo to investigate the PK profile and relative bioavailability of 2,4-DNP-released from 11-38 and to determine the time course of plasma levels of 2,4-DNP released from 11-38 after a single oral dose of 11-38 at 8, 40 and 80 mg/kg (eq. to 5, 25 and 50 mg/kg 2,4-DNP, respectively) or an i.v. bolus dose of 1.6 mg/kg (eq. to 1 mg/kg of 2,4-DNP) and compare the data to 2,4-DNP dosed orally at a single dose of 5 mg/kg or injected i.v. at 1 mg/kg in rats.
[00145] Following oral dosing, it can be noticed from the mean concentrations vs. time profile of 11-38 prodrug and 2,4-DNP released from 11-38 (Figures 19, 20, 21, and 22) that the carbamate linker in the codrug underwent hydrolysis to produce 2,4-DNP. 11-38 prodrug showed slow dissolution to its parent drug, 2,4-DNP in the plasma, providing sustained release of the 2,4- DNP. It is worth noting that the hydrolysis of 11-38 is not complete, as 11-38 prodrug can be seen along with 2,4-DNP at all time points after oral and i.v. administration (Figures 19, 20, 21, and 22).
[00146] Since 11-38 contains equimolar amounts of 2,4-DNP, it follows that an equal amount of 11-38 must have hydrolyzed in plasma unless the carbamate linkage underwent cleavage to release 2,4-DNP in the intestine and/or liver. Alternatively, 2,4-DNP may have underwent metabolism in plasma after formation from 11-38. Nonetheless, the predictions regarding in vivo stability of the 11-38 prodrug were correct, because significant levels of 2,4-DNP were observed in all of the rats after oral and i.v. administration as indicated by the bioavailabilities of 58.5 ± 8.1, 62.8 ± 5.8, 41 ± 5.1 and 50.1 ± 11.5 for 2,4-DNP released from oral administration of 11-38 at doses eq. to 5, 25 (methocel), 25, (PEG-400) and 50 mg/kg, respectively (Table 8).
A one-compartment model describes i.v. dosing of 2,4-DNP and 11-38. Peak plasma level of released 2,4-DNP (€ims: 2.2 ± 1.1 ^ig/mL) was detected within 5 min indicating rapid cleavage of 11-38. A non-compartment model adequately describes the PK of oral 11-38 prodrug and its released 2,4-DNP. It can be shown that at any time point, the 11-38 prodrug is present at a lower concentration than 2,4-DNP, Figures 19, 20, 21, and 22, and Tables 8 and 9. Thus, absorption of 11-38 prodrug appears to be very rapid followed by fast cleavage and sustained release of 2,4- DNP as the later was detected in plasma within 5 min after oral dosing reaching a Cmax of 3.2 - 15.2 μg/mL within a tmax of 120- 180 min. The half-lives of elimination (ti/2) being 136.3 ± 10.9 and 90.0 ± 9.9 min, for oral and i.v. dosing of 2,4-DNP, respectively. These results compare less with a prolonged average terminal half-life of 248.2 ± 45.3, 185.9 ± 18.1 and 334.1 ± 63.0 for 2,4-DNP-released from 11-38 at eq. doses of 25 (methocel), 25 (PEG-400) and 50 mg/kg (table 2.2), suggesting that oral administration of 11-38 resulted in a significant improvement in the delivery of 2,4-DNP compared to administration of 2,4-DNP alone. [00147] It was calculated that an approximately 12.0-, 2.2-, 3.4 - and 1.4-fold increased level of 2,4-DNP was observed following oral dosing of 2,4-DNP parent drug compared to 2,4-DNP released from its 11-38 prodrug after oral dosing of 11-38 at eq. to 5, 25 (methocel), 25 (PEG-400) and 50 mg/kg, respectively (Figure 23 and Table 8). The data from i.v. injection and oral dosing of 11-38 does suggest that 2,4-DNP released from the 11-38 prodrug may be subjected to other enzymatic activities taking place in different tissue compartments other than plasma, including the liver. In the rat plasma, the 11-38 prodrug and its released 2,4-DNP are free to partition into other sites of metabolism, whereas in vitro plasma studies relied solely on plasma enzymes. However, release of 2,4-DNP from its prodrug over prolonged half-lives of 141.7-334.1 min and delayed ax of 120-240 min due to its slow release means prolonged exposure and less unexpected high peaks from released 2,4-DNP. In other word, the released 2,4-DNP following oral 11-38 is suitable in suppressing acute adverse effects of 2,4-DNP due to rapid absorption and high plasma Cmax.
[00148] Conclusion
In this study, oral administration of 11-38 prodrug resulted in 2,4-DNP being significantly released and available from 11-38 over time leading to prolonged exposure (AUC) and significant bioavailability of 2,4-DNP. Apparently, the 11-38 prodrug is stable for formulation purposes and rapidly hydrolyzed in rat plasma.
[00149] Example 3: PK profile of 2,4-DNP- released from DNP-piperidino
Table 11 : PK profile of 2,4-DNP- released from DNP-piperidino after treatment with a single oral dose of DNP-piperidino equivalent to 5 mg/kg of 2,4-DNP formulated in DMSO:PEG-400:PBS (5:20:75)
Figure imgf000067_0001
[00150] Example 4: Hearing Loss Treatment
[00151] In vivo Noise Exposure Pilot DNP (2,4-DNP) & Prodrug of DNP (11-38): Rats, N=6/group: control, noise alone, noise + 2,4-DNP (5 mpk), noise + 11-38 (80 mpk). Noise exposure: 8h, 105 dB, noise band 8-16 kHz. Treatment duration 5 days oral gavage q.d. starting day of noise. Endpoint: Compound Action Potential (CAP) recorded from the round window membrane 1-week post exposure. Threshold: intensity in dB SPL needed to produce 4 μν CAP amplitude.
[00152] Results: As shown in Figure 3, II-38+Noise thresholds were 5 dB, approximately 20 dB lower (better) than the Noise alone group. These results suggest that DNP Prodrug (II-38( can protect against noise induced hearing loss. Also as shown in Figure 3, DNP (2,4- DNP)+Noise thresholds were 15 dB about 10 dB lower than Noise alone suggesting that DNP (2,4-DNP) can protect against noise induced hearing loss.
[00153] The description of the embodiments of the present invention is given above for the understanding of the present invention. It will be understood that the invention is not limited to the particular embodiments described herein, but is capable of various modifications, rearrangements and substitutions as will now become apparent to those skilled in the art without departing from the scope of the invention. Therefore, it is intended that the following claims cover all such modifications and changes as fall within the true spirit and scope of the invention.

Claims

We claim:
1. A composition for treating neuromuscular diseases, neuromuscular degenerative diseases, muscle wasting diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising one or more isomers of dinitrophenol (D P): 2,3- DNP, 2,4-D P, 2,5-DNP, 2,6-D P, 3,4-D P, or 3,5-D P.
2. A composition for treating neuromuscular diseases, neuromuscular degenerative diseases, muscle wasting diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: a DNP phosphate prodrug altered by introducing a water-soluble prodrug moiety into the molecule through conjugation with the free phenolic functionality.
3. A composition for treating neuromuscular diseases, neuromuscular degenerative diseases, muscle wasting diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: a prodrug, the prodrug being selected from the group consisting of
an amino acid (AA) ester of 2,3-D P, 2,4-D P, 2,5-DNP, 2,6-D P, 3,4-D P, or 3,5- DNP (Scheme 1, Formulas I-l to 1-10; Scheme 2, Formulas II-l to 11-10; Scheme 3, Formulas III-l to III-10; Scheme 4, Formulas IV-1 to IV-10; Scheme 5, Formulas V-1 to V-10; and Scheme 6, Formulas VI-1 to VI-10);
AA esters incorporating a methylene dioxide (a formaldehyde equivalent) spacer (Scheme 1, Formulas 1-11 to 1-13; Scheme 2, Formulas 11-11 to 11-13; Scheme 3, Formulas Hill to 111-13; Scheme 4, Formulas IV-11 to IV-13; Scheme 5, Formulas V-ll to V-13; and Scheme 6, Formulas VI-11 to VI-13);
amino carbamate 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP prodrugs (Scheme 1, Formulas 1-14 to 1-17; Scheme 2, Formulas 11-14 to 11-17; Scheme 3, Formulas III- 14 to 111-17; Scheme 4, Formulas IV-14 to IV-17; Scheme 5, Formulas V-14 to V-17; and Scheme 6, Formulas VI-14 to VI-17);
amino carbonate 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP prodrugs (Scheme 1, Formulas 1-18 and 1-19; Scheme 2, Formulas 11-18 and 11-19; Scheme 3, Formulas
III- 18 and 111-19; Scheme 4, Formulas IV-18 and IV-19; Scheme 5, Formulas V-18 and V-19; and Scheme 6, Formulas VI-18 and VI-19);
phosphate analogs 1-20, 1-21, 11-20, 11-21, 111-20, 111-21, IV-20, IV-21, V-20, V-21, VI- 20, and VI-21 (Schemes 1-6);
1,3 diketo analogs 1-22 to 1-32; 11-22 to 11-32; 111-22 to 111-32; IV-22 to IV-32; V-22 to V-32; and VI-22 to VI-32 (Schemes 1-6);
carbonate and carbamate analogs 1-33 to 1-39; 11-33 to 11-39; 111-33 to 111-39; IV-33 to
IV- 39; V-33 to V-39; and VI-33 to VI-39 (Schemes 1-6); and
benzoate analogs 1-40, 11-40, 111-40, IV-40, V-40, and VI-40 (Schemes 1-6);
and combinations thereof.
4. The composition of claim 2 or 3, wherein the prodrug is stable at a pH of 1-2.
5. The composition of claim 2 or 3, wherein the prodrug is stable at a pH of 4.5.
6. The composition of claim 2 or 3, wherein the prodrug is stable at a pH of 5-9.
7. The composition according to any of claims 1 to 6, wherein the composition is administered orally.
8. The composition according to any of claims 1 to 6, wherein the composition is administered through oral gavage.
9. The composition according to any of claims 2 to 6, wherein the water-soluble prodrug moiety is introduced into the molecule through conjugation with the free phenolic functionality.
10. The composition according to any of claims 2 to 6, wherein a prodrug linker moiety confers water-solubility properties on the prodrug molecule.
11. The composition of claim 10, wherein the prodrug is a soft alkyl ether prodrug.
12. The composition of claim 11, wherein the prodrug incorporates ethyleneoxy groups into promoieties such as alkyloxycarbonylmethyl (AOCOM) and N-alkyl-N-alkyloxycarbonylamino methyl (NANAOCAM) prodrugs.
13. A composition for treating neuromuscular diseases, neuromuscular degenerative diseases, muscle wasting diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising:
a prodrug, the prodrug being selected from the group consisting of, 2,3-D P, 2,4-D P, 2,5-D P, 2,6-D P, 3,4-D P, or 3,5-D P "Gemini" prodrugs, wherein the prodrug is represented by Formula VII:
Figure imgf000072_0001
VI I
14. The composition of claim 13, wherein the prodrug is stable at a pH of 1-2.
15. The composition of claim 13, wherein the prodrug is stable at a pH of 4.5.
16. The composition of claim 13, wherein the prodrug is stable at a pH of 5-9.
17. The composition according to any of claims 14-16, wherein the composition is administered orally.
18. The composition according to any of claims 14-16, wherein the composition is administered through oral gavage.
19. A method for synthesizing a prodrug for treating neuromuscular diseases, neuromuscular degenerative diseases, muscle wasting diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising:
reacting 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, and/or 3,5-DNP with an OH- protected oxyphthaloyl dichloride in the presence of a base, and removing the protecting group to afford the prodrug of Formula VII:
Figure imgf000072_0002
VI I
20. The method of claim 19, wherein the prodrug is stable at a pH of 1-2.
21. The method of claim 19, wherein the prodrug is stable at a pH of 4.5.
22. The method of claim 19, wherein the prodrug is stable at a pH of 5-9.
23. The method according to any of claims 20-22, wherein the prodrug is administered orally.
24. The method according to any of claims 20-22, wherein the prodrug is administered through oral gavage.
25. The method of according to any of claims 20-24, wherein the prodrug is an ester group.
26. The method according to claim 25, wherein the prodrug incorporates sterically hindered ester linkers into the prodrug structure.
27. The method according to claim 24, wherein the prodrug incorporates carbonate linkers into the prodrug structure.
28. The method according to claim 24, wherein the prodrug incorporates carbamate linkers into the prodrug structure.
29. The method according to claim 24, wherein the prodrug incorporates phosphate linkers into the prodrug structure.
30. The method according to claim 24, wherein the prodrug incorporates AOCOM and NANAOCAM based linkers into the prodrug structure.
31. The method of according to claim 24, wherein the prodrug conjugates the free phenolic group with appropriate hydrophilic moieties.
32. A composition for treating neuromuscular diseases, neuromuscular degenerative diseases, muscle wasting diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising:
one or more bioprecursors of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP that release 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP after oxidative metabolism by cytochrome P-450, wherein the bioprecursors are represented by Formulas VIII and IX:
Figure imgf000074_0001
Figure imgf000074_0002
IX
33. The composition of claim 32, wherein the bioprecursors are stable at a pH of 1-2.
34. The composition of claim 32, wherein the bioprecursors are stable at a pH of 4.5.
35. The composition of claim 32, wherein the bioprecursors are stable at a pH of 5-9.
36. The composition of claim 32, wherein the composition is administered orally.
37. The composition according to any of claims 32-36, wherein the composition is administered through oral gavage.
38. A composition for treating neuromuscular diseases, neuromuscular degenerative diseases, muscle wasting diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMAl, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising: DNP prodrugs and bioprecursors with linkers containing open functional groups delivered as depot nanoparticle formulations that release DNP in a slow, sustained fashion at low doses compared to dose and release of DNP alone.
39. The composition of claim 38, wherein the prodrugs and bioprecursors are stable at a pH of 1-2.
40. The composition of claim 38, wherein the prodrugs and bioprecursors are stable at a pH of 4.5.
41. The composition of claim 38, wherein the prodrugs and bioprecursors are stable at a pH of 5-9.
42. The composition according to any of claims 39-41, wherein the composition is administered orally.
43. The composition according to any of claims 39-41, wherein the composition is administered through oral gavage.
44. A method of treatment of neuromuscular diseases, neuromuscular degenerative diseases, muscle wasting diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising:
administering to a patient in need of treatment a dose of a composition,
wherein the composition comprises one or more of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6- DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6- DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, or combinations thereof, and
wherein the dose of the composition is: from about 0.01 mg/kg of body weight to about 25 mg/kg of body weight of the patient in need of treatment; or from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment.
45. A method of treatment of neuromuscular diseases, neuromuscular degenerative diseases, muscle wasting diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome, comprising:
administering to a patient in need of treatment a dose of a composition, wherein the composition comprises one or more of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- DNP; bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5- D P) prodrugs; Gemini prodrugs, bioprecursor molecules, or combinations thereof,
wherein the dose of the composition is from about 1 mg/70 kg of body weight to about 200 mg/70 kg of body weight of the patient in need of treatment.
46. The method of claim 44 or 45, wherein the neuromuscular diseases, neuromuscular degenerative diseases, muscle wasting diseases, neurodegenerative diseases, autoimmune diseases, developmental diseases, traumatic diseases of CNS, hearing loss related due to aging, noise, drug induced and/or genetic hearing loss,, and/or metabolic diseases is selected from the group consisting of Traumatic Brain Injury (TBI), Ischemic stroke, Huntington's disease (Adult- onset Huntington's, Juvenile Huntington's disease), Epilepsy (Cluster Seizures, Refractory Seizures, Atypical Absence Seizures, Atonic Seizures, Clonic Seizures, myoclonic seizures, tonic seizures, Tonic-Clonic Seizures, Simple Partial Seizures, Complex Partial Seizures, Secondary Generalized Seizures, Febrile Seizures, Nonepileptic Seizures, Gelastic and Dacrystic Seizures, and Absence Seizures), Multiple Sclerosis (MS) (relapse-remitting multiple sclerosis (RRMS), Secondary-progressive MS (SPMS), Primary-progressive MS (PPMS), and Progressive-relapsing MS (PRMS)), Lupus (Systemic Lupus Erythematosus (SLE), discoid (cutaneous), drug-induced lupus (dil) and neonatal lupus), Diabetes mellitus (Type-1 Diabetes, Type-2 Diabetes, Maturity Onset Diabetes of the Young (MODY: MODY1, MODY2, MODY3, MODY4, MODY5, MODY6, MODY7, MODY8, MODY9, MODY10, MODY11)), Nonalcoholic Steatohepatitis (NASH), Schizophrenia (Paranoid schizophrenia, Disorganized schizophrenia, Catatonic schizophrenia, Residual schizophrenia, Schizoaffective disorder), Myasthenia gravis (MG) (ocular myasthenia gravis, Congenital MG and generalized myasthenia gravis), rheumatoid arthritis (RA), Graves' disease, Guillain-Barre syndrome (GBS), Muscular Dystrophy (Duchenne Muscular Dystrophy (DMD), Becker, Myotonic, Congenital, Emery- Dreifuss, Facioscapulohumeral, Limb-girdle, Distal, and Oculopharyngeal), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Ataxia (Friedreich's Ataxia, Spinocerebellar ataxias 1 (SCAl), Spinocerebellar ataxias 2 (SCA2), Spinocerebellar ataxias 3 (SCA3), Spinocerebellar ataxias 6 (SCA6), Spinocerebellar ataxias 7 (SCA7), Spinocerebellar ataxias 11 (SCAl l), Dentatorubral pallidolusyian atrophy (DRPLA) and Gluten ataxia), Batten Disease or neuronal ceroid lipofuscinoses (NCL) (infantile NCL (INCL), late infantile NCL (LINCL), juvenile NCL (JNCL) or adult NCL (ANCL)), Alzheimer's Disease (Early-onset Alzheimer's, Late-onset Alzheimer's, and Familial Alzheimer's disease (FAD)), Optic neuritis (ON), Leber's hereditary optic neuropathy (LHON), Autism Spectrum Disorders (ASD) (Asperger's Syndrome, Pervasive Developmental Disorders (PDDs), Childhood Disintegrative Disorder (CDD), and Autistic disorder), Rett syndrome, Angelman's Syndrome, Leigh disease, Prader Willi Syndrome, Fragile-X Syndrome, Depression (Major Depression, Dysthymia, Postpartum Depression, Seasonal Affective Disorder, Atypical Depression, Psychotic Depression, Bipolar Disorder, Premenstrual Dysphoric Disorder, Situational Depression), Parkinson's disease (Idiopathic Parkinson's disease, Vascular parkinsonism, Dementia with Lewy bodies, Inherited Parkinson's, Drug-induced Parkinsonism, Juvenile Parkinson's and atypical parkinsonism), Wolfram syndrome (and any associated conditions such as diabetes issues, hearing, vision, ataxia, neurodegeneration, etc.), spinal muscular atrophy (SMA; type I, II, III and IV), hearing loss due to noise (blast and high noise), aging related hearing loss, drug induced hearing loss, and/or genetic hearing loss, concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolcott- Rallison syndrome, mitochondrial diseases, developmental disorders, metabolic syndrome (increased blood pressure, high blood sugar level, excess body fat around the waist and abnormal cholesterol levels) and/or autoimmune disorders insulin resistance disease, sleep apnea disease, hypertension disease, kidney disease, high blood pressure disease, obesity disease, inflammation disease, disease resulting in knee-joint complications, depression disease, cardiovascular disease, and cancer disease.
PCT/US2017/021080 2016-03-07 2017-03-07 Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases Ceased WO2017155940A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU2017229224A AU2017229224B2 (en) 2016-03-07 2017-03-07 DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases
MX2018010718A MX2018010718A (en) 2016-03-07 2017-03-07 DINITROPHENOL (DNP) AND DINITROPHENOL PRO-DRUG (DNP) TREATMENT FOR NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL, CONCUSSION, DRY EYE DISEASE AND / OR METABOLIC DISEASES.
CA3016465A CA3016465A1 (en) 2016-03-07 2017-03-07 Dinitrophemol and dinitrophenol prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental,traumatic brain injury, concussion, dry eye disease, hearing loss, and/or metabolic diseases______________________
BR112018067966-6A BR112018067966B1 (en) 2016-03-07 2017-03-07 COMPOSITION COMPRISING PRO-DRUG OF DINITROPHENOL ISOMER (DNP) AND USES THEREOF
EP17763866.5A EP3426233A4 (en) 2016-03-07 2017-03-07 DNP-TREATMENT OF DNP PRODRUGS OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE DISEASES, DEVELOPMENTAL DISEASES, COMMODITY, DRY-LIKE SYNDROME, AND / OR METABOLIC DISEASES
KR1020217037710A KR102475875B1 (en) 2016-03-07 2017-03-07 Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases
CN201780028100.7A CN109195589B (en) 2016-03-07 2017-03-07 DNP and DNP prodrug therapy for neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic disorders.
JP2018548116A JP7021098B2 (en) 2016-03-07 2017-03-07 DNP and DNP prodrug treatment for neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain damage, tremor, dry eye disease and / or metabolic disease
KR1020187028903A KR102436172B1 (en) 2016-03-07 2017-03-07 DNP and DNP prodrug treatment of neuromuscular disease, neurodegenerative disease, autoimmune disease, developmental disease, concussion, dry eye, and/or metabolic disease
CN202210496274.9A CN115227685A (en) 2016-03-07 2017-03-07 DNP and DNP prodrug treatment of diseases
KR1020227042687A KR20230003267A (en) 2016-03-07 2017-03-07 Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases
AU2023200805A AU2023200805A1 (en) 2016-03-07 2023-02-14 Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss, and/or metabolic diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662304584P 2016-03-07 2016-03-07
US62/304,584 2016-03-07
US201762460318P 2017-02-17 2017-02-17
US62/460,318 2017-02-17

Publications (1)

Publication Number Publication Date
WO2017155940A1 true WO2017155940A1 (en) 2017-09-14

Family

ID=59722537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/021080 Ceased WO2017155940A1 (en) 2016-03-07 2017-03-07 Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases

Country Status (10)

Country Link
US (3) US10548900B2 (en)
EP (1) EP3426233A4 (en)
JP (3) JP7021098B2 (en)
KR (3) KR20230003267A (en)
CN (2) CN115227685A (en)
AU (2) AU2017229224B2 (en)
CA (1) CA3016465A1 (en)
MX (2) MX2018010718A (en)
TW (1) TWI794161B (en)
WO (1) WO2017155940A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254481B2 (en) * 2018-09-11 2022-02-22 Selig Sealing Products, Inc. Enhancements for tabbed seal

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3426233A4 (en) * 2016-03-07 2019-10-16 Mitochon Pharmaceuticals, Inc. DNP-TREATMENT OF DNP PRODRUGS OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE DISEASES, DEVELOPMENTAL DISEASES, COMMODITY, DRY-LIKE SYNDROME, AND / OR METABOLIC DISEASES
PT3565806T (en) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novel phenyl derivatives
WO2019059344A1 (en) * 2017-09-22 2019-03-28 大日本住友製薬株式会社 Chemically activated water-soluble prodrug
DE102018117657A1 (en) 2018-07-20 2020-01-23 Thyssenkrupp Ag Method and device for producing ammonia or hydrogen and use of the device
WO2020257283A1 (en) * 2019-06-18 2020-12-24 Mitopower Llc Nicotinyl riboside compounds and their uses
US20220389067A1 (en) * 2019-11-05 2022-12-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treating Neurodegenerative Diseases Caused by G4C2 Expansion in C9ORF72
CN113045428B (en) * 2019-12-26 2022-04-22 中国农业大学 Compounds and their use in fat reduction
WO2023014882A1 (en) * 2021-08-04 2023-02-09 Mitochon Pharmaceuticals, Inc. 2,4 dnp and prodrugs thereof for treatment of cancer
EP4414485A4 (en) 2021-10-07 2025-11-05 Sumitomo Metal Mining Co Infrared absorbent fiber and fiber product
US20250161243A1 (en) * 2022-02-21 2025-05-22 The Scripps Research Institute Mef2 transcriptional activators to treat neurologic conditions
WO2023205625A2 (en) * 2022-04-18 2023-10-26 Mitochon Pharmaceuticals, Inc. 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
US20100234295A1 (en) * 2009-03-16 2010-09-16 Chien-Hung Chen Treating Alzheimer's Disease And Osteoporosis And Reducing Aging
WO2015031756A1 (en) * 2013-08-30 2015-03-05 Yale University Novel 2,4-dinitrophenol formulations and methods using same
WO2015031598A2 (en) 2013-08-30 2015-03-05 Yale University Therapeutic dnp derivatives and methods using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122364C (en) * 1960-05-30
US3287211A (en) * 1965-02-26 1966-11-22 Stauffer Chemical Co Controlling mites with certain alkyl-(2, 4-dinitrophenyl) carbonates
JPS4828654A (en) * 1971-08-23 1973-04-16
JP2964107B2 (en) * 1991-11-11 1999-10-18 日本電信電話株式会社 Positive resist material
JP2654892B2 (en) * 1992-07-27 1997-09-17 日本電信電話株式会社 Positive resist material
US5621129A (en) * 1995-03-09 1997-04-15 Sumitomo Chemical Co., Ltd. Optically active tertiary phosphine compound, transition metal complex comprising the same as ligand and process for preparing optically active organic silicon compound using said transition metal complex
CN102438620A (en) * 2009-03-01 2012-05-02 于明 Compounds, compositions and use for anticancer therapy
US9643933B2 (en) * 2013-04-23 2017-05-09 The General Hospital Corporation Compounds useful as antibiotic tolerance inhibitors
CZ2014237A3 (en) * 2014-04-09 2015-10-21 Agra Group A. S. Plant stimulators, their use and plant stimulation method
EP3426233A4 (en) * 2016-03-07 2019-10-16 Mitochon Pharmaceuticals, Inc. DNP-TREATMENT OF DNP PRODRUGS OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE DISEASES, DEVELOPMENTAL DISEASES, COMMODITY, DRY-LIKE SYNDROME, AND / OR METABOLIC DISEASES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
US20100234295A1 (en) * 2009-03-16 2010-09-16 Chien-Hung Chen Treating Alzheimer's Disease And Osteoporosis And Reducing Aging
WO2015031756A1 (en) * 2013-08-30 2015-03-05 Yale University Novel 2,4-dinitrophenol formulations and methods using same
WO2015031598A2 (en) 2013-08-30 2015-03-05 Yale University Therapeutic dnp derivatives and methods using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DHARESHWAR ET AL.: "Prodrugs of Alcohols and Phenols", PRODRUGS CHALLENGES AND REWARDS PART 1, vol. V, 2007, New York, pages 31 - 99, XP009122517, Retrieved from the Internet <URL:https://link.springer.com/chapter/10.1007/978-0-387-49785-3_21> [retrieved on 20170425] *
ISAACS ET AL.: "The E1cb route for ester hydrolysis; volumes of activation as an additional criterion of mechanism", JOURNAL OF THE CHEMICAL SOCIETY , PERKIN TRANSACTIONS, vol. 2, 1988, pages 557 - 562, XP009057679 *
MCQUAKER ET AL.: "A Prototypical Small-Molecule Modulator Uncouples Mitochondria in Response to Endogenous Hydrogen Peroxide Production", CHEMBIOCHEM, vol. 14, no. 8, 2 May 2013 (2013-05-02), pages 993 - 1000, XP055235983 *
PERRY ET AL.: "Reversal of Hypertriglyceridemia, Fatty Liver Disease, and Insulin Resistance by a Liver-Targeted Mitochondrial Uncoupler", CELL METABOLISM, vol. 18, 5 November 2013 (2013-11-05), pages 740 - 748, XP055348225 *
See also references of EP3426233A4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254481B2 (en) * 2018-09-11 2022-02-22 Selig Sealing Products, Inc. Enhancements for tabbed seal

Also Published As

Publication number Publication date
US11406642B2 (en) 2022-08-09
JP2019510017A (en) 2019-04-11
AU2017229224B2 (en) 2022-11-17
US20170252347A1 (en) 2017-09-07
KR102436172B1 (en) 2022-08-24
US10548900B2 (en) 2020-02-04
TW201808268A (en) 2018-03-16
JP7021098B2 (en) 2022-02-16
KR102475875B1 (en) 2022-12-07
CN109195589B (en) 2026-04-10
US20200093831A1 (en) 2020-03-26
US20230100940A1 (en) 2023-03-30
BR112018067966A2 (en) 2019-01-15
CN109195589A (en) 2019-01-11
EP3426233A4 (en) 2019-10-16
MX2022009725A (en) 2022-09-09
KR20180118217A (en) 2018-10-30
AU2023200805A1 (en) 2023-03-09
JP2023016939A (en) 2023-02-02
CN115227685A (en) 2022-10-25
AU2017229224A1 (en) 2018-09-27
MX2018010718A (en) 2019-06-20
KR20210145298A (en) 2021-12-01
KR20230003267A (en) 2023-01-05
EP3426233A1 (en) 2019-01-16
JP2021165319A (en) 2021-10-14
TWI794161B (en) 2023-03-01
CA3016465A1 (en) 2017-09-14
JP7399139B2 (en) 2023-12-15

Similar Documents

Publication Publication Date Title
US20230100940A1 (en) DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases
EP3445756B1 (en) Compounds and compositions for treating conditions associated with nlrp activity
US7741357B1 (en) Heterocyclic and carbonate derivatives of NDGA and their use as new anti-HIV and anti-cancer agents
KR101828934B1 (en) Methods for treating bipolar disorder
CN104640540A (en) Enhanced anti-influenza agents coupled with anti-inflammatory activity
CN112566894B (en) Potent inhibitors of D-amino acid oxidase (DAAO) and uses thereof
AU2018230805A2 (en) Antimicrobial compounds, compositions, and uses thereof
CN112654626A (en) Compound and use thereof
KR20190050372A (en) A pharmaceutical composition comprising aptamer and antioxidant complex
CN101146527A (en) Methods of controlling the QT interval
HK40082341A (en) Dnp and dnp prodrug treatment of diseases
BR112018067966B1 (en) COMPOSITION COMPRISING PRO-DRUG OF DINITROPHENOL ISOMER (DNP) AND USES THEREOF
CN106133024B (en) The novel hydrotrote based on polymer for hydrophobic drug delivering
WO2023205625A2 (en) 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases
KR20220165891A (en) Three-component prodrug, pharmaceutical composition and medical use thereof
US20220313682A1 (en) Pharmaceutical Compositions of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
ES2986199T3 (en) Polymeric compositions of monomethyl fumarate in the treatment of relapsing-remitting multiple sclerosis and psoriasis
WO2026073266A1 (en) High density brush shaped polymer lipids reduce anti-peg antibody binding to enable mrna lipid nanoparticle repeat administration
US20160362402A1 (en) Novel compounds having anti-allodynic and antihyperalgesic activity

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3016465

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 122021007069

Country of ref document: BR

Ref document number: MX/A/2018/010718

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2018548116

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017229224

Country of ref document: AU

Date of ref document: 20170307

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20187028903

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017763866

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017763866

Country of ref document: EP

Effective date: 20181008

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018067966

Country of ref document: BR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17763866

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 112018067966

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180905